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ABSTRACT 
Background: Hereditary Non-Polyposis Colon Cancer (HNPCC) is a dominantly 
inherited disorder caused by germ-line defects of mismatch repair (MMR) genes. 
HNPCC can be diagnosed using clinical and genetic criteria. Few population-based 
studies have been undertaken to determine the genetic basis of CRC. The purpose of this 
pilot project was to determine the proportion of hereditary vs. sporadic CRC cases on the 
Avalon Peninsula (AP) ofNewfoundland and to determine the genetic basis of disease in 
hereditary cases. 
Methods: The population studied was identified through the Newfoundland Cancer 
Treatment and Research Foundation (NCTRF) registry, the meditech system (a hospital 
reporting tool), and pathology reports. One hundred and sixty-eight potential probands 
were identified, diagnosed in either 1997 or 1998, between the ages of20-69, and 
residing on the AP. Probands, or an appropriate next of kin if a proband was deceased, 
were interviewed to determine family history of cancer. Contact was made with 158 
eligible participants ofwhich one hundred and six (67%) agreed to participate in the 
study. The final number of study subjects was 79, which was 74.5% of those who agreed 
to participate. The NCTRF registry and a review of medical charts were used for the 
collection of baseline characteristics which included demographic and clinical data. 
Probands were classified by their family history using the Amsterdam Criteria 
(AC), Amsterdam II Criteria, and several other criteria to identify familial risk of 
HNPCC. Microsatellite analysis (n= 74) and immunohistochemistry analysis (n= 71) for 
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hMLH1, hMSH2, and hMSH6 was completed on proband's normal and tumour DNA. 
We also examined the diagnostic utility of microsatellite analysis and of protein 
expression to identify High Risk (HR) families, in comparison to Low Risk (LR) families. 
Results: Twenty-two (28.2%) families were considered HR with 6 families fulfilling the 
AC I, 1 family fulfilling the AC II, and 15 families fulfilling our Age and Cancer 
Modified AC (youngest cancer:::; 60 rather than 50). Twenty-two (28.2%) families were 
Intermediate Risk (IR), and 34 (43.6%) families were (LR) for HNPCC. However 13 of 
the LR families had an uninformative family structure. All Amsterdam Criteria families 
had previously been referred to the Newfoundland Medical Genetics program. 
Sixteen cases (21.6%) had high frequency microsatellite instability (MSI-H) 
tumours. Sixteen cases (22.5%) had absence of protein expression for at least one of 
three proteins. For the HR group 6 (31.6%) had MSI-H tumours and all showed absence 
of protein expression. Fourteen (68.4%) of the HR group had microsatellite stable (MSS) 
tumours of which 13 (92.9%) expressed all the proteins. For theIR group 4 (22.2%) had 
MSI-H tumours and all showed absence of protein expression. Fourteen (77.8%) of the 
IR group had MSS tumours and all expressed the proteins. For the LR group 4 (12.5%) 
had MSI-H tumours and 3 (9.4%) of these showed absence of protein expression. 
Twenty-eight (87.5%) of the LR group had MSS tumours ofwhich 27 (96.4%) expressed 
all proteins. 
The sensitivity of the laboratory methods used in predicting cases that are high 
risk for HNPCC was 35.0% and the specificity of the methods in predicting cases that do 
not have HNPCC was 78.9%. 
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Conclusions: We conclude that in the Eastern Newfoundland population the risk for 
HNPCC is high. Twenty-eight percent of families with CRC are at high risk for 
HNPCC. Furthermore the prevalence of MSS tumours in the HR group was high. It is 
likely that novel genes predisposing to HNPCC occur in the Newfoundland population. 
The utility of testing for MSI and MMR protein expression for the diagnosis of HNPCC 
in this population was poor. 
lV 
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CHAPTER 1: INTRODUCTION 
This pilot project examines the family risk for Hereditary Non-Polyposis 
Colon Cancer (HNPCC) of probands identified in Eastern Newfoundland during 2 years. 
It was developed by two graduate students, one in Molecular Genetics and the other in 
Clinical Epidemiology. Both projects and their outcomes rely on the existence of the 
other. This study is a pilot project for the Newfoundland component of the Collaborative 
Interdisciplinary Health Research Team (IHRT) study, between Memorial University and 
Mt. Sinai Hospital, which includes development of a Newfoundland Familial Colorectal 
Cancer Registry (NFCCR). The development of a specialized colorectal cancer (CRC) 
population-based registry could lead to estimates of the true incidence ofHNPCC within 
the population of Newfoundland. Such registries specific to CRC exist in other 
populations. 
The Newfoundland Cancer Treatment and Research Foundation (NCTRF) is a 
provincial organization responsible for the delivery of cancer services including 
prevention, treatment, support, and research to the people of Newfoundland and 
Labrador. It contains a detailed provincial tumour registry. The registry collects data on 
all new cancer diagnoses within the province. It contributes to the Canadian Cancer 
Statistics providing detailed information concerning the incidence and mortality of cancer 
within the province. However it does not contain family risk information. 
Screening has been shown to reduce the occurrence of CRC in HNPCC (Jarvinen 
et al, 1995). By identifying families affected with HNPCC, and offering screening 
programs to those at risk, earlier diagnosis and treatment is possible with better prognosis. 
1 
It is important to determine the incidence of HNPCC in Newfoundland so that the need 
for appropriate resources for management will be put into place. 
1.2 LITERATURE REVIEW 
The following factors have all led to improved prevention and treatment options 
for CRC: the early recognition of cancer clusters; the identification ofHNPCC kindreds; 
the search for genes and mutations in kindreds; the use of known mutations to develop 
new and better techniques for mutation detection; and the use of mutations to find and 
screen family members at risk. 
HNPCC occurs worldwide as documented in Australia (Scott et al, 2001), Canada 
(Bapat et al, 1999 ), Denmark (Jager et al, 1997), Finland (Moisio et al, 1996), France 
(Wang et al, 1999), Germany (Lamberti et al, 1999) Great Britain (Dunlop et al, 1997), 
Italy (Ponz de Leon et al, 1999), Japan (Miyaki et al, 1995), Korea (Han et al, 1996), 
Netherlands (Wijnen et al, 1998a), Spain (Godino et al, 2001), Sweden (Liu et al, 1998), 
Switzerland (Buerstedde et al, 1995), United States (Weber et al, 1997), and others. 
Finland has reported two out of four of the world's known founder mutations to date that 
are responsible for the majority of putative HNPCC (51%) and HNPCC (68%) families in 
Finland (Nystrom-Lahti et al, 1996). This finding was possible not only because of an 
efficient cancer registry and population registry, but also because of its unique population. 
Other founder mutations have been reported in both the Danish (Jager et al, 1997), 
Newfoundland (Froggatt et al, 1999), and more recently American (Wagner et al, 2003) 
populations. 
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Studies to determine the population prevalence of genotypes and phenotypes are 
influenced by lack of consistency in methods and definitions. Efforts to collaborate have 
been facilitated by several groups. The international collaborative group on HNPCC 
(ICG-HNPCC) was initially formed by experts in the field in the early 1990's (Vasen et 
al, 1991). This group plays a pivotal role in HNPCC education, development of 
registries, and continuing international research. The National Cancer Institute (NCI) is 
an establishment in the United States. NCI's mandate is to support cancer research and to 
develop and implement the findings of the research. Currently there are 6 international 
sites participating in the Co-operative Familial Colorectal Cancer Registries sponsored by 
the NCI (Cotterchio et al, 2000). 
1.21 Genetic Epidemiology 
A new discipline has emerged that combines the methodologies of both 
Epidemiology and Genetics. It aims to describe and determine disease distribution in 
populations and families. It draws on a number of sources including newly developing 
registries and monitors to help understand etiologic heterogeneity, genetic-environmental 
interactions, and natural history of diseases (Khoury et al, 1986). Efforts are made to 
collect data on disease status, risk factors, family history, and to collect DNA Analysis 
of a combination of these sources will lead to intervention and prevention, and will 
impact disease trends in populations (Vogel et al, 1979; Khoury et al, 1986). The 
observation of patterns for familial aggregation can be a starting point of genetic-
epidemiological studies (Khoury et al 1986; Wickramartrie, 1995). This provides an 
opportunity to study modifying factors in kindreds that possess the same mutation. 
3 
Mendelian disorders are single-gene traits that segregate within families, and 
should occur in fixed proportions among the offspring. They are often characterised by 
their pattern of inheritance in families. There are 4 basic patterns of single gene 
inheritance; autosomal dominant, autosomal recessive, X-linked dominant, X-linked 
recessive (Thompson, 1991). Management of these disorders assumes that interpretation 
of the mode of inheritance is correct, and that the affected individual is classified 
correctly and representative of the condition (Watson and Lynch, 1993). Identifying 
specific genetic mutations improves the management. However, numerous obstacles can 
complicate finding these mutations and thus complicate the management of Mendelian 
disorders. These include incomplete penetrance, small family size, new mutations, 
variable expressivity of the trait, and variable age of onset. Environment, gene-
environment, and gene-gene interactions potentially influence gene expression. Although 
individual genetic disorders are rare in the general population, in combination they are an 
important cost to society as they lead to serious morbidity and mortality. Large studies 
are needed to study these rare genetic traits. 
Cancer is a relatively common occurrence in the general population and a serious 
cause of morbidity and mortality in the world. The goal of genetic epidemiology 
research in cancer is to ultimately lead to prevention and control. Providing surveillance 
and prevention programs for identified groups with an increased risk of developing cancer 
could impact the cancer burden. There are twenty hereditary or familial cancer 
syndromes in which the risk of cancer is high (Fearon, 1997). 
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1.22 Cancer 
Cancer is a universal term used to describe a variety of diseases that share a 
common feature of uncontrolled cellular growth (V ogelstein and Kinzler, 2002). Cancer 
is the principal cause of premature death in Canada. In 2002, it was estimated that 
136,900 Canadians were diagnosed with cancer and 66,200 died of cancer. Although 
cancer may develop at any age, 25% of new cases occur in those 60-69 and 44% of new 
cases occur above age 69. Therefore a person's risk of developing a cancer increases 
with age. It is estimated that approximately 3 8% of women and 41% of men will develop 
a cancer in their lifetime (National Cancer Institute of Canada, 2002). 
Early diagnosis and early treatment of cancer are imperative to survival. 
Therefore an important aim of research is to identify individuals at increased risk for 
cancer before development of cancer. Risk factors influencing the development of 
cancer include age, diet, level of physical activity, smoking, alcohol intake, and family 
history. Modifications to lifestyle habits may decrease the risk of developing a cancer. 
Protective factors include adding fibre and vegetables to the diet (Canadian Cancer 
Society, 2003). Research indicates that NSAIDS and hormone replacement therapy 
appear to have a protective effect (Potter et al, 1993). 
The processes involved in the pathogenesis of cancer are unclear and may in fact 
include a combination of gene-gene interactions, gene-environment interactions, or single 
gene mutations. It is believed that progression to cancer is a multistep process that 
involves multiple mutations. These mutations can occur in both somatic and germline 
cells. Oncogenes, tumor suppressor genes and mismatch repair genes are three types of 
genes that have been implicated in this multistep process. Normally these genes act 
5 
simultaneously to control and optimise cellular growth. Mutations arising in these genes 
begin the multistep process that leads cells to malignant growth (Vogelstein and Kinzler, 
2002). While non-genetic factors are suspected to be responsible for the majority of all 
cancers (sporadic cancers) it is estimated that potentially 0.1%-10% of all cancers has an 
inherited component (Fearon, 1997; Vogelstein and Kinzler, 2002). Much of the current 
knowledge about the pathogenesis of cancer has been gained through research in 
colorectal cancer (Fearon, 1995). 
1.23 Colorectal Cancer 
Colorectal cancer (CRC) is one of numerous cancers that affect the digestive 
system, the majority ofwhich occurs in the sigmoid colon and rectum (Canadian Cancer 
Society, 2003). In Canada, it is the 3rd most common cancer occurring in both men and 
women, and the second most common cause of mortality due to cancer. It is responsible 
for 10% of all cancer deaths. Clinical outcomes are related to stage at diagnosis. In 
2002, five year survival rates of 59% and 56% were reported for females and males 
respectively. Fifty-three percent of all new cases occur after age 70 therefore CRC is 
generally associated with an elderly population. Incidence rates in men and women 
appear almost equal with estimation that 6.3% ofwomen and 6.7% of men will develop 
CRC in their lifetime (National Cancer Institute of Canada, 2002). Like any cancer, CRC 
is a major economic and social problem for patients and their families. 
In Canada a declining incidence and mortality rate of CRC has been observed 
over the past decade and a half and may be explained by changes in lifestyle habits and 
casual screening (National Cancer Institute of Canada, 2002). Contrary to this, during the 
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period of 1996-1998, CRC was the most common occurring cancer (12-13% of all cancer 
diagnoses within that period) seen in both sexes within the Newfoundland population; it 
had increased 14% from previous years. CRC occurrence was second to breast cancer in 
females and prostate cancer in males (H Bliss Murphy Cancer Center, 2000). 
CRC is recognised as a preventable disease if caught at an early stage. However, 
because adenomas and early stage CRC are often symptom free the prevention is 
complicated (Toribara et al, 1995; Thiis-Evensen et al, 1999). Symptoms ofCRC include 
changes in bowel habits, blood in stools, changes in stools, abdominal discomfort, weight 
loss, and tiredness (Canadian Cancer Society, 1993). Screening is the process oftesting 
people without symptoms to identify early signs of disease. A variety of screening 
methods have been shown to reduce the incidence of CRC (Winawer et al, 1993; Thiis-
Evensen et al, 1999). Barium enema, fecal occult blood test, flexible sigmoidoscopy and 
colonoscopy are often used alone or together as screening and diagnostic tools. 
Colonoscopic polypectomy is a procedure carried out for the removal of polyps. 
The removal of these polyps is common practice for the prevention of CRC (Winawer et 
al, 1993). It would be unethical and not feasible to determine the legitimacy of this 
practice through randomised controlled trials. Instead, observations were made from 
studies such as The National Polyp Study (0' Brien et al, 1990; Winawer et al, 1992; 
Winawer et al, 1993). Subjects were randomised into two groups: those screened at 3 
years; or those screened at both 1 and 3 years. Follow-up of these subjects was then 
compared to retrospective data of individuals who refused colonoscopic polypectomy 
after polyps were found on initial screening and who were followed for an average of 9 
years. A major conclusion of the study was that colonoscopic polypectomy resulted in a 
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lower than expected incidence of CRC compared to the observed incidence of CRC in 
those who refused colonoscopic polypectomy (Winawer et al, 1993). 
The aim of any screening program is to improve the general health of the 
population by reduction in morbidity and mortality rates. In order to accomplish this task 
the screening program needs to be feasible, economical and benefits must outweigh the 
risks. There is no population screening for CRC in Canada, although screening for CRC 
is recommended beginning at age 50 (Canadian Cancer Society, 2003). Diagnosis of 
CRC is usually made when symptoms are evident or sometimes by the presence of 
asymptomatic iron deficiency. Standard therapy for CRC is surgical resection and this is 
tailored around the presentation at the time of diagnosis. Chemotherapy and radiation are 
utilised as neoadjuvant and adjuvant treatment (Canadian Cancer Society, 2003). 
Although the etiology of CRC remains uncertain, a number of environmental, pre-
existing medical conditions and genetic factors are involved. Epidemiological studies 
demonstrate that environmental factors play a role in the development of CRC. Diets 
high in fat and low in fibre are implicated in the pathogenesis of CRC (Giovannucci and 
Willett, 1994; Winawer et al, 1997). The best known example of this is the study of 
Japanese immigrants to the United States. Even though a very low incidence of CRC was 
observed in Japan at the time, this dramatically increased in Japanese immigrants 
(Haenszel et al, 1968). Also more recently, the incidence ofCRC in Japan has increased 
and the incidence of stomach cancer has decreased possibly due to adaptation of the 
western influences in the diet (Lee, 1976). 
Other risk factors for CRC include the inflammatory bowel diseases (ffiD), 
Crohn's disease and ulcerative colitis (UC) (Potter et al, 1999). The lifetime risk is 
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greater for UC than for Crohn' s disease and the development of cancer is dependent upon 
the site, extent, severity and age of onset of the disease. The risk is 10% for UC 
(Lennard-Jones, 1996), CRC risk begins to increase at 8-10 years after IBD diagnosis 
(Levin B, 1995). In Canada more than 150,000 people have IBD and some have a 10% 
increased lifetime risk of developing CRC (Crohn's and Colitis Foundation of Canada, 
2003) 
CRC usually develops from an adenoma (commonly known as a polyp) on the 
inner lining of the gastrointestinal tract. Adenomas are quite common in the general 
population and most people with adenomas do not go on to develop a cancer, even though 
adenomas are a risk factor (Spencer et al, 1984; Bide et al, 1986; Lotfi et al, 1986; Atkin 
et al, 1992). An adenoma begins as a benign tumour that may undergo malignant 
transformation. Abnormal cells (dysplasia) arising within these adenomas will eventually 
give rise to adenocarcinomas (O'Brien et al, 1990). Muto et a1 (1975) proposed the 
adenoma-carcinoma sequence theory. Over the years this theory has been supported and 
developed through observational and biochemical studies (Stryker et al, 1987; Williams et 
al, 1990; Winawer et al, 1993). This process of adenoma to carcinoma development 
occurs over time, usually decades, and involves multiple genes. 
Fearon and Vogelstein (1990) developed a model that has improved the 
understanding of the molecular genetics of sporadic CRC. This model states that seven 
genetic changes have to take place in order for the development of a cancer. These 
changes are characterised by major chromosomal alterations and somatic mutations. 
Mutations of the Adenomatous Polyposis Coli (APC), p53, and K-ras-2 genes, and loss of 
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heterozygosity (LOH) commonly but not invariably on chromosomes 5q, 8p, 17p, 18q, 
and 22q occur during the adenoma-carcinoma sequence (Vogelstein and Kinzler, 2002). 
While the majority of CRC is sporadic in nature, genetic factors are believed to 
contribute to 15% of all CRC (Cannon-Albright et al, 1988; Roulston et al, 1992). An 
increased risk of CRC has been observed in first-degree relatives of those affected (Ponz 
de Leon et al, 1987; Fuchs et al, 1994; Slattery et al, 1994; Negri et al, 1998) and, 
although minor, there is also an increased risk in twins (Lichtenstein et al, 2000). Several 
inherited predispositions to CRC have been described. There are two main forms of 
hereditary CRC: Hereditary Non-polyposis Colon Cancer (HNPCC), and Familial 
Adenomatous Polyposis (F AP). Investigations into these syndromes have not only 
improved the understanding of hereditary and sporadic CRC but also of other cancer 
types (Fearon et al, 1990). HNPCC is the number one risk factor for CRC (Mecklin, 
1987). 
1.24HNPCC 
HNPCC, as its name implies, is characterised by CRC with a demonstrable lack of 
polyposis (multiple polyposis). Clinical descriptions of HNPCC include: a younger age 
of presentation than seen in the general population with an average age of onset of 44, 
proximal location (right-sided cancers), extracolonic cancers, synchronous, 
metachronous, multiple, and mucinous cancers. It is an autosomal dominantly inherited 
syndrome, therefore offspring of affected individuals have a 50% chance of inheriting the 
mutation. (Vasen et al, 1990; Mecklin et al, 1991; Watson et al, 1993; Lynch et al, 1997). 
10 
HNPCC is reported as responsible for anywhere from 0.5-13% of all CRC (Vasen 
et al, 1991; Aaltonen et al. 1994a; Brassett et al, 1996; Bellacosa et al, 1996; Lynch et al, 
1996a; Ponz de Leon, 1996; Evans et al 1997; Lynch et al, 1997; Lynch and de la 
Chapelle, 1999; Moore and Cowled, 1999; Peel et al, 2000). It has been difficult to 
estimate the true incidence of HNPCC, however Lynch et al (1996b) suggest that it is 
responsible for 2-4% of all western CRC. The difficulty stems from an ever changing 
definition of HNPCC because of the clinical and genetic heterogeneous nature of the 
condition. Currently HNPCC is identified by multiple methods. Initially, the syndrome 
was defined clinically, then attempts were made to define it pathologically and now it is 
possible to identify HNPCC at a molecular level. The optimal diagnostic method would 
be a molecular diagnosis. However, currently this is expensive, time-consuming, and 
inconclusive due to the heterogeneity of mutations identified and the inability to detect all 
mutations. Therefore until improvements are made in laboratory studies, the gold 
standard for HNPCC diagnosis will be by evaluating family history by standardised 
clinical criteria. 
The earliest description of HNPCC was in 1913 by a pathologist Dr. Alfred S. 
Warthin (Warthin, 1913). This description was of the occurrence of cancers in a family 
now known as "Family G'' (Lynch et al, 1971). HNPCC was first labelled "cancer family 
syndrome" in 1971 by Henry T. Lynch. Lynch was instrumental in describing the clinical 
manifestations ofthis disease and is still an important researcher in HNPCC (Lynch et al, 
1971; Lynch et al, 1996a; Lynch et al, 1999). In 1984 HNPCC was divided into the two 
subcategories Lynch syndrome I (absence of extracolonic malignancies) and Lynch 
syndrome II (presence of extracolonic malignancies) (Boland et al, 1984; Lynch et al 
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1985). It is apparent now that there is no genetic basis for this classification (Nystrom-
Lahti et al, 1994). 
Although HNPCC 1s uncommon, it represents a group of individuals with an 
increased risk of developing cancer who might benefit from strategic surveillance and 
prevention. Screening in other hereditary syndromes has been shown to be economically 
favourable to health care systems and families, by reducing psychosocial costs to 
families, and resulting in preferred patient outcomes (Green, thesis 1995). Clinical 
screening is usually offered to high risk individuals who have been identified by pedigree 
analysis or predictive genetic testing. Colonoscopy, starting 5 years before the earliest 
diagnosis of CRC in the family, at one to five year intervals has been recommended by 
several groups (Mecklin et al, 1986a; Fitzgibons et al, 1987; Vasen et al, 1989; Roulston 
et al, 1990; Vasen et al, 1993). Rationale for this is based on evidence that screening for 
CRC in families with HNPCC has been shown to reduce the incidence of CRC, and 
decrease CRC deaths and overall mortality (Jarvinen et al, 1995; Vasen et al, 1998; 
Jarvinen et al, 2000). In a controlled 15-year trial, Jarvinen et al demonstrated a 65% 
decrease in the overall death rate in screened subjects compared to control subjects, all of 
whom were members of 22 HNPCC families, and at 50% risk of having a mutation. 
Planning screening for HNPCC is difficult because of the variable expression of the 
syndrome and non-penetrance ofthe gene. If no mutation is identified within a family, 
then current screening recommendations for at risk family members are based on clinical 
observations. This means that screening for extracolonic cancers may be included 
beginning usually 5- 10 years before the earliest cancer appears in the family (J. Green, 
personal communication). 
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1.241 Genetic Identification 
Today we know that HNPCC is a genetically heterogeneous condition which can 
be identified presymptomatically by mutation testing (Peltomaki and de la Chapelle, 
1997). Yet this is only possible for individuals in families that harbour an identified 
mutation in the mismatch repair (MMR) genes and unfortunately finding these mutations 
are difficult. 
Microsatellite instability (MSI) (Originally referred to as replication error (RER), 
is defined as "a change of any length due to either insertion or deletion of repeating units, 
in a microsatellite within a tumour when compared to normal tissue" (Boland et al1998). 
This characteristic was first observed in human CRC (Peinado et al, 1992; Ionov et al, 
1993; Thibodeau et al, 1993). Previously bacteria and yeast studies identified new genes, 
named mismatch repair (MMR) genes, believed to play a vital role in DNA repair 
(Levinson and Gutman, 1987; Strand et al, 1993). MSI was noted in these organisms 
with mutations in the MMR genes. Therefore MSI was believed to result from defects 
in the MMR genes and human homo logs of the yeast and Ecoli genes were then suspected 
to be involved in tumour formation in HNPCC (Strand et al, 1993). 
Experimental evidence confirmed that mutations in MMR genes induce the 
mutator phenotype MSI (Loeb et al, 1994). MSI was reversed and MMR activity was 
restored when the normal copy of a MMR gene was reinserted into human cancer cell 
lines with deficient MMR (Koi et al, 1994). Biochemical investigations also supported 
these findings (Parsons et al, 1993; Umar et al, 1994). 
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Seven MMR genes including human mutS homolog 2 (hMSH2), human mutL 
homolog 1 (hMLH1 ), human mutS homolog 6 (hMSH6), human post-meiotic segregation 
1 (hPMS 1 ), human post-meiotic segregation 2 (hPMS2), human mutS homolog 3 
(hMSH3), and human mutL homolog 3 (hMLH3) have been identified thus far. Linkage 
analysis of some large HNPCC families mapped the relevant gene to chromosome 2p 16 
(Peltomaki et al, 1993). The first human homolog was then cloned by two groups 
simultaneously and localised to 2p21-22 (Fishel et al, 1993; Leach et al, 1993) and it was 
hypothesized to be responsible for HNPCC (Strand et al, 1993). This hypothesis was 
confirmed by Leach et al, 1993 following the identification of hMSH2 mutations in 
HNPCC kiridreds. Soon after a second HNPCC locus was mapped to chromosome 3p21 
(Lindblom et al, 1993), and hMLH1 was cloned and localised to 3p21 (Bronner et al, 
1994; Papadopoulous et al, 1994). Later, hPMS1 and hPMS2 were identified and 
localised to chromosome 2q31-33 and 7p22 respectively (Papadopoulos et al 1994; 
Nicolaides et al, 1994). The identification of hMSH6 (initially called the GTP binding 
protein) was reported in 1995 and it was mapped to chromosome 2p15 (Drummond 1995; 
Palombo 1995; Papadopoulos, 1995). 
The hMSH2, hMLH1, hPMS2, and hMSH6 functions are required for effective 
MMR (Fischel, 1995). These genes encode proteins that function together with other 
proteins to repair mismatched bases at the S phase of the cell cycle (Kolodner et al, 1995). 
Each protein product plays a specific role in repairing damaged DNA The proteins form 
heterodimeric complexes: hMSH2 with either hMSH6 or hMSH3 forms the mutS 
homolog alpha (hMutSa) complex; and hMLH1 either with hPMS2, hPMS1, or hMLH3 
forms the mutL homolog alpha (hMutLa.) to carry out the specific repair of the DNA 
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The mutS homologs (hMSH2, hMSH6, hPMS2) recogmse mistakes in the DNA 
(Palombo et al, 1996); hMSH2-hMSH6 binds to single-base mismatches, whereas 
hMSH2 in combination with another gene is postulated to bind extrahelical mismatched 
nucleotides (Acharya et al1996; Alani et al 1996; Marsischky et al 1996). Following the 
recognition of the mismatches the hMutLa complex then joins the hMutSa complex to 
form the MutSa/MutLa complex. hMutLu assembles other proteins (involved in DNA 
synthesis) that complete the MMR system and the DNA is then repaired by removal and 
replacement of nucleotide sequences (Guerrett et al, 1999). It is not yet clear whether or 
how the loss of function of a gene affects the other genes in the heterodimers. 
Preliminary findings suggest that the hMSH6 protein is unstable in the absence of 
hMSH2 (Marra et al, 1998; Chang et al, 2000) and hMSH6 mutation carriers often show 
reduced levels ofhMSH2 (de Wind et al1999; Leeuw et al, 2000). 
Pathogenic mutations in six of the MMR genes have been identified to be 
causative in cancer susceptibility (Papadopoulos et al 1994; Rhyu et al, 1996; Miyaki et 
al, 1997; Peltomaki et al, 1997; Wu et al, 2001). To date no mutations have been 
identified in hMSH3 (Fischel et al 1993; Lindblom et al 1993; Papadopoulous et al 1994; 
Huang et al, 2001; Lipkin et al, 2001). Currently more than 300 different mutations are 
identified in 500 kindreds worldwide (Peltomaki et al, 2001; International Collaborative 
Group on HNPCC, 2003). These include inactivating truncating mutations due to splice-
site defects, :frameshifts involving entire exons, nonsense mutations causing stop codons, 
and numerous missense mutations (Han et al, 1995; Kolodnel et al, 1995; Liu et al, 
1995a; Luce et al, 1995; Nystrom-Lahti et al, 1995; Tannengard et al, 1995). The 
majority (90%) of mutations in HNPCC are attributed to the hMLHl and hMSH2 genes 
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(Kinzler et al1996, Liu et al1996; Lindor et al, 1998). Mutations in MSH6 are suspected 
to be responsible for 5-10% ofHNPCC (Kolodner et al, 1999; Wijnen et al, 1999) and 
mutations in PMS 1 and PMS2 are expected to account for less than 5% of HNPCC (Liu 
et al, 1996). 
Inheriting a mutation m one of the MMR genes does not guarantee the 
development of cancer. Instead this inheritance deems that an individual has a greater 
susceptibility to a cancer outcome. DNA MMR activity is sufficient with one functioning 
allele, i.e. a heterozygous state (Parsons et al, 1993). A cancer develops when the second 
allele (wild type) is also lost due to a somatic alteration (mutation or hypermethylation) 
(Bellamy et a1 1995). The two hit hypothesis, originally purposed by Knudson, and 
applied to tumour suppressor genes, illustrates how inherited and somatic mutations 
collaborate in tumour formation (Knudson, 1971). With a normal MMR gene it would 
take two somatic mutations, one in each allele, for tumour development, whereas 
inheriting one defect at birth greatly increases the odds of developing a cancer because 
only one somatic mutation is needed. In vitro studies further supported this hypothesis 
when it was demonstrated that CRC cell lines with mutations in both alleles in hMLH1 
(Papadopoulous et al, 1994; Parsons et al, 1995) or in hMSH2 (Umar et al, 1994), are 
deficient in MMR activity. 
The pathway to developing a CRC in HNPCC appears to be different than in 
sporadic CRC (Liu et al, 1995a; Konishi et al, 1996). In HNPCC the adenoma to 
adenocarcinoma sequence is accelerated. An increased mutation rate is observed in 
MMR deficient cells compared to normal cells: the second hit induces the mutator 
phenotype (MSI) in the cell leading to the rapid accumulation of mutations in tumour 
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suppressor genes and oncogenes, and ultimately decreasing the time for formation of the 
adenocarcinoma (Ahlquist et al, 1995; Kinzler and Vogelstein 1996; Lynch et al1996b). 
Potential differences are accounted for by observations of the different order and number 
of mutations occurring. For example, mutations in the APC gene (responsible for tumour 
initiation in sporadic cancer) have been shown to occur at a higher frequency in non-
HNPCC tumours than in HNPCC tumours (Konishi et al, 1996, Salahshor et al, 1999), 
and mutations in the transforming growth factor ~ II receptor (TGFB-Rll) , which occur 
in more than 90% ofMSI tumours, probably play a role in tumour progression in HNPCC 
tumours and not in non-HNPCC tumours (Markowitz et al, 1995). 
Also, somatic, rather than germline mutations in MMR genes may be responsible for the 
sporadic cancers with MSI (Liu et al, 1995a). 
1.242 Clinical Identification 
As a consequence to the genetically heterogeneous nature of HNPCC it is also a 
clinically heterogeneous condition. The identification of large HNPCC kindreds 
contributed much of what is now known about HNPCC. Analysis of these kindreds has 
demonstrated intrafamilial and interfamilial variables such as; ages of onset, sites of 
tumours, severity, and order of occurrence of HNPCC cancers (Green, thesis 1995). 
Beside CRC, numerous extracolonic malignancies are associated with HNPCC. 
Extracolonic cancers reported are varied and include malignancies of the endometrium, 
ovary, stomach, renal pelvis/ureter, upper biliary tract, skin (sebaceous tumours), small 
bowel, and brain (Watson et al, 1993; Aarnio et al, 1995; Vasen et al, 1996a; Vasen et al, 
1999). Lynch et al (1993) showed increased frequency of endometrial, gastric, ovarian, 
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small intestine, biliary, uroepithelial, and kidney cancers. These extracolonic cancers 
appear in some but not all HNPCC families. 
Variable expression of disease reported within and between families, in separate 
studies, may be due to geographical variation, different mutations, or modifier genes, but 
also could be affected by differences in methodologies such as different ascertainment 
methods. Overestimation and underestimation of cancer risk is possible because of 
selection biases. The subjects chosen may not be a true representation of the population. 
To further support the clinical spectrum of this syndrome, MSI and loss ofMMR function 
has been identified in extracolonic tumours (Han et al, 1993; Risinger et al, 1993; 
Kobayashi et al, 1995). 
1.243 Tumour Spectrum 
CRC is the main manifestation of the syndrome, and diagnosis of HNPCC has 
typically occurred from identifying clusters of CRC cases (Lynch et al, 1988; Mecklin et 
al, 1991). Aarnio et al (1995) studying 293 putative mutation carriers in 40 AC families 
demonstrated that CRC was the most common tumour in HNPCC, including 190 of 293 
( 65%) of all tumours in their study. They reported a 78% lifetime risk of CRC in these 
families. A similar result was seen in a study by Green at al, (2002) in a study of 151 
hMSH2 mutation carriers. By age 60, 77% of males had developed a CRC. Gender 
differences appear to occur as the risk of CRC was shown to be 2.8 times higher in males 
compared to females in a recent study of known mutation carriers (Green et al, 2002). 
The lifetime risk of CRC is similar in hMSH2 and hMLH1 mutation carriers (Vasen et al, 
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1994; Vasen et al, 1996a; Lin et al, 1998a) but may be lower in hMSH6 mutation carriers 
(Miyaki et al, 1997; Wijnen et al, 1999; Wu et al, 1999; Wagner et al, 2001). 
Endometrial cancer is the most common extracolonic cancer in HNPCC (Mecklin 
et al, 1991). It is estimated that 5% of all endometrial cancer is caused by HNPCC 
(Vasen et al, 1990; Hakala et al1991; Watson et al, 1993; Boyd et al, 1996). However, 
HNPCC families have been described that have either low frequency of endometrial 
cancers (Lynch and de la Chapelle, 1999) or none (Lynch et al, 1977; Lynch et al, 1988). 
The risk for endometrial cancer was shown to exceed the risk for CRC in female mutation 
carriers in some studies (Aarnio et al, 1995; Dunlop et al, 1997; Aarnio et al, 1999; Green 
et al, 2002). Aarnio et al (1995) demonstrated that the lifetime risk of endometrial cancer 
was 43% in female mutation carriers. Green et al (2002) reported a risk of 59% by age 60 
in female carriers with a specific hMSH2 mutation. Such an observation may be 
gene/mutation specific. Lifetime risks of endometrial cancer were calculated to be 61% 
for hMSH2 mutation carriers and 42% for hMLH1 carriers (Vasen et al, 1996). 
Cumulative incidences of 36% in hMSH2 and 19% in hMLH1 of endometrial cancer 
were observed in a study of 105 known and putative mutation carriers (Lin et al, 1998). 
Although lower than reported for CRC, de Leeuw et a1 (2000), found MSI in 75% of 
HNPCC endometrial tumours. 
Over the past century a decreasing incidence of stomach cancer has been observed 
in the western world. Environmental factors are believed to be responsible for this trend 
which may also be implicated in the increase of other types of cancer (Howson et al, 
1986). The first description of HNPCC (originally referred to as Cancer Family 
Syndrome) reported more stomach cancer than CRC (Lynch et al, 1999). Watson et al 
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(1993) observed significant excess rates of stomach cancer in HNPCC compared to the 
general population. In Aamio's study (1995), gene carriers were estimated to have a 
19% lifetime risk of developing stomach cancer. Vasen et al (1996) studied hMSH2 and 
hMLH1 mutation carriers and reported an increased relative risk of 19.3 for stomach 
cancer in hMSH2 mutation carriers. 
The hepatobiliary tract encompasses the liver and gallbladder. Watson et al 
(1993) reported significant excess rates ofhepatobiliary tract cancer in HNPCC compared 
to the general population. Aarnio et al (1995) reported that gene carriers have an 18% 
lifetime risk of developing biliary tract cancer. 
Numerous studies support an increase in transitional cell cancer of the renal pelvis 
and ureter in HNPCC families (Watson et al, 1993; Vasen et al, 1996a; Sijmons et al, 
1998). Risk of bladder cancer does not appear to be increased in HNPCC (Watson et al, 
1993; Sijmons et al, 1998; Vasen et al, 1996a). Watson et al (1993) reported significant 
excess rates of transitional cell cancers in HNPCC compared to the general population. 
Aamio et al (1995) found that gene carriers have a 10% lifetime risk of developing 
urinary tract cancer. In Vasen's study (1996a) of mutation carriers, an extremely high 
relative risk of 75.3 was reported for renal pelvis/ureter cancers in hMSH2 mutation 
earners. 
Initially, Watson et al (1993) reported significant excess rates of ovarian cancer in 
HNPCC. This was followed by Aarnio's study (1995) on putative gene carriers where a 
9% increased lifetime risk of ovarian cancer was demonstrated. However it has been 
noted that MSI rarely occurs in ovarian tumours (Fujita et al, 1995). In a recent review, 
ovarian tumours in HNPCC were compared to those in the general population and several 
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important findings were made. In this group, ovarian tumours occurred at an earlier age, 
were more likely to be epithelial in nature, and individuals were more likely to have a 
synchronous endometrial cancer (Watson et al, 2001). 
Cancer of the small bowel is rare in the general population. Watson et al ( 1993) 
reported significant excess rates of small bowel cancer in HNPCC compared to the 
general population. A 1% (Aamio et al, 1995) and 4% (Vasen et al, 1996a) increased 
lifetime risk of developing small bowel cancer has been reported in gene carriers. 
The majority of pancreatic cancer is believed to be sporadic. However, the 
occurrence of pancreatic cancer in HNPCC has been described (Lynch et al 1985a; Vasen 
et al, 1990; Mecklin et al, 1991; Aarnio et al 1995; Dunlop et al ,1997) and without 
significant increased risk in HNPCC (Ponz de Leon et al, 1989; Watson et al, 1993). It is 
also associated with other cancer susceptibility syndromes where germline mutations in 
p16, BRCA1, BRCA2, and APC genes have been identified (Flanders and Foulkes, 
1996). 
No excess risk of brain cancer was reported in high risk members of 23 HNPCC 
kindreds (Watson et al, 1993). In contrast, Aarnio et al ( 199 5) demonstrated a 1% 
increased lifetime risk of developing brain cancer in putative gene carriers. In another 
study, the relative risk for brain tumours was 6 times the amount seen in the general 
population when 14 brain tumours were reported in 1,321 subjects from 50 HNPCC 
kindreds (Vasen et al, 1996b). The occurrence ofbrain tumours and CRC was recognised 
in Turcot's syndrome which is characterised by colorectal polyposis, malignancies of the 
central nervous system, and cafe au lait spots. Now understood to be a molecularly 
heterogeneous disorder, both mutations in APC and MMR genes are believed to be 
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causative. Mutations in APC are associated with colonic polyposis and medulloblastomas 
seen in Familial Adenomatous Polyposis (F AP), while mutations in hMLH1 and hPMS2 
are associated with CRC's and glioblastomas seen in HNPCC (Hamilton et al, 1995). 
Like brain cancer, the significance of skin cancer in HNPCC was recognised 
through a syndrome, the Muir-Torre Syndrome (MTS). MTS is defined by the rare 
occurring sebaceous gland tumours, including sebaceous cell carcinomas and 
keratocanthomas (Hall et al, 1994a; Hall et al, 1994b ), along with internal malignancies 
including CRC and extracolonic cancers observed in HNPCC (Muir et al, 1967; Torre et 
al, 1968). An autosomal dominant mode of inheritance is also observed. This led Lynch 
et al (1985b) to suggest that both MTS and HNPCC share a common genetic basis. MTS 
has been identified in large HNPCC kindreds (Green et al, 1994; Paraf et al, 1995). 
Honchel et al (1994) linked MTS to MMR genes by demonstrating MSI in skin lesions. 
The association to MRR genes was confirmed when MTS was mapped to the hMSH2 
locus 2p22-21 (Hall et al, 1994b; Kolodner et al, 1994) and further when a germ-line 
mutation in exon 12 ofhMLH1 was identified in a MTS kindred (Bapat et al, 1996). 
Like stomach cancer the incidence of lung cancer has changed over time. It is 
now the number one cause of death due to cancer in both sexes. It is a fairly common 
cancer in the general population and is dramatically increasing in females (National 
Cancer Institute of Canada, 2002). On the other hand, a decreased incidence of lung 
cancer is observed in HNPCC kindreds (Pal et al, 1998). Currently no evidence exists to 
suggest that HNPCC kindreds are exposed to fewer carcinogens than the general public 
(Mecklin et al, 1986b ). 
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Familial breast cancer is responsible for 6-19% ofbreast cancer cases seen in the 
general population (Colditz et al, 1993; Slattery et al 1993). Although breast cancer is 
most common in females, it does occur in males (Boyd et al, 1999). Two breast cancer 
genes BRCA1 and BRCA2 are identified and mutations in these are estimated to increase 
the lifetime risk of breast cancer up to 85%. Ovarian cancer is a common malignancy 
seen in mutation carriers of the same genes and a slight increase in prostate cancer has 
been reported in male mutation carriers (Ford, 1994; Thompson et al, 2001). There is 
little evidence that breast cancer occurs as a tumour in HNPCC (Watson et al, 1993 ), 
however an increased risk has been reported (Itoh et al, 1990). Several studies have 
shown breast tumours with MSI (Aldaz et al, 1995; Risinger et al, 1996) and a loss of the 
MMR gene MLH1 (Risinger et al, 1996). Wooster et al (1994) found that MSI occurs in 
approximately 10-20% of sporadic breast tumours. An explanation for the low 
occurrence of breast cancer in HNPCC is that it could occur as a low penetrant tumour 
(Boyd et al, 1999). 
Several studies have supported the observation of multiple CRC' s occurring in 
individuals in HNPCC kindreds (Mecklin and Jarvinen, 1993; Wijnen et al, 1998b; Box et 
al, 1999; Wang et al, 1999). Shah et al (1993) suggested that double primary tumours 
infer the presence of genetic susceptibility. A study by Box et al (1999) reported a 40% 
incidence of metachronous and 18% incidence of synchronous CRC in HNPCC at 10 
years. Their study compared groups considered high risk for HNPCC (Amsterdam 
Criteria, suggestive HNPCC, and MMR defect) with population statistics. The HR group 
had rates significantly higher than general population rates for synchronous CRC ( 10.7%) 
and metachronous CRC (24.2%). This evidence supports the recommendation that a total 
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abdominal colectomy is justified in suspected HNPCC once a CRC has developed. 
Possibly in the future this recommendation will be based on genotyping. 
1.244 Pathology 
There are conflicting results concerning the use of pathological studies for the 
diagnosis of HNPCC. This is because of findings that a subset of sporadic CRC tumours 
display the MSI phenotype (Ruschoff et al, 1997) and also have similar 
clinicopathological features of HNPCC tumours displaying MSI. MSI tumours are 
usually proximally located, poorly differentiated (Jass et al, 1994; Ruschoff et al, 1997), 
mucinous, with neuroendocrine differentiation (Lynch et al, 1991; Lynch et al, 1993), 
diploid (Kouri et al, 1990; Frei et al, 1992; Losi et al, 1995), and signet-ring-cell-type 
carcinomas (Kim et al, 1994). 
It is suggested that a better survival is observed with certain types of pathology 
and this pathology is associated with HNPCC (Kokal et al, 1986; Schutte et al, 1987) or 
tumours displaying MSI (Lethe et al, 1993; Thibodeau et al, 1993; Berney et al, 2000). 
The nature of DNA content has been compared in HNPCC and sporadic CRC. The 
impression is that HNPCC tumours tend to be diploid in nature and sporadic CRC tends 
to be aneuploid. Diploid tumours behave less aggressively supporting a better survival 
(Losi et al, 1995). Also, a certain protective immune response (Branch et al, 1995) has 
been postulated to play a role in the observed favourable outcome. 
As adenomas are premalignant lesions they are associated with an increased risk 
of CRC. It is difficult to accurately determine the prevalence of adenomas in HNPCC. 
Nonetheless, a general consensus seems to be that the presence of adenomas increases 
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one's risk of CRC. Pathologists could draw attention to an individual at increased risk 
which could lead to better surveillance and removal of future adenomas in their 
premalignant state. 
1.245 Genotype-phenotype Correlations 
Today it is possible to estimate genotype-phenotype correlations and researchers 
are using identified mutation carriers from large HNPCC kindreds to achieve this. These 
correlations are poorly understood due to the phenotypic variation observed in a growing 
number of identified mutations, and because no mutation has given a distinctive 
phenotype. Numerous studies have been completed from various populations. 
Preliminary evidence suggests that extracolonic cancers occur more frequently in hMSH2 
than hMLH1 mutation kindreds (Vasen et al, 1996a; Jager et al, 1997; Lin et al, 1998; 
Peltomaki et al, 2001). A recent study by Green et al (2002) looked at the impact of 
gender and parent of origin on the phenotypic expression of HNPCC in a large 
Newfoundland kindred with a common hMSH2 mutation. The study concluded that the 
mutation was passed on by women more than by men; women were more likely to 
develop and die of CRC if they received the mutation from their fathers; and that men 
developed CRC and died of cancer earlier than women. It also estimated age of onset of 
certain cancers. Studies of this nature not only provide insights into the heterogeneous 
nature of HNPCC but also help improve the surveillance and care of known mutation 
positive HNPCC family members. However, many more questions arise demonstrating 
the complexity of the research. For example a variable age of onset has been noted in 
family members with the same mutation and also in different families with the same 
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mutation (Liu et al, 1996; Peltomaki et al, 2001); one quarter of extracolonic cancers in 
the mutation carriers were non-HNPCC tumours (Peltomaki et al, 2001). 
Of particular interest is the finding that a mutation in the hMSH6 gene leads to 
features atypical of HNPCC. This is characterised by a reduction in CRC, an increase in 
endometrial tumours and a delayed age of onset of both (Wagner et al, 2001 ). Wagner 
et al (200 1) reported an older mean age of onset than previously reported for HNPCC, age 
55 for CRC and age 55 for endometrial cancer. Other studies have also reported the 
delayed age of onset for hMSH6 by comparing hMSH6, hMSH2, and hMLH1 mutation 
carriers with CRC (Vasen et al, 1996) and with endometrial cancer (Wijnen et al, 1999); 
the mean age of CRC was 50 years for hMSH6 compared to 44 (hMSH2) and 41 
(hMLH1 ), and the mean age of endometrial cancer was 53 years (hMSH6) compared to 
49 (hMSH2) and 48 (hMLH1 ). Also the presence of MSI is observed less frequently in 
hMSH6 mutation carriers; tumours are either completely stable or display another 
mutator phenotype, a low MSI (Wu et al, 1999). 
1.246 Penetrance 
Penetrance is the probability that a gene will have any phenotypic expression at 
all. A reduced penetrance means that not all gene carriers will develop a cancer. Aarnio 
et al (1995) estimated that more than 20% of mutation carriers will never develop a CRC. 
Several studies have attempted to address the issue of penetrance (Aarnio et al, 1995; 
Vasen et al, 1996a; Vasen et al, 1996b; Dunlop et al, 1997; Lin et al, 1998b; Froggatt et 
al, 1999; Green et al, 2002), yet the level of penetrance remains unknown, although one 
suggestion is that there is a 92% penetrance by age 75 and 57% by age 50 (Vasen et al, 
26 
1996a). To add to the difficulty, inter gene variation is reported. Wagner et al (2001) 
reported on a large hMSH6 kindred that showed a reduced penetrance of CRC; only 7% 
and 32% of those affected had developed a CRC by age 50 and age 80 respectively. 
Both genetic and environmental modifying factors may a play a role in reduced 
penetrance. This has implications for the recommendation of preventative surgery for 
known or putative mutation carriers and leads to complications in genetic counselling. 
1.3 Other Hereditary Syndromes at Increased Risk for CRC 
Unlike HNPCC, Familial Adenomatous Polyposis (F AP) usually has a 
distinguishable phenotype. It is characterised by the presence of hundreds to thousands of 
polyps. In contrast to HNPCC, a higher rate of adenoma formation, but a normal adenoma 
to carcinoma progression, is observed in F AP (Vogel stein and Kinzler, 2002). F AP is not 
a cancer diagnosis but can lead to an increased cancer risk for an individual. The risk is 
believed to be extremely high as a 100% penetrance is believed for mutation carriers. 
F AP is caused by germline mutations in a tumour suppressor gene, the APC gene 
(Groden et al 1991; Nishisho et al, 1991). These mutations usually cause truncation of 
the encoded protein that can result in many different phenotypes; extracolonic 
manifestations of the disease include retinal lesions, osteomas, epidermal cysts, desmoid 
tumours, and brain tumours. Also, an attenuated form ofFAP (AFAP) exists where only 
a small number or more variable number of polyps develops (Spirio et al, 1993; Lynch et 
al, 1995). 
Investigations of the APC gene and F AP have lead to an improved understanding 
concerning mutations in the APC gene which are believed to be necessary for tumour 
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initiation in both FAP and sporadic cancer (Kinzler and Vogelstein, 1996). Studies of 
FAP have attributed to Knudson's "two-hit" hypothesis that explains the necessity of the 
loss of the wild type allele by somatic mutation enabling tumour initiation. Those 
identified as carriers of an APC mutation or manifesting the phenotype (colonic 
polyposis) should undergo prophylactic colectomy as a preventative measure. Genetic 
counselling and genetic testing is recommended for at risk individuals. Flexible 
sigmoidoscopy or colonoscopy for AF AP families is recommended at puberty for 
mutation positive individuals, or for those at risk in families with unknown mutations. In 
Newfoundland, at least 25 families are identified with classical F AP or AF AP. Five 
families are known to harbour an AF AP "founder" mutation and 2 families have 2 of the 
most common (20% of total known) FAP identified mutations. To date the other families 
have no mutation identified (J. Green, personal communication). 
Peutz-Jeghers syndrome (PJS) is characterised by multiple gastrointestinal 
hamartomatous polyps of the gastrointestinal tract, melanocytic macules, an early age of 
onset and autosomal dominant transmission (Spigelman et al, 1989). Pathology should be 
able to identify the specific polyps that usually form in the jejunum and lead to 
intussusception of the small bowel (Tomlinson et al, 1996). Although this blockage 
usually occurs before a cancer develops (Tomlinson et al, 1996), the affected individual 
or other family members have a high risk of developing various types of adult onset 
cancer including breast (54%), colon (39%), pancreas (36%), stomach (29%), and ovarian 
cancer (21%) (Giardiello et al, 2000). Germline mutations in a suspected tumour 
suppressor gene (STK11) have been identified in approximately half of recognised PJS 
families (Hemminiki et al, 1998; Jenne et al, 1998). The variable phenotype has led to 
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the difficulty of identifying this rare syndrome. In Newfoundland one family is known to 
the Medical Genetics program but PJS probably occurs in as many as 5 families (J. 
Green. personal communication). 
Juvenile polyposis syndrome (JPS) is an extremely rare condition that presents in 
childhood and that was originally believed to occur sporadically (Bussey et al, 1978). It 
is characterised by gastrointestinal hamartomatous polyps. Mutations in the germline of 
the MADH4 gene and in the gene-encoding bone morphogenic protein receptor 1A 
(BMPR1 A) are responsible for the autosomal dominantly pattern that is observed in some 
cases (Friedl et al, 2002). An increased risk of CRC has been reported in patients with 
JPS (O'Riordain et al, 1991). Its occurrence in the Newfoundland population is not 
reported (J. Critch, personal communication; J. Green, personal communication). 
1.26 Variation in Identifying HNPCC 
A fast developing molecular basis for the identification of HNPCC has led to a 
wide variation of opinion in the literature as to how best to identify HNPCC. Methods 
currently used to identify HNPCC include the use of a variety of clinical and molecular 
techniques. 
1.261 Clinical Criteria 
The first criteria used to identify HNPCC (originally referred to as Cancer Family 
Syndrome) were proposed by Henry Lynch (Lynch et al, 1981). The criteria were based 
on decades of research where large families were identified who had manifested the 
occurrence of cancers over generations. The criteria were general and non-specific, 
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including early age of onset, proximal location of colonic tumours, multiple primary 
tumours, vertical genetic transmission, common occurrence of endometrial and other 
adenocarcinomas in a kindred. 
International clinical criteria for the diagnosis of HNPCC have since been 
established (Vasen et al, 1991; Rodriguez- Bigas et al, 1997). This was first developed 
in 1990 by an international group of researchers know as the International Collaborative 
Group for HNPCC. The criteria were called the Amsterdam Criteria I (AC I): 
1. at least three relatives with histologically verified colorectal cancer, one of 
them being a first degree relative of the other two (F AP excluded); and 
u. at least two successive generations affected; and 
m. in one of the individuals, diagnosis of colorectal cancer before age 50 
The criteria would enable researchers from different geographic areas to present 
their HNPCC patients and would be instrumental in the identification of mutations. 
The establishment of these criteria was initially accepted but since that time it is 
widely criticized. The criterion does not consider extracolonic cancers, family size, and 
reduced penetrance (Percesepe et al, 1994, 1995; Ponz de Leon, 1996; Becket al1997; 
Bapat et a11999). The introduction ofthese strict criteria into clinical practice may result 
in failure to identify true HNPCC families. Individuals and their family members would 
miss valuable genetic counselling and screening. The identification of many mutations 
would be missed. However, the criteria were originally designed to eliminate those who 
did not have the condition (specificity) rather than to identify those who did (sensitivity) 
(Vasen et al, 1999), to guide the search for relevant genes, not to guide clinical practice. 
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Researchers continue to develop their own sets of minimum criteria for their 
publications. Many similarities exist between the criteria. Examples include the 
Modified Amsterdam Criteria (Bellacosa et al, 1996) which includes: 
L two CRC cases in first-degree in very small families that cannot be explained 
further; 
n. CRC affecting more than one generation; at least one CRC case diagnosed before 
age 55 years 
1. two first degree relatives affected by CRC, plus 
11. a third relative with an unusually early-onset neoplasm or endometrial cancer. 
Japanese criteria established the following criteria (Fujita et al, 1996): 
1. three or more CRC cases among first degree relatives; 
u. two or more CRC among first-degree relatives and any of the following: diagnosis 
before age 50 years; right colon involvement; synchronous or metachronous 
multiple CRC; and association with extracolonic malignancy. 
Other groups have used the AC 1 criteria and their own less strict criteria to 
capture families that might be suspected of an inherited condition. For example the 
Korean Hereditary CRC Registry used the AC 1 and their own "suspected HNPCC" 
criteria which includes: 
1. vertical transmission of CRC or at least two siblings affected with CRC in a 
family; 
u. development of multiple CRC tumours or at least one CRC diagnosed before the 
age of 50 years (Han et al 1996). 
In order to compensate for the narrow criteria, the ICG-HNPCC, in 1998, revised 
the existing criteria and developed a new set of criteria that includes extracolonic cancers 
(Vasen et al 1999); this is known as the "The Amsterdam Criteria II" (AC II). 
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This includes: 
1. at least 3 relatives with an HNPCC-associated cancer (CRC, cancer of the 
endometrium, small bowel, ureter, or renal pelvis); 
u. one should be a first-degree relative of the other; 
111. at least 2 successive generations should be affected; 
tv. at least 1 should be diagnosed before age 50; 
v. FAP should be excluded in the CRC case(s) if any; 
v1. tumours should be verified by pathological examination 
The HNPCC cancers included in this criterion were CRC, endometrial, small 
bowel, ureter, or renal pelvis. These cancers were selected, after a review of the literature 
(Watson et al, 1993; Aarnio et al, 1995; Vasen et al, 1996a; Vasen et al, 1996b; Sijmons 
et al, 1998; Vasen et al, 1999), because they demonstrated the highest relative and 
lifetimes risks in HNPCC kindreds. Other cancers, stomach, ovary, brain, and 
hepatobiliary tract were noted to be associated with HNPCC (Watson et al, 1993; Aarnio 
et al, 1995; Vasen et al, 1996a; Vasen et al, 1996b; Sijmons et al, 1998; Vasen et al 
1999). There was some debate over exclusion of these other extracolonic cancers. For 
example, stomach cancer presented more often in Asian compared to western HNPCC 
kindreds. The ICG-group decided that establishment of these criteria, and any future 
changes, should not be country specific. The criteria also omitted the need to identify 
CRC in kindreds. This was based on the presentation of kindreds with endometrial 
cancer which were also found to have MMR mutations (Wagner et al, 2001). 
1.262 Molecular Identification 
Tumour microsatellite instability (MSI) analysis is currently the primary approach 
used for the selection of CRC patients who that should undergo mutation analysis (Liu et 
al 1996; Aaltonen et al, 1998). As referred to earlier, MSI analysis may serve as a 
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prognostic marker. Also a recent study has demonstrated different responses of 
chemotherapy in MSI-high (MSI-H) and MSS tumours (Elsaleh et al, 2000). 
Micro satellite instability analysis utilises PCR for the detection of micro satellites that are 
present in tumour DNA and absent in normal DNA. MSI-H is reported in 63 to 92% of 
HNPCC tumours (Jass et al, 1995; Liu et al, 1996; Calistri et al, 2000; de Leeuw et al, 
2000) compared to reports of 12 to 28% of sporadic tumours (Aaltonen et al 1993; Ionov 
et al 1993; Lothe et a1 1993; Thibodeau et al, 1993; Young et al 1993; Aaltonen et al 
1994b; Kim et al1994; Calistri et al, 2000). Therefore MSI analysis lacks specificity for 
HNPCC (Aaltonen et al, 1994b). Cunningham et al (2001) suggested that the pathway 
leading to carcinogenesis in sporadic MSI-H CRC is probably different than in HNPCC 
CRC. Instead of germline defects in MMR genes an epigenetic mechanism causing 
hMLH1 inactivation may account for the MSI-H findings in sporadic CRC (Kane et al 
1997; Cunningham et al 1998; Herman et al 1998; Veigl et al, 1998; Wheeler et al 1999). 
This inactivation is caused by promoter hypermethylation of both hMLH1 alleles at the 
somatic level and probably accounts for approximately 8-12% of all CRC (Cunningham 
et al2001). 
Although the majority of tumours in HNPCC families are MSI-H, tumours have 
been found in HNPCC families that are microsatellite stable (MSS) (Farrington et al, 
1998; Bapat et al, 1999; Debniak et al, 2000; Liu et al, 2000 ). The presence ofMSI-H is 
reported in CRC and extracolonic cancers (Risinger et al, 1993; Aaltonen et al, 1994). 
The Bethesda guidelines were established to identify individuals who may benefit 
from further investigation, the first of which would be MSI analysis (Rodriguez-Bigas et 
al, 1997). Individuals must meet one of seven criteria. 
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These include: 
1. individuals with cancer in families that meet the Amsterdam Criteria; 
11. individuals with two HNPCC-related cancers, including synchronous and 
metachronous CRC or associated extracolonic cancers; 
111. individuals with CRC, plus CRC and/or HNPCC related extracolonic cancer and 
or/colorectal adenoma in a first-degree relative; at least one of the cancers 
diagnosed before age 45 years and the adenoma diagnosed before age 40 years; 
1v. individuals with CRC or endometrial cancer diagnosed before age 45; 
v. individuals with right-sided colorectal cancer with an undifferentiated 
histopathological pattern (solid/cribiform) diagnosed before age 45 years; 
v1. individuals with signet-ring cell type CRC diagnosed before age 45 years; 
v11. individuals with colorectal adenomas diagnosed before age 40 years. 
Confusions in the literature led the National Cancer Institute in 1997 to sponsor 
"The International Workshop on Micro satellite instability and RER Phenotypes in Cancer 
Detection and Familial Predisposition." The goals of this workshop were to review the 
current knowledge and to set guidelines to direct researchers so that comparison of data is 
possible at an international level. Five microsatellite markers were recommended and 
definitions for microsatellite analysis were agreed upon: CRC tumours are microsatellite 
stable (MSS) if no markers show instability, microsatellite instable low (MSI-L) if 1 of 5 
markers show instability, and microsatellite high (MSI-H) if 2 or more show instability 
(MSI-H >30% of loci examined, MSI-L <30% of loci examined, MSS no instability at 
any site (Boland et al1998). 
An abundance of information in a short period has resulted in difficulties in 
determining the diagnostic utility of the previously mentioned criteria. Syngal et al 
(2000) reported on the sensitivities and specificities ofthe AC I, AC II, modified AC, and 
the Bethesda Criteria for the detection of MMR mutations. The sensitivity of the AC I 
was 81% (95% CI 43-79) and specificity was 67% (50-85). Sensitivities ofthe modified 
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AC I and AC IT were 72% (95% CI 58-86) and 78% (95% CI 64-92) respectively. The 
sensitivity of the Bethesda Criteria was 94% (95% CI 88-1 00) and the specificity was 
25% (95% CI 14-36). The authors increased the specificity of the Bethesda guidelines to 
49% (95% CI 34-64) when they only included the 1st three criteria. They concluded that 
the latter approach was the most sensitive for the detection of MMR mutations. However 
the value of these criteria has not been established in a population based study. MSI-H is 
a sensitive predictor for the presence of MMR mutations but not specific to HNPCC as 
15% of sporadic CRC's also show MSI-H (Aaltonen et al, 1994b). 
Recently a new technique has been used in laboratories studying HNPCC. 
Immunohistochemistry (IHC) analysis is a technique which determines if a MMR protein 
is present or absent in tumour tissue by staining for antibodies which recognise the 
proteins. Lindor et a1 (2002) demonstrated that IHC analysis is specific (100%) and also 
highly sensitive (92.3%) for the detection ofMMR mutations (all IHC-deficient tumours 
were MSI-H whereas MSS tumours did not show loss of protein expression). This study 
only tested tumours for deficiency of hMLH1 and hMSH2. Also, tumour samples were 
selected from HNPCC registries which biases the analysis (therefore cannot be applied to 
the general population). 
Correlation between MSI and IHC analysis has been reported to range from 75% 
to 100% (Lindor et al, 2002). Fujiwara et al (1998) stained for hMSH2 in 39 selected 
MSI-H tumours from twenty HNPCC families (12 families were known mutation 
carriers) and reported sensitivity for germ-line mutations of hMSH2 of 86%, specificity 
of 93%, a positive predictive value of 92%, a negative predictive value of 88%, and 
overall accuracy of 90%. 
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Mutation detection can be done by several different methods, none of which are 
100% sensitive (Eng et al, 1997). The apparent choice for mutation detection in HNPCC 
has been exon-by-exon genomic sequencing, though this technique probably misses about 
20% of all mutations. Southern hybridization has been used to detect large deletions 
(Wijnen et al 1998a) and a new technique, MLPA (multiplex ligation-dependent probe 
amplification), has recently been developed for the detection of genomic deletions 
detection (Gille et al, 2002). Inter gene variation is observed in the size ofthe gene and 
the types of mutations seen. For example, large deletions are common in hMSH2 and 
missense mutations are common in hMLH1. 
A definitive diagnosis of HNPCC can only be established by demonstrating a 
germline mutation (Peltomaki et al1997). In approximately half of the families that meet 
the clinical (Amsterdam) criteria, germline HNPCC gene mutations have not yet been 
identified (Liu et al, 1996; Weber et al, 1997; Sijmons et al, 1998). However, germline 
mutations have been found in families not fulfilling the AC (Moslein et al, 1996; 
Nystrom-Lahti et al, 1996; Wijnen et al, 1997; Genuardi et al, 1998) and also in patients 
with early onset CRC and no family history (Liu et al, 1995b ). 
1.27 Population-Based Registries 
Registries are an invaluable source for the collection of vast amounts of data. A 
registry's aims include improving screening, early detection and treatment, and education 
about the particular condition. The registry will uphold these aims by collecting and 
updating relevant data and adapting these methods as science and technology improves. 
The use of registries enhances epidemiological research both retrospectively and 
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prospectively and does this in an interdisciplinary manner. The collaboration of 
numerous registries is possible when there is a need to increase the population size and to 
compare trends in populations. 
Registries have been used extensively for the management of hereditary 
syndromes (Jarvinen et al, 1984; Vasen et al, 1990) which has resulted in improved 
outcomes. For example, a decrease of mortality due to cancer in FAP from 57% to 6%, 
over 14 years is attributed to the development of the Ontario F AP registry (Madlensky et 
al, 1995). Population-based CRC and HNPCC registries exist in numerous countries 
such as Australia, Canada, Denmark, Finland, Italy, Japan, and United States. These 
registries are able to document and expand the family histories of incident CRC cases. 
By expanding family histories they will determine the contribution of hereditary cancers 
to the total cancer burden (Ponz de Leon, 1993) which in tum would lead to better 
services. The data collected includes a range from demographic information, family 
history, medical records, and now mutation testing results. Certain governmental 
regulations may exist to protect individual's right to privacy. Usually registrants in these 
specialised registries sign consent forms to be registered, and consent to the release of 
medical and family information, DNA and pathological specimens. 
1.28 Population-Based Studies 
Specialised population based HNPCC studies began in the late 1980's. The goals 
of these studies were to determine the frequency of HNPCC in the general population. 
Population-based studies provide an unbiased method of case ascertainment thus leading 
to improved estimates ofHNPCC both at a clinical and molecular level. The variety of 
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methods utilised in these studies cover a variety of definitions ofHNPCC and definitions 
of a population. Primarily, a variety of criteria has been used to collect and interpret 
family history data. 
An early study of the Finnish population, using 3 cases of CRC in first degree 
relatives as a clinical definition of HNPCC , reported that HNPCC was responsible for 
3.8-5.5% of all CRC and 29.4% of all CRC less than 50 years old (Mecklin et al, 1987). 
One of the first population based studies using the Amsterdam Criteria I reported on the 
experiences of an Italian registry after 6 years in existence. Using the AC I they reported 
a frequency of HNPCC 3.4 -4.5% (Ponz de Leon et al, 1993). A retrospective and 
prospective study conducted in the UK utilised the AC I, and less strict criteria which 
included 3 cases ofHNPCC cancers at any age. Of 1137 consecutive cases, 0.3% (n=3) 
fulfilled the AC I, and 1.4% (n=16) fulfilled their less strict criteria (Evans et al, 1997). 
Identifying HNPCC families has enhanced the ability to identify unique mutations 
in specific populations. Due to the recent advances in molecular genetics the methods to 
identify HNPCC have expanded to include a combination of microsatellite analysis, lliC 
analysis, and mutation testing. Salovaara et al (2000) reported on the population based 
molecular detection ofHNPCC in Finland. Of 535 consecutive CRC cases tested by MSl 
analysis, 66 (12%) were MSI-H and 18 (3.4%) of the 66 had germline mutations in either 
MLHl or MSH2. Only 3 of the 535 cases fulfilled the AC I, and another 2 cases fit more 
relaxed criteria. One of the 5 tumours had MSS and a germline mutation was not 
detected. The authors combined their data with a similar previous study (Aaltonen et al, 
1998) in the Finnish population for a total of 1044 cases. They reported that germline 
mutations account for 2. 7% (n=28) of CRC in their population. 
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Percesepe et al (2001) reported on the population-based molecular screening for 
HNPCC in an Italian region. Of 336 cases that were tested by MSI analysis, 28 (8.3%) 
were MSI-H. IHC analysis revealed lack of expression of the hMLH1 protein in 20 of the 
28 MSI-H cases (71.4%). Promoter hypermethylation of the hMLH1 gene was 
implicated in 14 (70.0%) of these MSI-H cases. Although hMSH2 expression was 
normal in all cases, one (0.3%) case had a germ line mutation in this gene. The authors 
explained that the mutation occurred at the COOH terminus causing expression of the 
protein during IHC analysis. The most recent study (Katballe et al, 2002) reported an 
even lower HNPCC frequency of 1.1% in the Danish population. Subjects were 
classified as HNPCC if they were either AC1 or AC2 along with MSI- H or MSI-L and/or 
harboured an hMLH1 or hMSH2 mutation. 
1.281 Canadian Studies 
An early population-based study reported on the frequency of HNPCC in 
Southern Alberta. The selection criteria were all CRC's diagnosed in individuals less 
than age 50 over a 15 year period. They identified HNPCC in 12 families (3.1%). They 
also proposed that if less strict criteria for HNPCC were used then another 25 families 
could have been added to their total with a HNPCC frequency of 9. 5% (Westlake et al 
1991). 
Ontario developed a CRC registry in 1997. It is the first population-based family 
CRC registry to be developed in Canada. Their specialised registry was created on the 
basis of the need to strengthen strategies for managing high risk CRC which in tum 
would strengthen the management of sporadic CRC. It mirrored existing breast cancer 
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registries within the province. The many components and goals of the registry include: 
determining the genetic epidemiology of CRC, gene discovery, primary prevention, 
psychosocial research, screening, and treatment. This would be accomplished by 
improving resources for CRC research in a multidisciplinary approach. Cotterchio et al 
(2000) reported,on their first year experiences. They had a 61% response rate and found 
that low risk families were less likely to participate. A high participation rate is 
necessary in order to ensure that information obtained in the study is applicable to the 
general population. An approximately 65% response rate has been reported in other CRC 
studies (Le Marchard et al, 1999; Kampman et al, 1999). Issues preventing participation 
include time commitments, confidentiality, high mortality rates, and selection. A 
population-based study of this nature has not been carried out in Newfoundland. 
Newfoundland is accredited with the reputation of an attractive place to conduct 
genetic research. Little out migration, after settlement of the province began in the 
1700's, has resulted in Newfoundland's unique genetically isolated population {Bear et al, 
1987). The cooperation of large families has provided the means to identify and define 
inherited conditions in Newfoundland. For example, a cluster of four large kindreds 
have been identified that have a Multiple Endocrine Neoplasia, type 1 {MEN-1) founder 
mutation, a common nonsense mutation (R460X) (Olufemi et al, 1998). Similar clinical 
manifestations ofMEN-1 in the 4 families from a common geographic location led to the 
discovery of this founder mutation. Linking of these large families to a common ancestral 
location was possible from analysis of phenotypes (Green, thesis 1995). Ongoing 
research into other hereditary disorders, including polycystic kidney disease, von Rippel-
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Lindau disease, and cardiomyopathies, are providing unique insights into the clinical and 
molecular management of these autosomal dominant hereditary conditions worldwide. 
Newfoundland HNPCC families have been described by a number of key 
individuals within the province. Dr. Jane Green and Dr. Roger Green are two geneticists 
in Newfoundland who have had an interest in HNPCC. Currently there are 41 HNPCC 
families identified within the province. There are numerous others that are suspected 
HNPCC families. The identification and collection of family information has contributed 
to the development of improved services and to a better understanding of hereditary CRC 
within the province and also worldwide. The discovery of a large Newfoundland HNPCC 
kindred was crucial in mapping the first HNPCC gene, hMSH2 (Peltomaki et al, 1993; 
Leach et al, 1993). The mutation, an A-T transversion at the +3 position ofthe splice-
donor site of exon 5 (referred to as the "family C" mutation in Newfoundland) is the most 
common recurring hMSH2 mutation worldwide and was shown to have a founder effect 
in Newfoundland. Following discovery of the same mutation in American and European 
families, haplotype analysis disproved the worldwide founder-effect (Froggatt et al, 
1999). In Newfoundland the mutation occurs in 13 families, 4 of whom have been traced 
back to an original ancestor. Individuals in these families have and can have pre-
symptomatic gene testing to identify those who are at greater risk of developing a cancer. 
Approximately 176 individuals are carriers of the "family C" mutation. Currently, 
screening for the "family C" mutation is recommended for all Newfoundland HNPCC 
families. This family has been used in analysis by researchers from around the world 
(Aaltonen et al, 1993; Froggart et al, 1999; Green et al, 2002). 
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1.3 Purpose 
The purpose of the pilot study is to determine the proportion of hereditary CRC 
within the Avalon Peninsula, Newfoundland, over the period 1997-1998. In addition, the 
objective is to discover possible obstacles that will impede the development of a 
Newfoundland Familial Colorectal Cancer Registry. 
Primary Research Objectives 
1. To determine the proportion of Hereditary vs. Sporadic CRC cases on the Avalon 
Peninsula. 
2. To identify families affected by inherited CRC. 
3. To describe the molecular characteristics ofHereditary vs. Sporadic CRC. 
4. To evaluate current methods of diagnosing HNPCC. 
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CHAPTER2:METHODS 
2.1 Design 
This ts a population-based study in which CRC probands were identified 
retrospectively during a given time period and two investigations were undertaken 
including a family history study and laboratory study of CRC probands, using DNA and 
tumour. Joint Masters Degree and PhD Degree projects in Clinical Epidemiology and 
Medical Genetics were designed in which the family history studies were performed by 
myself and the laboratory studies were performed by Angela Hyde. In this report, only 
the laboratory results in those with completed family histories will be reported. Only a 
brief description of the laboratory methods will be given here as they will be reported in 
detail in the PhD thesis, of Angela Hyde, to be prepared in the near future. 
2.2 Ethical Considerations 
Ethics approval was granted by the Human Investigation Committee (Ill C) of the 
Faculty of Medicine, Memorial University of Newfoundland following a review of the 
proposal (Appendix B). Approval for the project was also obtained from the two Health 
Boards involved in the study: the Health Care Corporation of St. John's (Research 
Proposal Approval Committee) and the Avalon Peninsula Health Board (see Appendix 
B). 
A number of concerns arose while applying for ethics approval. One of the 
objectives of this pilot project was to obtain ethics approval that would establish the 
process for ethics applications for similar projects in the future. The nature of the study 
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was instrumental in developing a template for future studies of its type in Newfoundland. 
The first application was submitted on July 24th, 2000 and full approval for the project 
was given on Oct 12,2000. 
The application included a detailed description of the objectives, rationale, data 
collection, time commitment, finances, study consent form, and study materials of the 
project. Included in the consent form was consent to participate in genetic research. The 
participants were informed of measures to be taken in order to ensure their privacy. 
There were no identifiable risks to participants except a blood sample taken may cause 
some bruising. Participants could withdraw from the study at any time and all family 
history data collected to that point would be destroyed however, all clinical and 
demographic data collected to that point would not be destroyed but kept in the database. 
2.3 Family History Study 
2.31 Study population 
The population studied included all incident CRC cases in 1997 and 1998, 
identified through the provincial tumour registry at the Newfoundland Cancer Treatment 
and Research Foundation (NCTRF). A review of the meditech coding system (a regional 
hospital reporting tool), and of pathology reports was also used in order to identify other 
cases that may have been overlooked by the registry. The Newfoundland Center for 
Health Information has developed population estimates for each Health Board Region: 
Health Board regions 1 and 2 are found on the Avalon Peninsula, and include 
approximately half (250,000) of the Newfoundland and Labrador population. Because 
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half of the island's population resides on the Avalon Peninsula, and extensive travel to the 
rest of the province was not possible, these Health Board regions were chosen for this 
study. The Health Science Centre, St. Clare's Mercy Hospital, The Salvation Army 
Grace General Hospital, and Carbonear General Hospital served the region at the time. 
The Salvation Army Grace General Hospital closed in 2000. The most recent year with 
completed information in the NCTRF registry was 1998. We identified 179 potential 
probands for the years 1997 and 1998 who fit the inclusion and exclusion criteria. 
2.311 Inclusion Criteria 
Eligible cases were defined as all males and females diagnosed with CRC (ICD9 
codes 153 and 154), in either 1997 or 1998 who were between the ages of 20-69 
inclusive, and resided in either Health Board Region 1 or Health Board Region 2. If a 
proband was deceased an appropriate next of kin was asked to participate for the 
collection of the family history. Some probands had previously been identified as having 
a hereditary cancer by the Medical Genetics program here at Memorial University. These 
individuals and the data collected by the Medical Genetics group were included in the 
study. 
2.312 Exclusion Criteria 
Ineligible cases were defined as CRC cases with age greater than or equal to 70, 
and those who did not reside in either Health Board regions 1 or 2 at time of diagnosis. 
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2.313 Ascertainment of Study Participants 
The NCTRF registry records all cases of cancer as well as diagnosis information, 
demographic data, treatment data, and physician data. All attending physicians and 
family physicians when necessary were contacted in order to obtain consent from 
individuals eligible for the study (See Appendix C). A proband was excluded if the 
physician making the initial contact felt that the individual was not appropriate for this 
study. In the case of a deceased proband, a next of kin was identified by the physician to 
serve as a proxy. 
Initial contact with the patient or next of kin was made by the physician. A 
standardised letter (Appendix D) was developed to aid the physician in this process. This 
letter introduced the project and the research team. The letter also provided the potential 
participant with an opt in or opt out method of study enrolment. The individual did this by 
contacting the physician's office or the research team by telephone. Those who did not 
respond were called by a third party (an employee of the NCTRF) and asked if they were 
interested in participating in the study. After oral consent was obtained, a consent form 
was sent to the participant (Appendix E). The consent form explained the study in detail. 
After the signed consent form was returned, an appropriate time was arranged for an 
interview with the study participant. 
2.314 Baseline Characteristics 
The NCTRF registry and a review of medical charts were used for the collection 
of baseline characteristics which included demographic and clinical data. An extraction 
form (Appendix F), identifying the proband only by a unique identity number, was 
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constructed and used to collect this data. The baseline characteristics included: birth 
place, residence, sex, age, age of diagnosis, status (alive or dead), pathological 
descriptions of tumours, symptoms leading to diagnosis, named treating physicians, 
diagnosing and treating hospitals, and treatments. 
The tumour was defined as occurring in the proximal colon if it was located in the 
cecum, ascending colon, or the transverse colon, and the tumour was defined as occurring 
in distal colon if it was located in the descending or sigmoid colon or in the rectum. 
2.32 Collection of Family History Data 
An interview was held at the convenience of the participant. Participants were 
interviewed at the Health Sciences Centre, Carbonear General Hospital, or the 
participant's residence. Some participants requested to fill out a form and others 
completed a telephone interview. During the interview details of the study were 
described and the participants were given the opportunity to ask questions or discuss any 
concerns. At this time they were also asked to read and sign the Newfoundland and 
Labrador Medical Genetics program consent form (Appendix D) and a release of medical 
information form (Appendix D). A standardised form for the collection of family 
histories was provided by the Medical Genetics program, and was used as a guide for the 
collection of a three generation pedigree. Details about types of cancer, age at diagnosis, 
date of birth, current age, age of death, cause of death, other related medical information, 
place of birth, and place of residence were recorded about family members. A brief 
medical history, reported by the proband, including symptoms leading to diagnosis, 
treatments and any other medical history was recorded. 
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At this time, the importance of reviewing the medical charts of possibly affected 
family members was explained to the study participant, in an attempt to include their 
family member's participation in the study. Participants were provided with copies of a 
release of medical information form to give to family members who were affected with a 
cancer. Participants previously referred to the Medical Genetics program were re-
interviewed where possible. Permission was obtained to review the Medical Genetics 
chart and information obtained in an interview was added to that obtained from the chart. 
2.33 Primary Outcome Family History Study 
The primary outcome of interest was the risk of HNPCC in a proband and his/her 
family. A proband's three generation family history was collected to determine this risk: 
first degree relatives include siblings, offspring and parents; second degree relatives are 
aunts, uncles, nieces, nephews, grandparents and grandchildren; cousins are third degree 
relatives. 
2.34 Classification of Primary Outcome 
Pedigrees were constructed using the computer package Cyrillic 2.1. Under the 
supervision ofDr. Jane Green, probands were classified as having hereditary or sporadic 
cancer. This included 3 risk categories for HNPCC: 1) high risk; 2) intermediate risk (as 
defined by the OFCCR); 3) low risk. It was also noted if a proband potentially had FAP. 
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HNPCC Risk Criteria 
HIGH RISK 
• Amsterdam Criteria 
At least 3 family members with CRC; one is a first degree relative of the 
other two; two consecutive generations represented; at least one 
individual younger than 51 years at diagnosis; F AP excluded. 
• Amsterdam II Criteria 
At least 3 family members with a HNPCC cancer ( colorectal, endometrial, 
small bowel, ureter, or renal pelvis); one is a first degree relative of the 
other two; two consecutive generations represented; at least one 
individual younger than 51 years at diagnosis; F AP excluded. 
• Age and Cancer Modified Amsterdam Criteria 
At least 3 family members with a OFCCR HNPCC cancer ( colorectal, 
endometrial/uterine, gastric, small bowel, gastroesophageal, liver, 
pancreas, biliary duct, hepato-biliary, ovarian, kidney, ureter, brain, 
lymphoma); one is a first degree relative of the other two; two consecutive 
generations represented ; at least one individual younger than 61 years at 
diagnosis; F AP excluded. 
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INTERMEDIATE RISK 
1. Proband and two relatives with any of the following cancers: colorectal, 
endometrial/uterine, gastric, small bowel, gastroesophageal, liver, 
pancreas, biliary duct, hepato-biliary, ovarian, kidney, ureter, brain, 
lymphoma AND 2 of the 3 are 1st degree relatives. 
2. Proband and any family member with one of the above ca ~ 35 years. 
3. Proband~ 50 and relative with CRC ~50 (1st and 2nd degree relative only). 
4. Proband ~ 3 5 years. 
5. Proband with multiple primary CRC. 
6. Proband with other primary HNPCC cancer listed above. 
7. Proband meets at least 1 pathologic criterion: Multiple primary CRC, 
multiple adenomas (~ 5), inflammatory bowel disease (IBD) Ulcerative 
colitis (UC), Crohn's disease, active chronic colitis, colitis-associated 
neoplasia, or other (concurrent or previous) cancer. 
LOW RISK 
• Proband does not meet high or intermediate risk categories 
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2.342 HNPCC Cancers 
According to the Amsterdam criteria, HNPCC cancers are CRC, cancer of the 
endometrium, small bowel, ureter, or renal pelvis. For the Age and Cancer Modified 
Amsterdam Criteria, and the intermediate criteria, HNPCC cancers (recommended by the 
OFCCR) include cancers of the endometrium, stomach, small bowel, gastroesophagus, 
liver, pancreas, biliary duct, hepato-biliary system, ovary, kidney, ureter, brain, and 
lymphoma. In this study the above cancers, in all risk criteria, were classified as HNPCC 
cancers. However, for the low risk criteria, it is unlikely that these cancers are HNPCC 
cancers. 
2.343 Cancer Diagnosis in Relatives 
All reported family cancers were used in this analysis. An attempt was made to 
consent family members and examine medical records to confirm reported cancers. We 
also used the NCTRF as a resource to confirm reported cancers. Information including 
name (first, last, maiden), age, date ofbirth and residence of family members was used to 
search the registry. 
2.344 Non-familial 
A proband was considered to be non-familial or sporadic if he/she did not meet 
the high risk criteria or the intermediate risk criteria for HNPCC. 
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2.345 Informative vs. Uninformative Families 
We developed a system to categorise families as either informative or 
uninformative. Informative families were defined as those having six relatives at risk in 
two consecutive generations for whom we had confirmed or unconfirmed medical history. 
Parents and their siblings must have reached age 60 or developed a HNPCC cancer. 
Uninformative families were defined as those failing to meet the informative criteria. 
2.4 Laboratory Study 
Pathology specimens (normal and tumour tissue) from probands were obtained for 
examination by microsatellite (MSI) analysis and immunohistochemistry (IHC) analysis. 
Normal tissue served as a control. If the participant was willing, a blood sample was 
drawn for study at a later date. 
2.41 Study Population 
2.411 Inclusion Criteria 
Participants were included in the molecular study after tissue samples were 
reviewed by principle investigator Dr. Des Robb, a pathologist at Memorial University 
Hospital. Carcinoma arising within a polyp was included only if there was invasion into 
the stalk 
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2.412 Exclusion Criteria 
Cases were excluded if tumour was not resected, or the tissue sample was not 
appropriate (e.g. not enough tumour, multiple polyps in the same block, non-invasion in 
the sample). 
2.413 Retrieval of Pathological Specimens 
All Pathology reports identifying CRC cases occurring in the 1997 and 1998 
calendar years were requested from the Health Sciences Centre, St. Clare's Mercy 
Hospital, The Salvation Army Grace General Hospital, and Carbonear General. They 
were then sorted by age categories: 20-69, and the remaining. Each report was reviewed 
carefully to ensure that the case was an adenocarcinoma. The meditech system was then 
used to eliminate all cases that did not reside on the Avalon Peninsula at the time of their 
diagnosis (n= 39). A final list was sorted and submitted to each of the hospitals. Paraffin 
. blocks containing formalin-fixed tumour and normal tissue, removed at the time of 
surgery, were collected. 
2.42 Primarv Outcome Molecular Study 
MSI analysis and IHC analysis were performed on the tissue of each proband. 
2.421 Microsatellite Analysis 
The normal and tumour DNA from each patient's tissue was compared for MSI at 
a total of five microsatellite markers, including two mononucleotide markers BAT 26, 
BAT 25, and three dinucleotide markers D2Sl23, D17S250 and D5S346. These are well 
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characterized markers known to be very informative when testing for MSI, and are the 
accepted panel of markers described in literature for MSI analysis of CRC (Boland et al, 
1998). DNA was extracted from the tumour and normal blocks, using the Qiagen 
DNeasy Tissue Kit (cat# 69504) (Appendix G). PCR reactions were carried out on the 
DNA for each of the markers used. The PCR products were run on acrylamide gels. 
Initially each case was examined by two independent investigators, Ms. Angela 
Hyde and Dr. Ban Y ounghusband. When it was confirmed that both investigators were 
reaching the same conclusions Angela Hyde continued this process alone. If there were 
any questionable results then Dr. Y ounghusband assessed the situation and if necessary 
the procedure was repeated. Each case was described as either MSI-high (2: 30% markers 
demonstrate instability) MSI-low (< 30% demonstrated MSI), or MSS (no markers 
exhibited MSI) after results had been obtained for each of the five markers (Boland et al 
1998,; Thibodeau et al 1998.) MSI-high indicates that at least 40%, or two of the five, 
markers examined showed instability in the tumour DNA. MSI-low indicates that only 
one of the five markers show instability. When this result was obtained a second set of 
markers was used, including Bat 40, D17S787, D18S58, D20S100, and D7S519. The 
final description of MSS indicates microsatellite stability, whereby none of the five 
markers examined show instability in the tumour DNA. MSI-L tumours were reported as 
MSS for the purpose of this project. Loss of Heterozygosity (LOH) was also noted. LOH 
was noted if an allele was absent from the tumour but present in the normal tissue and the 
tumour was considered to be MSS. 
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2.422 Immunohistochemistry (IHC) Analysis 
Microscope slides were prepared of formalin-fixed paraffin-embedded tissue 
containing approximately 50% tumour and normal tissue. The tissue was stained by 
immunohistochemistry using antibodies against three proteins MSH2, MLH1, and MSH6. 
These proteins are coded by mismatch repair genes that are responsible for over 90% of 
mutations leading to HNPCC. Large Volume DAKO LSAB and System method was 
used for staining with the MLH1 and MSH6 antibodies. The DAKO ENVISION method 
was used to stain for the MSH2 antibody. These staining procedures are sensitive, 
versatile, and enable the processing of numerous specimens in just over one hour (Dako 
instructions) (Appendix H). 
Dr. Des Robb and Angela Hyde reviewed the slides. If the nucleus of the cell 
stained a brown color then the protein was present but if the nucleus failed to stain brown 
then the protein was absent. Two methods of grading the slides were developed. 
Intensity of the staining was determined by a 4 point scale: 0 = no stain; 1 = weak stain; 
2= moderate stain; and 3 = strong stain. Frequency of staining (% positive tumour cells) 
was determined by a 5 point scale: 0= all cells negative; 1 = (1-10%); 2 = (11-50%); 3= 
(51-75%); and 4= (> 75%). 
If a patient carries a mutation affecting the antibody epitope, such as a truncating 
mutation in one of these genes, the tumour will not express a full copy of the associated 
protein. In that case the antibody may not bind, and the gene containing the disease 
causing mutation can be determined. This determination will be of immense value when 
searching for the mutation itself 
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2.5 Family History and Laboratory Study 
Correlations were made comparing family history classification, MSI and me 
analysis. Correlations were also made between MSI analysis and tumour location. 
2.51 Diagnostic Utility of the Tests 
Sensitivity and specificity analysis for microsatellite classification for HNPCC 
cases was defined using family history as the gold standard. In this study sensitivity was 
defined as MSI-H by MSI analysis in high risk cases, and specificity was defined as MSS 
by MSI analysis in sporadic cases. Sensitivity and specificity analysis for laboratory 
methods for detection of HNPCC cases was defined using Family history as the gold 
standard. Sensitivity was defined as MSI-H or absence of expression ofhMSH6 by me 
in high risk cases. Specificity was defined as MSS and expression of all protein 
expression by me in sporadic cases. Sporadic cases included informative families only. 
2.6 Follow-up 
A follow-up letter was sent to all probands and any participating family members. 
This letter explained all study outcomes. Each participant was informed of the family 
history risk assessment. They were not given the results of the lab tests. These tests were 
performed for research purposes and not clinical purposes. A referral to a geneticist was 
given to those individuals suspected of having a hereditary form ofCRC. 
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CHAFTER3:RESULTS 
3.1 Baseline Results 
Proposal Development 
179 incident cases of CRC on the Avalon Peninsula during 1997 and 1998 were 
identified. Figure 1 summarises the recruitment process. 
FIGURE 1: Recruitment of study participants (n= 79) 
TOTAL# IDENTIFIED 
= 179 
~ 
LETTERS SENT 
= 168 
(93.9%) 
~ 
CONTACT 
= 158 REFUSAL 
(94.0%) =52 (33.0%) 
*Not done AGREE 
=27 =106 
(25.5%) (67.0%) 
FINAL 
PARTICIPANTS 
=79 
(74.5%) 
*not done because of difficulties making contact. They are being followed up by 
theNFCCR 
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After initial contact letters were sent out by treating physicians, 79 individuals 
participated and 52 opted out. There was contact with another 29, but their participation 
in the study has not been confirmed. There was no contact with 19 individuals. 
3.12 Recruitment of Study Participants 
The initial method used to identify study participants was the NCTRF tumour 
registry. This method identified 178 CRC cases. This group is representative of 
approximately half of the Newfoundland CRC cases for 1997 and 1998. Eight of the 
178 cases were excluded: 4 were inappropriately diagnosed, 2 were recurrences, 1 
appeared twice, and one did not live in the selected regions. All Pathology reports and 
discharge summaries of the St. John's Health Care Corporation (meditech) were also 
searched for CRC cases. There were 14 individuals identified who were not on the 
NCTRF list. These were reported to the NCTRF and they are now registered. Five of 
these cases were excluded on the basis that 4 were inappropriately diagnosed and the 
identity of one was questionable. The other nine were included in the study. Of the total 
eligible group of 179 (Table 1), 168letters were sent out, and contact was made with 158 
patients. Fifty-two patients declined to participate, 27 patients need further follow-up and 
79 participated in the current study. Thus contact was made with 88.3% of eligible 
participants and 50.0% of those contacted enrolled in this current study. 
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TABLE 1: Identification of participants through the NCTRF, Meditech, and 
pathology reports 
IDENTIFYING 
RESOURCE 
NCTRF 
MEDITECH 
178 Identified 
8 excluded - 4 inappropriate diagnosis 
- 2 recurrences 
- 1 appeared twice 
- 1 not in region 
170 APPROPRIATE 
6 Additional Identified 
3 excluded - 2 inappropriate diagnosis 
- 1 questionable identity 
3APPROPRIATE 
PATHOLOGY REPORTS 8 Additional Identified 
2 excluded - 2 inappropriate diagnosis 
6APPROPRIATE 
Total Selected for recruitment = 179 
NCTRF Recheck 
(Summer 2002) 8 out of 9 additional colorectal cancers identified through 
Pathology reports and meditech were registered with the 
NCTRF 
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Of 79 study participants there were 65 probands and 14 proxies (Table 2). Ten 
proxies were identified because the proband was deceased. Two were identified as the 
most appropriate contact to provide a detailed family history and two were identified as 
guardians. Diagnosis was in 1997 in forty-one cases and in 1998 in 38 cases. The total 
included 34 females (43%) and 45 male probands (57%). The mean age of CRC 
diagnosis was 56.1 years, and the age range of CRC diagnosis was 36-69 years of age. 
Twenty-six of these cases occurred in the proximal colon, 45 occurred in the distal colon, 
and the location ofthe remaining (n=8) was not specified. The participants resided in a 
total of 30 towns on the Avalon Peninsula within Health Boards 1 and 2. Sixty-one 
individuals resided in Health Board 1, and 18 individuals resided in Health Board 2 at the 
time of their diagnosis. Parents and grandparents originated from many different areas of 
the province (n= 124) or from outside ofNewfoundland (n= 18). 
At-test was conducted to determine if there was a difference in age for 
participants and non-participants. Pearson chi-squared test was conducted to determine if 
there was difference in either gender or tumour location for participants and non-
participants. There was no significant difference between participants and non-
participants for age of diagnosis (p= 0.48), gender (p= 0.51), and tumour location (p= 
0.60). This would suggest that the group studied is representative of the whole population 
for these factors. 
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Table 2: Characteristics ofProbands (n = 79) and of Non-Participants (n = 100) 
PRO BANDS NON-PARTICIPANTS 
Mean Age (yrs) colorectal cancer diagnosed 56.1 56.6 
Median age (yrs) 57 58.0 
Age Range 33 (36-69) 44 (25-69) 
Male 45 (57%) 52 (52.0%) 
Female 34 (43%) 48 (48.0%) 
Dead 11 (13.9%) 46 (46.0%) 
Tumor Site 
Proximal colon 26 (32.9%) 39 (39.0%) 
Distal colon 45 (57.0%) 53 (53.0%) 
Not specified 8 (10.1%) 8 (8.0%) 
Diagnosis Year 
1997 41 (51.9%) 54 (54.0%) 
1998 38 (48.1%) 46 (46.0%) 
Newfoundland Health Board 
Health Care Corporation St. John's 61 (77.2%) 74 (74.0%) 
Avalon Health Board 18 (22.8%) 26 (26.0%) 
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3.13 Data Collection 
Family history was collected from 79 study participants. Sixty-eight study 
participants were interviewed in person either at the Health Sciences Centre, Carbonear 
General, or in the individual's home. Two individuals reported their medical family 
history by standardised mail-in form. One chose to conduct a telephone interview. 
Another eight requested that family history previously obtained by the Medical Genetics 
program be used. Medical records from the NCTRF and hospitals were collected on 
study participants and some of their affected family members. The collection of family 
medical records was difficult and will be continued, where necessary, by a genetic 
counsellor. 
Twenty-six families were previously identified through the Medical Genetics 
program at the Health Sciences Centre in St. John's, Newfoundland. Twenty pro bands 
were seen themselves, and for 6 families another family member had been seen. Dr. 
Jane Green was responsible for the collection of family history and clinical data from 
these families. The reasons for referral to Medical Genetics program varied but most 
were to rule out a hereditary cancer. For 12 study participants the Medical Genetics file 
were reviewed after initial interview and after permission was given. Eight participants 
gave permission to access their chart initially so that a repeat of the information was not 
necessary. Six participants were not aware that they family history was previously 
collected by the Medical Genetics program. It was on review of the study pedigrees that 
Dr. Green recognised these 6 families. 
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3.2 Family History Study 
3.21 Risk Classification 
Three generation family histories were collected from all study participants. Two 
study participants (#11, #12) are first cousins and are therefore considered to have the 
same risk for HNPCC. They were included in the analysis only once. Therefore there 
were a total of78 families for risk analysis (Table 3). 
Table 3: HNPCC Risk Classification for 78 families 
IDGH(ACI) 
IDGH(ACIT) 
Age and Cancer Modified AC 
(included families in which youngest cancer was 51-60, 
OFCCR HNPCC cancers) 
N 
6 
1 
15 
INTERMEDIATE 1 14 
(no age limit, 2 of 3 affected are 1st degree, any OFCCR HNPCC cancer) 
INTERMEDIATE 2 
(Relative with CRC :S 35) 
INTERMEDIATE 5 
(Double primary) 
INTERMEDIATE 7 
(pathology) 
LOW 
Total 
AC -Amsterdam Criteria 
1 
3 
4 
34 
78 
% 
Total 
7.7 
1.3 
19.2 
17.9 
1.3 
3.8 
5.1 
43.6 
>lAllA >IIi-
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Twenty-two families (28.2%) were considered High Risk (HR.) for HNPCC. Six 
of these families (27.3%) fulfilled the Amsterdam Criteria I (AC I), 1 family (4.5%) 
fulfilled the Amsterdam Criteria IT (AC IT), and 15 families (68.2%) fulfilled the Age and 
Cancer Modified Amsterdam Criteria. 
Twenty-two families (28.2%) were considered Intermediate Risk (IR) for 
HNPCC. Fourteen of these probands (63.6%) fulfilled the intermediate criteria based on 
having 2 relatives with any of the HNPCC cancers (intermediate 1 (IR.-1)). One proband 
(4.5%) fulfilled the intermediate criteria based on having a relative with colon cancer~ 
35 years old (IR.-2). Three probands (13.6%) fulfilled the intermediate criteria based on 
having had multiple primary colon cancers (IR.-5). Four probands (18.2%) fulfilled the 
pathological criterion for intermediate risk (IR-7) of which 3 (75.0%) had multiple 
adenomas as well as CRC and one (25.0%) had inflammatory bowel disease (IBD). No 
families fulfilled the intermediate criteria 3, 4, and 6. 
Thirty-four families (43.6%) did not meet either the HR. or IR criteria and were 
therefore considered Low Risk (LR) for HNPCC. 
3.22 Family Informativeness 
Of 34 low risk families, 21 (61.8%) were informative, and 13 (38.2%) were 
uninformative. Reasons for uninformative families included: less than 6 primary (siblings 
and parents) or secondary (aunts and uncles) relatives at risk (n= 3); less than six siblings 
at risk who were 2: and 60 years old (n=3); insufficient family history (n=7). 
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3.23 Description of Cancers 
Tables 4 through 8 summarize the occurrence of different types of cancer in each 
of the HR. groups, theIR group1, and the LR study group. These tables show that CRC 
was the most common occurring cancer in the HR, IR, and LR families. 
Fifteen different cancers were reported for the AC I group (Table 4). Stomach 
cancer was the most common extracolonic cancer. It occurred once in each of five 
families. 
Five different cancers were reported for the AC IT group (Table 5). Endometrial 
cancer was the most common extracolonic cancer, it occurred 2 times in this family. 
Twenty-four different cancers were reported for the Age and Cancer Modified AC 
group (Table 6). Breast cancer was the most common extracolonic cancer occurring 17 
times in 5 of 15 families. Twelve of the breast cancers occurred in the same family, a 
suspected hereditary breast cancer family (189). In this group stomach cancer was the 
most common HNPCC cancer occurring 13 times in 8 of 15 families. 
Eighteen different cancer types were reported for the IR group 1 (Table 7). In this 
group stomach cancer was the most common extracolonic cancer occurring 13 times in 9 
of 14 of the IR families. 
Seventeen different cancer types were reported for the LR group (Table 8). Breast 
cancer (n=34) was the most common extracolonic cancer in the LR group. Eleven of the 
breast cancers occurred in the same family, a suspected hereditary breast cancer family 
(116). 
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Table 4: Cancers in Amsterdam Criteria I Families (n=6) 
Family 11 Family 19 Family 35 
Age Age Age 
Mean # Min Max Mean # Min Max Mean # Min Max Mean 
44.2 7 28 49 39.1 4 47 64 56.0 5 44 81 60.6 
-
2 40 43 41.5 0 
- - - 0 - - -
84.0 1 68 68 68.0 1 53 53 53.0 1 40 
-
0 
- - -
0 
- - -
0 
- - -
44.0 0 - - . 0 . - - 0 . . . 
. 0 . . . 1 53 53 53.0 0 . 
- -
36.0 0 - - - 0 - - . 0 - - -
54.0 0 - . - 0 - - - 0 - . -
43.0 0 - - - 0 - . - 1 56 56 56.0 
-
0 -
- - - -
. . 1 40 40 40.0 
-
0 -
-
. 0 
- - - 1 62 62 62.0 
0 
- - -
1 46 46 46.0 0 . - -
67.0 0 - - - 0 - - - 0 - - . 
44.0 0 . . - 0 - . - 0 . . . 
0 . . . 0 - . . 2 40 83 61.5 
Family 110 Family 156 
Age Age 
# Min Max Mean # Min Max Mean 
4 48 69 60.0 4 39 66 52.5 
0 - - - 0 - - -
0 -
- - 1 ? ? ? 
0 - - - 0 
- - -
0 
- - - 0 
- - -
0 
- - - 0 -
-
-
0 - - - 0 - - . 
0 
- - - 0 
- - -
0 
- - - 0 - - -
0 -
- - 0 - - -
0 - - - 0 - - -
0 - - - 0 -
- -
0 . . 
- 0 . - . 
0 - - . 0 - . -
0 . . - 0 - - - I 
i 
Table 5: Cancers in Amsterdam ll Criteria Family (family 122) 
CANCER # Age 
Min Max Mean 
Colo rectal 2 34 36 35 
Endometrial 2 37 40 38.5 
Ovary 1 40 40 40.0 
Oesophagus 1 43 43 43.0 
Tongue 1 60 60 60.0 
Unknown 1 41 41 41.0 
*age unknown 
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Table 6: Cancers in Age and Cancer Modified Amsterdam Criteria Families (n=l5) 
CANCER # of Families Age 
Min Max Mean 
Colo rectal 50 15 45 94 61.9 
(*1) 
Stomach 13 8 50 89 69.1 
(*1) 
Endometrial 2 1 38 58 48.0 
Brain 2 2 62 62 62.0 
(*1) 
Ovary 3 3 60 75 67.5 
(*1) 
Pancreas 6 3 52 69 61.7 
Small Bowel 1 1 54 54 54.0 
Kidney 1 1 47 47 47.0 
Gallbladder 1 1 58 58 58.0 
Oesophagus 1 1 59 59 59.0 
Uterus 2 2 47 47 47.0 
(*1) 
Breast 17 **5 28 72 51.3 
(*1) 
Prostate 3 3 64 73 67.7 
Lung 7 5 31 69 50.2 
(*1) 
Bladder 1 1 64 64 64.0 
Basal cell cancer 1 1 40 40 40.0 
Ocular Melanoma 1 1 38 38 38.0 
Testicular 2 1 2 35 19.0 
Multiple myeloma 1 1 70 70 70.0 
Cervix 3 3 31 67 47.7 
Leukemia 1 1 13 13 13.0 
Leg 1 1 15 15 15.0 
Ear 1 1 85 85 85.0 
Mouth 1 1 43 43 43.0 
Unknown 3 2 86 86 86.0 
(*2) 
*age unknown 
**one family with 12 breast cancers (family 189) 
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Table 7: Cancers in Intermediate Risk 1 families (n= 15) 
CANCER # #ofFamHies Age 
Min Max Mean 
Colo rectal 37 14 43 81 60.6 
(*1) 
Stomach 13 9 49 81 64.0 
(*3) 
· Endometrium 3 2 57 83 72.7 I 
I 
Liver 2 2 ? ? ? 
(*2) 
Lymphoma 1 1 78 78 78.0 
Gastroesophagus 1 1 52 52 52.0 
Bladder 1 1 ? ? ? 
(*1) 
Breast 10 7 56 93 66.4 
(*5) 
Prostate 9 7 50 75 62.2 
Lung 5 4 57 78 67.0 
(*1) 
Lip 1 1 ? ? ? 
(*1) 
Throat 3 3 40 69 55.0 
Melanoma 1 I 54 54 54.0 
Cervix 3 3 36 74 57.0 
Basal cell 1 1 87 87 87.0 
Bone 1 1 76 76 76.0 
Leukemia 1 1 61 61 61.0 
Skin 4 3 56 65 60.3 
(*l) 
Unknown 8 5 79 87 83.0 
(*5) 
*age unknown 
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Table 8: Cancers in Low Risk Families (n=34) 
CANCER # # of Families Age 
Min Max Mean 
Colo rectal 46 34 36 80 57.0 
Stomach 6 6 50 75 64.8 
Ovary 1 1 59 59 59.0 
Pancreas 2 2 49 72 60.5 
Brain 1 1 60 60 60.0 
Kidney 2 2 50 66 58.0 
Lymphoma 1 1 78 78 78.0 
Prostate 13 9 60 92 76.8 
(*3) 
Lung 5 4 49 72 58.4 
Breast 34 **15 30 87 59.1 
(*1) 
Leukemia 4 3 25 78 50.5 
Throat 3 2 55 88 71.5 
(*1) 
Cervix 1 1 65 65 65.0 
BCC 1 1 63 63 63.0 
Melanoma 1 1 55 55 55.0 
Skin 2 1 50 58 54.0 
Bone 2 2 55 72 63.5 
Unknown 13 11 45 92 65.1 
(*2) 
*age unknown 
**one family with 11 breast cancers (family 116) 
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3.24 Confirmed HNPCC Cancers 
The NCTRF tumour registry and the Newfoundland and Labrador Medical 
Genetics clinic files were searched to confirm reported cancers. Table 9 shows that these 
resources confirmed 207 of 404 (51.2%) reported cancers. Thirty-two cancer cases could 
not be confirmed because the individuals did not reside in Newfoundland. Twenty-one of 
the 207 cancers (10.1%) were reported incorrectly which resulted in a change in a 
classification for two families (families 7 and 35, both HR.). 
Table 9: Confirmed cancers NCTRF and Medical Genetics Program for All 
Risk categories 
Total NCTRF Searched 
Total Confirmed 
Total Med Genetics Searched 
Total Confirmed 
*TOTAL SEARCHED 
TOTAL CONFIRMED 
Low 
# % 
82 
23 28.0 
19 
11 57.9 
*Total searched excludes those out of province 
Inter 
# % 
116 
44 37.9 
18 
10 55.6 
404 
207 
High 
# % 
53 
16 30.2 
148 
103 69.6 
51.2 
71 
3.25 Previously Identified Families by Medical Genetics Program 
Twenty-one families were previously seen for suspected hereditary CRC (Table 
10). Two probands were identified as part of the Newfoundland "family C"; a previously 
recognised Newfoundland HNPCC family with a known hMSH2 germ-line mutation. 
The proband (#122) is positive for the mutation. Her pedigree drawn suggests that her 
family is at HR. for HNPCC. The second proband (#ll5) was part of a branch of the 
"family C". Her immediate pedigree does not suggest that she is at risk for HNPCC. 
Testing for the "family C" mutation is currently on going for this individual. Three 
families (#'s116, 180, 189) were previously seen for suspected hereditary breast cancer. 
One proband (#112) was recognised to be related to individuals with Bardet-Biedl (BBS) 
syndrome. Another proband (100) was recognised as a relation to a rod cone dystrophy 
family. 
Table 10: Families previously referred to Medical Genetics (n= 26) 
N % 
Total 
Referred previously to Medical Genetics 
Proband 
Other family member 
Not referred 
Reason for Previous referral 
Colorectal Cancer 
Breast Cancer 
Bardet-Biedel syndrome 
Other 
20 
6 
53 
N 
21 
3 
1 
1 
72 
25.3 
7.6 
67.1 
3.26 Non-Participants and Those Previously Referred to Medical Genetics 
Due to limitations in the design of the study it was not possible to collect the 
reasons for non-participation. The opt-out plan consisted of two options. Pro bands who 
received letters and wished to opt-out were to call their family doctor or the research team 
where an answering machine was available. 
Ten individuals who opted out were identified to be under the care of the Medical 
Genetics department (Table 11 ). One individual was a member of the "family C". 
Another is currently being tested for Peutz-Jegher syndrome. Three were deceased, two 
of whom met intermediate risk criteria for HNPCC, and it is Dr. Green's opinion that one 
of the deceased would have participated in this study. Another was a member of a 
breast/ovarian cancer family, another had 2 primaries and therefore would be intermediate 
risk, another was definitely at a low risk for HNPCC and the other was diagnosed at a 
young age. 
Table 11: Non-Participant Families Previously Referred to Medical Genetics 
(n= 10) 
Referred previously to Medical Genetics 
Colorectal cancer 
(Family C) 
Breast/ Ovarian 
N 
10 
9 
(1) 
1 
73 
3.3 Laboratory Study 
3.31 Microsatellite Instability Analysis 
Microsatellite instability analysis was completed for 74 of79 cases. Analysis was 
not possible for two individuals due to an inappropriate sample. Three are pending. 
Sixteen cases (21.6%) had high frequency microsatellite instability (MSI-H) tumours. 
Fifty-eight cases (78.4%) had microsatellite stable (MSS) tumours. Five of the 58 MSS 
cases had low microsatellite instability (MSI-L) tumours. LOH occurred in 2 MSS cases 
(Table 12). 
Table 12: Microsatellite Analysis Results for 74 cases 
Complete 
High Microsatellite instability 
*Microsatellite stable 
Incomplete 
In progress 
No sample 
Total 
TOTAL 
*Low microsatellite instability= 5/58 
N 
16 
58 
74 
3 
2 
79 
% 
21.6 
78.4 
% 
Total 
20.3 
73.4 
3.8 
2.5 
74 
3.32 Immunohistochemistry Analysis 
Immunohistochemistry analysis (IHC) was completed for 71 of79 (89.9%) cases. 
Six cases are pending. Analysis was not possible for two cases due to an inappropriate 
sample. Sixteen cases (22.5%) had negative expression for one of the three proteins: 
seven cases (9.9%) are negative for hMLH1, two cases (2.8%) are negative for hMSH2, 
four cases (5.6%) were negative for hMSH6, and three cases (4.2%) were negative for 
hMSH2 and hMSH6. Fifty-five cases (77.5%) had positive expression of all three 
proteins (Table 13). 
Table 13: Immunohistochemistry Analysis Results for 71 cases 
Complete 
Protein Absence 
hMLH1 negative 
hMSH2 negative 
hMSH6 negative 
N 
hMSH6 and hMSH2 negative 
7 
2 
4 
3 
Protein expression 55 
Incomplete 
Pending 
No sample 
Total 
TOTAL 71 
6 
2 
79 
% 
9.9 
2.8 
5.6 
4.2 
% 
Total 
8.9 
2.5 
5.1 
3.8 
75 
3.4 Family Risk and Molecular Correlation 
There is family risk and molecular data for 71 cases. Two cases are members of 
the same family therefore were only included once. 
IDGHRISK 
Twenty cases, high risk for HNPCC with their molecular data, were completed 
(Figure 2 & Figure 3). Analysis for five out of six cases fulfilling the Amsterdam criteria 
I were completed: one case (1.4%) was MSI-H and negative for hMSH2, another case 
(1.4%) was MSS and negative for hMSH6, and three cases (4.3%) were MSS and positive 
for all proteins (Figure 3). The case (7.0%) fulfilling the AC IT was MSI-H and negative 
for both the hMSH2 and hMSH6 proteins. Fourteen of the 15 Age and Cancer Modified 
AC cases were completed: four cases were MSI-H of which 3 were negative for hMLH1 
and one was negative for hMSH6, ten cases were MSS and positive for all proteins. 
Figure 2: Family and Molecular Data for High Risk Families (n=20) 
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Figure 3: Family and Microsatellite Analysis for 20 Families 
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INTERMEDIATE RISK 
Eighteen cases intermediate risk for HNPCC with molecular data were completed 
(Figure 4 and Figure 5). Ten cases (14.1%) of the Intermediate 1 criteria are complete: 
two cases (2.8%) were MSI-H of which one was negative for hMLH1 and the other was 
negative for hMSH2 and hMSH6, eight cases (11.3%) were MSS and positive for all 
proteins. The one case (1.4%) in the intermediate 2 criteria was MSI-H and negative for 
hMSH2 and hMSH6 proteins. Three cases (4.2%) were complete for the intermediate 5 
criteria of which one case was MSI-H and negative for the hMLH1 protein and the two 
MSS cases were positive for all proteins. The 4 completed cases in the intermediate 7 
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criteria were MSS and positive for all proteins. Four intermediate cases (5.6%) do not 
have IHC analysis completed: two cases are microsatellite stable and two are incomplete 
for microsatellite analysis. 
Figure 4: Family and Molecular data for Intermediate Families (n= 18) 
Intermediate Risk 
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Figure 5: Family and MicrosateUite Analysis for 18 Families 
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LOW RISK 
Thirty-two of 34 (94.1%) low risk cases (45.1% of 71 families) had laboratory 
results completed, but only nineteen of these (59.4%) were from informative families 
(Figure 6). Of 19 informative cases, 3 were MSI (15.8%) and 16 were MSS (84.2%). For 
the informative MSI cases the h.MLH1 protein was negative in one case, the hMSH6 
protein was negative in another, and no loss of protein . was observed in the 3rd case. 
Another informative case was MSS with negative expression of the hMSH6 protein. 
Only one of the 13 uninformative cases (7. 7%) was MSI and it was negative for the 
h.MLH1 protein. 
Figure 7: Family and Molecular Data for 32 Informative and Uninformative Low 
Risk Families. 
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3.5 Pathology and MicrosateHite Instability Analysis Correlation 
Twelve (75%) of 16 MSI-H tumours were located in the proximal colon, two 
(12.5%) were located in the distal colon, and for two MSI-H tumours (12.5%) the 
location was unknown. The proportion ofMSI-H and MSS tumours at each tumour 
location is shown in Table 14. To determine if there is an association between location of 
tumour and microsatellite analysis a pearson chi-square test was conducted. There is a 
significant difference (p= 0.002) in tumour location between the MSI-H tumours and 
MSS tumours. 
Table 14: Tumour Location and Microsatellite Instability Analysis for 74 cases 
Tumour Site 
Proximal colon Distal colon Unspecified 
N % N % N % 
MSI-H 12 46.2 2 4.9 2 28.6 
MSS 14 53.8 39 95.1 5 71.4 
Total 26 41 7 
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3.6 Diagnostic Utility of Methods 
The sensitivity of micro satellite instability analysis in predicting cases that are 
high risk for HNPCC was 30.0% (Table 15). The specificity ofmicrosatellite instability 
analysis in predicting cases that do not have HNPCC was 84.2%. The proportion of cases 
that had MSI-H tumours and that have HNPCC (positive predictive value) was 66.7%, 
and the proportion of cases that had MSS tumours that do not have HNPCC (negative 
predictive value) was 53.3%. 
Table 15: Sensitivity and Specificity Analysis for Microsatellite Analysis Identifying 
HNPCC (n=38 families) 
HIGH LOW TOTAL 
MSI-H 6 3 9 
MSS 14 16 30 
Total 20 *19 39 
*informative families 
Two tumours (one HR and one LR) were MSS and did not express the hMSH6 
protein. The sensitivity of either laboratory methods (MSI-H by microsatellite analysis or 
loss of protein expression by IHC) in predicting cases that are high risk for HNPCC was 
35.0% (Table 16). The specificity of the methods in predicting cases that do not have 
HNPCC was 78.9%. The proportion of cases that have a positive laboratory finding 
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(MSI-H or loss of protein expression) and that have HNPCC (positive predictive value) 
was 63.6%, and the proportion of cases that have negative laboratory results (MSS and 
expressed all proteins tested) and do not have HNPCC (negative predictive value) was 
53.6%. 
Table 16: Sensitivity and specificity analysis for laboratory results diagnosing 
HNPCC (n=38 families) 
MSI-H 
or 
hMSH6-
MSS 
+ 
All proteins 
expressed 
Total 
*informative families 
High 
7 
13 
20 
Low Total 
4 11 
15 28 
*19 39 
83 
3. 7 Family Descriptions 
3.71 ffiGH RISK (n= 22 families) 
Amsterdam Criteria (n=6 families) 
MSI-H and hMSH2- (n= 1) 
Pro bands number 11 (pedigree 1) and 12 (pedigree 2) are first degree cousins. 
Proband number 11 is a 45 year old female who was diagnosed with a well-differentiated 
cancer of the cecum at age 41. Pathology revealed the presence of 4 polyps: 2 
hyperplastic, 1 tubular adenoma, and one mucin producing. The colon cancer was 
identified upon screening recommended by the Dr. Green. She was born in St. John's 
where she now resides, and both parents and maternal and paternal grandparents also 
originated from St. John's. The pedigree constructed consists of 56 relatives. She has 4 
first degree relatives: 2 siblings, and her parents. Her father was diagnosed with 2 
HNPCC cancers: a CRC at age 41 and a stomach cancer at 68. He has also had a number 
of polyps (multiple tubular and villous adenoma) removed. Her mother was diagnosed 
with a breast cancer at age 61. There were no other cancers reported in first degree 
relatives. She has 17 second degree relatives. Four HNPCC cancers were reported; three 
in paternal relatives, and one in a maternal relative. A paternal aunt was diagnosed with 
endometrial cancer at age 43. A paternal uncle was diagnosed with CRC at age 38 and 
another paternal uncle was diagnosed with a CRC at age 49. A maternal aunt was 
diagnosed with a stomach cancer at age 55. Two non-HNPCC cancers were reported 
including a lung cancer in a maternal uncle and a breast cancer in her maternal 
grandmother. There were no other cancers in second degree relatives. Two paternal 
cousins (siblings) were each diagnosed with two HNPCC primaries. One cousin was 
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diagnosed with a CRC at age 28 and age 39. His sister was diagnosed with CRC at age 
38 and endometrial cancer at age 40. This cousin is also a proband (12) in this study. 
There were no other cancers reported in this family. Both probands were previously 
referred to the Medical Genetics program. 
Proband number 12 (pedigree 2) is a 44 year old female who was diagnosed, in 
1997, with a well differentiated cancer of the cecum at age 38. This diagnosis was made 
on routine screening. Pathology also revealed the presence of a hyperplastic polyp. She 
was diagnosed with a second primary, an endometrial cancer, in 1999. She underwent a 
total hysterectomy and bilateral salpingo-oophorectomy. She was born in St. John's 
where she now resides. Her mother and her maternal grandparents originated from 
Harbour Grace. Her father and paternal grandparents originated from St. John's. The 
pedigree constructed consists of 35 relatives. She has 6 first degree relatives: 4 siblings, 
and her parents. Two HNPCC cancers were reported in her first degree relatives. Her 
brother was diagnosed with 2 CRC at age 28 and age 3 9. There were no other cancers 
reported in first degree relatives. Her mother is 75 and well. Her father is 71 and was 
reported to have had 6 polyps removed but records are not available, and whether he had 
subsequent screening is not known. Hyperplastic polyps were reported in 2 brothers. She 
has 19 second degree relatives. Three HNPCC cancers were reported in her second 
degree relatives. A paternal uncle was diagnosed with a CRC at age 49, another paternal 
uncle was diagnosed with a CRC at 41, and a third paternal uncle had CRC at 41 and 
stomach cancer at 68. A paternal aunt was diagnosed with an endometrial cancer at age 
44. There were no other reported cancers in second degree relatives but her first cousin 
(proband 11) had a CRC at age 41. 
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MSS and hMSH6- (n= 1 family) 
Proband number 7 (pedigree 3) is a 62 year old male who was diagnosed, in 1998, 
with a moderately differentiated cancer of the sigmoid colon. Pathology revealed the 
presence of one small polyp. He was born in St. John's where he now resides. His 
mother originated from Brookfield. His maternal grandparents originated form 
Bonnavista Bay North. His father and paternal grandfather originated from Hodge's 
Cove. His paternal grandmother originated from Winterton. The pedigree constructed 
consists of 52 relatives. He has 5 first degree relatives: 1 child, 2 siblings, and parents. 
His mother was diagnosed with a breast cancer at age 43 and died at 75 due to heart 
complications. Polyps were reported in his son at age 38 and in 2 siblings. No other 
cancers were reported in first degree relatives. He has 20 second degree relatives. A 
maternal uncle was diagnosed with a colon cancer at age 60. His paternal grandfather 
was diagnosed with an oesophageal cancer at age 66. A maternal cousin was diagnosed 
with a colon cancer at age 50. A maternal aunt was diagnosed with a cancer, type 
unknown at age 60. Review of the pedigree with Dr. Green identified that he was a 
member of a previously referred family to the Medical Genetics program. The proband 
did not appear to be aware of this. Seven HNPCC cancers were previously reported in his 
maternal relatives compared to his report of two HNPCC cancers. Some differences were 
noted. A maternal aunt was diagnosed with a CRC at age 28, a kidney cancer at age 36, a 
uterine cancer at age 43 and a coccyx cancer at age 44. The maternal uncle had bladder 
cancer at age 54 with extension to the colon. A maternal aunt was diagnosed with CRC at 
age 57. His maternal grandmother was diagnosed with stomach cancer (younger than age 
84). No other cancers were reported in second degree relatives. A maternal cousin was 
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diagnosed with CRC at age 36 and another maternal cousin was diagnosed with a CRC at 
age 43 and a pancreatic cancer at age 44. Extension of his maternal grandfather's family 
indicates HNPCC cancers in other branches. 
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MSS and no loss (n= 3 families) 
Proband number 19 (pedigree 4) is a 56 year old female who was diagnosed, in 
1998, with a well-differentiated cancer of the sigmoid colon at age 51. She was born 
Chance Cove, Trinity Bay where she now resides. Her mother and maternal grandparents 
originated from Chance Cove. Her father originated from Norman's Cove. Her paternal 
grandparents originated from Chance Cove. The pedigree constructed consists of 55 
relatives. She has 12 first degree relatives: 4 children, 6 siblings, and parents. Two 
HNPCC cancers were reported in first degree relatives. Her mother was diagnosed with a 
CRC at age 64. She died at age 70 after the cancer had reoccurred. Her brother was 
diagnosed with CRC at age 47. Two non-HNPCC cancers were reported which include a 
lung cancer in her father and a cervical cancer in a sister. There were no other cancers 
reported in first degree relatives. One daughter and three siblings had colonoscopy 
investigations. She has 36 second degree relatives. Two HNPCC cancers were reported. 
A maternal uncle was diagnosed with CRC at age 62 and another maternal uncle was 
diagnosed with a liver cancer at age 53. There were no other cancers reported in this 
family. She was on the waiting list for the Medical Genetics program. Records are 
currently being retrieved by the department. 
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Proband number 3 5 (pedigree 5) is 54 year old male who was diagnosed, in 1998, 
with a moderately differentiated cancer of the sigmoid at age 49. He had a recurrence a 
year later and has also been diagnosed with liver metastasis. He was born in Wesleyville, 
Bonavista Bay and now resides in St. John's. His mother and maternal grandparents 
originated from Griquet. His father and paternal grandparents originated from Pound 
Cove, Bonavista Bay. The pedigree constructed consisted of 59 relatives. He has nine 
first degree relatives: seven siblings, and parents. The proband reported that his mother 
was diagnosed with a uterine cancer at age 60, a maternal uncle was diagnosed with a 
leukemia, a maternal aunt was diagnosed with a cancer, type unknown, and his maternal 
grandmother was also diagnosed with a cancer, type unknown. There were no other 
cancers in this family as reported by the proband. Review of the pedigree with Dr. Green 
identified that the proband's family had previously been referred to the Medical Genetics 
program. Comparisons were made between the two pedigrees and a different story 
emerged. HNPCC cancers were previously documented. The proband's mother was 
diagnosed with uterine cancer at age 56 and also a cancer of the sigmoid colon at age 62. 
She is still alive. The maternal uncle that he had reported as having leukemia in fact had 
a CRC at age 67. A maternal aunt had leukemia at age 62. Another maternal uncle had a 
CRC at age 81 and a cancer of the cerebellum at age 83. Two maternal cousins were 
diagnosed with HNPCC cancers. They include a CRC at age 44 and a stomach cancer 
(age not given). His father died from kidney failure at age 69. Extension of the 
maternal grandmother's family identifies HNPCC in other branches of her family. The 
grandmother's sister had an astrocytoma at age 69, and her brother had a CRC at age 63. 
Another brother died at age 42 from heart complications. All three have offspring with 
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HNPCC cancers including CRC, liver, brain, and other possible HNPCC cancers 
including skin and transitional cell cancer of the bladder. 
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Proband number 110 (pedigree 6) is a 67 year old male who was diagnosed, in 
1998, with a moderately differentiated cancer of the rectosigmoid junction at age 62. 
Pathology revealed the presence of hyperplastic polyps. He was born in Harbour Deep, 
White Bay and now resides in St. John's. His mother and maternal grandparents 
originated from Harbour Deep, White Bay. His father and paternal grandmother 
originated from Fair Island, Bonavista Bay. His paternal grandfather originated form 
Swain's Island. The pedigree constructed consists of 51 relatives. He has 10 first degree 
relatives: 6 children, 2 siblings, and parents. His parents were both diagnosed with 
possible HNPCC cancers. His mother was diagnosed with CRC at age 69 and she died at 
the age of 83. His father was diagnosed with stomach cancer at age 79. No other cancers 
were reported in first degree relatives. One brother was scoped. The proband has 19 
second degree relatives. Four HNPCC cancers were reported in his second degree 
relatives. A maternal aunt was diagnosed with CRC at age 61. Another maternal aunt 
was diagnosed with CRC at age 48. It was reported that his paternal grandfather was 
diagnosed with stomach and CRC and died at age 72. This proband was previously 
referred to the Medical Genetics program. Extension of the paternal grandfather's family 
identifies possible HNPCC in other branches of his family. Two of the grandfather's 
brothers were reported to have HNPCC cancers. One of these brothers had three sons 
who were reported to have CRC and stomach cancers. 
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Proband number 157 (pedigree 7) is a 45 year old female who was diagnosed with 
a well-differentiated cancer of the rectosigmoid junction at age 39. Polyps were indicated 
(no details given). She was born in St. John's where she now resides. Her mother and 
maternal grandfather originated from Mobile, Southern Shore. Her maternal grandmother 
originated from Tors Cove. Her father and paternal grandfather originated from Little 
Paradise, Placentia Bay (PB). Her paternal grandmother originated from St. Leonard's, 
PB. The pedigree constructed consists of 78 relatives. She has 6 frrst degree relatives: 1 
child, 3 siblings, and parents. Her father was diagnosed and died with a CRC at age 66. 
There are no other cancers reported in first degree relatives. Two of her sisters were 
scoped. She has 31 second degree relatives. Four HNPCC cancers were reported in 
second degree relatives. A paternal aunt was diagnosed with a CRC at age 58. A 
paternal uncle was diagnosed with a CRC at age 47. Her paternal grandmother was 
diagnosed with a stomach cancer. Her maternal grandfather was diagnosed with an 
esophageal cancer. Non-HNPCC cancers reported include two prostate cancers in 
paternal uncles, and lung cancer in a maternal uncle and maternal aunt. There were no 
other reported cancers in second degree relatives. Two paternal cousins (siblings) had 
tubular adenomas on screening scopes. This proband was previously referred to the 
Medical Genetics program. Extension of the paternal grandmother's family and the 
maternal grandmother's family identifies a history of cancers. There are no available 
records. 
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Amsterdam II Criteria (n= 1 family) 
MSI-H and hMSH2- and hMSH6- (n=l family) 
Proband number 122 (pedigree 8) is a 41 year old female who was diagnosed, in 
1997, with a well differentiated cancer of the rectum at age 36. Pathology revealed the 
presence of a hyperplastic polyp. At age 37 she was diagnosed with a cancer of the 
endometrium. She was born on Bell Island. Her maternal grandparents originated from 
Pound Cove, BB. The pedigree constructed consists of 45 relatives. She has seven first 
degree relatives: 2 children, 3 siblings, and parents. Her mom was diagnosed with two 
HNPCC cancers, an ovarian cancer and an endometrial cancer at age 40. No other 
cancers were reported in first degree relatives. Three HNPCC cancers were reported in 
second degree relatives. A maternal uncle was diagnosed with a CRC at age 34 and an 
oesophageal cancer at age 43. Her maternal grandfather was diagnosed with a tongue 
cancer at age 60 and a HNPCC cancer, stomach cancer, at age 63. Her maternal 
grandmother died at age 41 of a cancer, type unknown. The proband is a member of the 
previously identified family ("Family C") which has a known mutation of hMSH2. The 
proband has been seen by the Medical Genetics program and she and three others in 
family 122 have tested positive for this mutation. 
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Age and Cancer Modified Amsterdam Criteria (n= 15 ) 
MSI-H and hMSH6- (n= 1 family) 
Proband number 17 (pedigree 9) is a 63 year old male who was diagnosed, in 
1997, with a well differentiated cancer of the ascending colon at age 57. Chart review 
indicated three adenomatous polyps throughout the colon in 1997. He was also diagnosed 
with a stomach cancer at age 49. He was born in St. John's where he now resides. His 
mother and maternal grandmother originated from St. John's. The origin of his maternal 
grandmother was not given. His father and paternal grandparents also originated from St. 
John's. The pedigree constructed consists of 114 relatives. He has 23 first degree 
relatives: 1 child, 20 siblings, and parents. Three HNPCC cancers were diagnosed in first 
degree relatives. CRC was diagnosed in his mother at age 60 and she died at age 84. 
Stomach cancer was diagnosed in a sister at age 64 who died a year later, and also in a 
brother at age 69. Three siblings died at a young age from tuberculosis, another died just 
after birth and another died at age 55 from complications of rheumatoid arthritis. His 
daughter was diagnosed with ulcerative colitis at age 26 and two brothers have been 
diagnosed with Crohns disease. His father was diagnosed with lung cancer at age 67, and 
died at age 69. No other cancers were reported in his first degree relatives. He has 57 
second degree relatives. Two HNPCC cancers, both CRC, were reported in a niece and a 
nephew (siblings) in their 40's. There were no other reported cancers in second degree 
relatives. There were a number of cancers reported in paternal cousins. Two HNPCC 
cancers, both CRC, were reported at age 63 and at age 65. Other cancers reported 
include a lung cancer at age 45, and three others type unknown. The proband was 
previously referred to the Medical Genetics program. Correspondence between Alberta 
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and the Medical Genetics program, regarding the proband's niece who was diagnosed 
with CRC last year at age 4 7 is on going. 
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MSI-H and hMLHl- (n=3) 
Proband number 14 (pedigree 1 0) is a 62 year old male who was diagnosed, in 
1998, with a moderately differentiated cancer of the cecum at age 58. Two small polyps 
are reported. A cousin was identified as the proband's proxy because he is mentally 
delayed. He was born in Point LaHaye, St. Mary's Bay (SMB) and now resides in St. 
Mary's. His mother and maternal grandparents originated from Point LaHaye, SMB. 
There is no paternal history available. The pedigree constructed consists of 16 relatives. 
He has 1 first degree relative, his mother. His mother was diagnosed with a HNPCC 
cancer, CRC, at age 69. He has 6 second degree relatives. Two HNPCC cancers are 
reported in his second degree relatives. A maternal aunt was diagnosed with CRC at age 
57 and a recurrence at age 84. His maternal grandmother was diagnosed with CRC in 
her 70's. The proband was previously referred to the Medical Genetics program. 
Proband number 50 (pedigree 11) is now deceased. She was diagnosed, in 1997, 
with a poorly differentiated cancer of the cecum at age 64. Her daughter was identified as 
her proxy. She resided in Dunville, Placentia Bay. Her father originated from Isle 
Valen, Placentia, and her mother originated from Dunville, Placentia Bay. The pedigree 
consists of 56 relatives. She has 14 first degree relatives: 5 children, 7 siblings, and 
parents. Five HNPCC cancers were diagnosed in first degree relatives. Her mother was 
diagnosed with a CRC at age 69 and died at age 72. Her father was diagnosed with a 
CRC at age 62 and died that year. Three siblings were diagnosed with colon cancer; two 
sisters at ages 51 and 64, and a brother at age 53. No other cancers were reported in first 
degree relatives but two other siblings had polyps. A daughter had a tubular adenoma 
removed at age 41 and two other daughters had polyps removed. The proband has 42 
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second degree relatives. A nephew was diagnosed with a testicular cancer at age 3 5 and a 
niece was diagnosed with a breast cancer at age 39. No other cancers were reported in 
her immediate family. The proband was previously referred to the Medical Genetics 
program. 
Proband number 78 (pedigree 12) is a 56 year old female who was diagnosed, in 
1997, with a poorly differentiated cancer of the ascending colon at age 51. Pathology 
revealed the presence of 2 sessile polyps and a pedunculated tubulovillous adenomatous 
polyp. She was born in Tacks Beach, Placentia Bay, and now resides in Renews. Both of 
her parents and grandparents originated from Tacks Beach, Placentia Bay. The pedigree 
constructed consists of 101 relatives. She has 19 first degree relatives: 6 children, 11 
siblings, and parents. She has 42 second degree relatives. Her father died at age 72 with 
a HNPCC cancer, stomach cancer. Her mother died ofParkinsons at age 83. A sibling 
died at 3 months. She has 42 second degree relatives. Three HNPCC cancers are 
reported in second degree relatives. A paternal uncle was diagnosed with a stomach 
cancer in his 60's and paternal aunt was diagnosed with an ovarian cancer at age 70. A 
maternal uncle was diagnosed with a brain cancer in his 70's. A nephew was diagnosed 
with a leg cancer at age 15. No other cancers were reported in second degree relatives. A 
HNPCC cancer, a lymphoma and an unknown cancer are reported in paternal cousins. 
No other cancers were reported in her family. 
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Proband 183 (pedigree 13) is a female who was diagnosed, in 1997, with a 
moderately differentiated cancer of the sigmoid colon at age 63. In 1998 she was 
diagnosed with a second primary, a well differentiated cancer of the sigmoid colon. She 
resides in St. John's. Her parents and maternal grandparents originated from Spaniard's 
Bay. The pedigree constructed consists of 48 relatives. She has seven first degree 
relatives: a child, 4 siblings, and parents. Her son was diagnosed with villo-tubular and 
tubular adenomas at age 3 9. Her mother was diagnosed with two HNPCC cancers, 
endometrial cancer at age 58 and pancreatic cancer at age 65. No other cancers were 
reported in first degree relatives. She has 18 second degree relatives. Four HNPCC 
cancers are reported in second degree relatives. A maternal uncle was diagnosed with a 
stomach cancer at age 64. A maternal aunt was diagnosed with a stomach/throat cancer at 
age 64. A maternal aunt was diagnosed with an ovarian cancer at age 60. Her paternal 
grandfather is suggested to have died in his 20s of a rectal cancer. No other cancers were 
reported in second degree relatives. Seven HNPCC cancers are reported in maternal 
cousins. A maternal cousin was diagnosed with a CRC at age 76. Another maternal 
cousin was diagnosed with an endometrial cancer at age 38. Gallbladder cancer was 
diagnosed in a maternal cousin at age 58. Pancreatic cancer was diagnosed in 3 maternal 
cousins, at ages 52, 65, and 69. A maternal cousin was diagnosed with a kidney cancer 
(RCC) at age 47. Another maternal cousin was diagnosed with a bladder cancer at age 
64 and prostate cancer at age 64. The proband was screened and was negative for the 
Family C mutation. The proband was previously referred to the Medical Genetics 
program. 
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Proband number 57 (pedigree 14) is 66 year old female who was diagnosed, in 
1998, with a moderately differentiated cancer of the sigmoid colon at age 62. She was 
diagnosed with a recurrence in 2000 and another recurrence with liver metastases in 2001. 
Previous history reveals a hysterectomy and bilateral salpingo-oophorectomy at 31. She 
was born in Bar Haven, Placentia Bay and now resides in St. John's. Her mother and her 
maternal grandfather originated from Great Paradise, Placentia Bay. The origin of her 
maternal grandmother was not given. Her father and her paternal grandparents originated 
from Bar Haven, Placentia Bay. The pedigree constructed consists of 19 relatives. She 
has three first degree relatives: 1 sibling, and parents. Her father was diagnosed with a 
HNPCC cancer, CRC, at age 86. She has 10 second degree relatives. A paternal aunt 
was diagnosed with a HNPCC cancer, stomach cancer, at age 50. No other cancers were 
reported in this family. 
99 
·20's 
CRC 
-10 
ut 
73 
pr@73 
Pedigree 13 High age/cancer mod AC-Famlly 183 
MSS 
no loss 
65 
pa@65 
en@58 
64 60 
st@64ov@60 
., 
ea 
42 
cx@31 
82 
66 
pa@52 pr@64 
bl@64 
"40's 
86 
67 ·4o's ·7o 
pa @65 Kl @47 pa @69 CRC@76 
lu@69 
45 
mo@43 
68 
st@67 
58 
gb@68 
80 
Pedigree 14 High age/cancer mod AC-Famlly 57 
MSS 
no loss 
50 70 
st@70 
50 
st@50 
br 
68 
br@68 
20 85 
CRC@85 
CRC@62 
recur@64 
chDdblrth 
66 
63 
Proband number 70 (pedigree 15) is a 68 year old man who was diagnosed, in 
1997, with a poorly differentiated cancer ofthe sigmoid colon at age 63. Chart review 
indicated the presence of polyps: in 1989 an adenomatous polyp and 5 hyperplastic 
polyps, in 2000 a tubular polyp and a cancer insitu, and in 2002 two polyps were 
reported. He was born in St. John's where he now resides. His mother and maternal 
grandparents originated from Bay L' Argent, Fortune Bay. His father and paternal 
grandfather originated from St. John's. His paternal grandmother originated from 
Manuels. The pedigree constructed consists of 77 relatives. He has ten flrst degree 
relatives: 2 children, 6 siblings, and parents. His mother died at age 98 and his father died 
at age 97. No other cancers were reported in first degree relatives. He has 32 second 
degree relatives. A maternal aunt was diagnosed with a stomach cancer younger than age 
80. His maternal grandfather was diagnosed with an ear cancer and died at age 85. His 
paternal grandmother was diagnosed with a stomach cancer at age 85. No other cancers 
were reported second degree relatives. Four HNPCC cancers are reported in maternal 
cousins. They include CRC diagnosed at ages 46, 59, and 66 and a pancreatic cancer 
diagnosed at age 58. A paternal cousin was diagnosed with a lung cancer at age 61. 
Proband number 39(pedigree 16) is a 65 year old male who was diagnosed, in 
1997, with a moderately differentiated cancer of the rectum at age 60. Pathology revealed 
the presence of a hyperplastic polyp at time of surgery. A tubular polyp with moderate 
dysplasia is reported on follow-up colonoscopy in 1998. He was born in Stones Cove, 
Fortune Bay and now resides in St. John's. His mother and his maternal grandfather 
originated from Stones Cove, Fortune Bay. His maternal grandmother originated from 
Belloram, Fortune Bay. His father originated from St. Jacques, Fortune Bay. His 
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paternal grandmother originated from English Harbour, Fortune Bay. His paternal 
grandfather originated from Dublin, Ireland. The pedigree constructed consists of 54 
relatives. He had fourteen first degree relatives: 5 children, 7 siblings, and parents. Two 
HNPCC cancers are reported in first degree relatives. His father died at age 89 from a 
stomach cancer. A brother was diagnosed with a pancreatic cancer at age 61. No other 
cancers were reported in his first degree relatives. His mother died at 79 from heart 
disease. He had 33 second degree relatives. A HNPCC cancer, stomach cancer, is 
reported in a maternal uncle at approximately age 50. No other cancers were reported in 
the family. 
Proband number 99 (pedigree 17) is a 73 year old female who was diagnosed, in 
1997, with a moderately differentiated cancer of the splenic flexure at age 68. Chart 
review indicates a history of a polyp removed in 1985 which had adenomatous changes 
and a possible adenocarcinoma at the top of the polyp. Another polyp in 1997 was also 
revealed to be a small tubular adenoma. She was born in Bay Roberts. Her mother 
originated from Holyrood. Her maternal grandparents originated form Salmonier. Her 
father and paternal grandfather originated from Job's Cove, Carbonear. The origin of her 
paternal grandmother was not given. The pedigree constructed consisted of 57 relatives. 
She had 12 first degree relatives; 5 children, 5 siblings, and parents. A HNPCC cancer, 
CRC, is reported in her mother at age 60. A sister was diagnosed with uterine cancer at 
age 4 7. There are no other reported cancers in first degree relatives. Her father and three 
siblings are deceased from unrelated causes. She has 25 second degree relatives. A 
maternal aunt was diagnosed with a HNPCC cancer, CRC, at age 75. No other cancers 
were reported in second degree relatives. HNPCC cancers, CRC, were reported in two 
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maternal cousins (siblings) at 59. A maternal cousin was diagnosed with a breast cancer, 
age unknown. A paternal cousin was diagnosed with a HNPCC cancer, lymphoma at age 
50. No other cancers were reported in this family. 
Proband number 109 (pedigree 18) is a 59 year old man who was diagnosed, in 
1998, with a poorly differentiated cancer of the rectum at age 55. Chemotherapy and 
radiation were required. He was born in Newtown, Bonavista Bay and now resides in St. 
John's. His mother and maternal grandfather originated form Cape Island, Bonavista 
Bay. His maternal grandmother originated from Cape Freels. His father and paternal 
grandparents originated from Newtown. The pedigree constructed consists of 41 
relatives. He has 6 first degree relatives: 3 children, 1 sibling, and parents. His mother 
was diagnosed with a HNPCC cancer, CRC, at age 72. His father was diagnosed with 
prostate cancer at age 76 and died at age 79. He has 17 second degree relatives. A 
maternal uncle was diagnosed with a HNPCC cancer, brain cancer, at age 62. His 
paternal grandfather was diagnosed with prostate cancer. No other cancers were 
reported in the family. 
Proband number 141 (pedigree 19) is a 63 year old male who was diagnosed, in 
1998, with a moderately differentiated cancer of the ascending colon at age 58. He was 
diagnosed, in 1999, with a malignant melanoma. He was born in Garnish and resided in 
Chapel's Cove. His mother and maternal grandparents originated from Garnish. His 
father and paternal grandparents originated from Moreton's Harbour. The pedigree 
constructed consists of 59 relatives. He has 14 first degree relatives: 4 children, 8 
siblings, and parents. His mother was diagnosed with a HNPCC cancer, small bowel 
cancer, at age 54 and died at age 55. His father died at age 61 from diabetes 
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complications. His brother was diagnosed with prostate cancer at age 73. No other 
cancers were reported in his first degree relatives. Two HNPCC cancers were reported in 
second degree relatives. His maternal grandfather was diagnosed with CRC at age 81. A 
maternal uncle was diagnosed with a CRC at age 60. He has 41 second degree relatives. 
No other cancers were reported in the family. 
Proband number 151(pedigree 20) is a 66 year old male who was diagnosed, in 
1997, with a moderately differentiated cancer of the rectosigmoid junction at age 60. 
Pathology reveals the presence of a polyp. He was born in St. John's where he now 
resides. His mother originated from St. John's. His maternal grandparents originated 
from Western Bay. His father and paternal grandfather originated from Harbour Grace. 
The demographics of his paternal grandmother were not known. The pedigree 
constructed consists of33 relatives. He has 8 first degree relatives, 6 siblings and parents. 
Two HNPCC cancers were reported in first degree relatives. His mother died from CRC 
at age 94. His sister was diagnosed with CRC at age 64. His father died from heart 
complications at age 91. He has 25 second degree relatives. No other cancers were 
reported in the family. 
Proband number 163 (pedigree 21) is a 65 year old female who was diagnosed, in 
1997, with a well differentiated cancer of the ascending colon at age 60. Chart review 
revealed the presence of 2 polyps. She was born in St. John's where she now resides. 
Her parents and grandparents originated from St. John's. The pedigree constructed 
consisted of 70 relatives. She had 12 first degree relatives: 5 children, 5 siblings, and 
parents. Her mother was diagnosed (age unknown) with a HNPCC cancer, colorectal 
cancer, and died at age 73 from a heart attack. Cervical cancer was diagnosed in her 
103 
sister at age 67. No other cancers were reported in first degree relatives. A brother is 
deceased at age 48 due to heart complications. Her father died at age 61 from a heart 
attack. She has 37 second degree relatives. A HNPCC cancer, CRC, was diagnosed in a 
maternal aunt at age 63. Two HNPCC cancers were reported in maternal cousins; a CRC 
at age 53 (cousin is participant in the NFCCR) and an ovarian cancer (age unknown). A 
maternal cousin died at age 13 due to leukemia. There were no other reported cancers in 
this family. The proband was previously referred to the Medical Genetic program. 
Proband number 189(pedigree 22) is a 56 year old female who was diagnosed, in 
1997, with a cancer of the rectum at age 51. She resides in Portugal Cove. Her extended 
family originated from Portugal Cove. The pedigree constructed consisted of 64 
relatives. She has 23 first degree relatives: 21 siblings, and parents. Two HNPCC 
cancers are reported in first degree relatives. Her mother was diagnosed with a CRC at 
age 65, a breast cancer at age 68 and died at age 74. Her father was diagnosed with CRC 
at age 75. A sister was diagnosed with a breast cancer at age 60. She has 11 second 
degree relatives. Four HNPCC cancers were reported in second degree relatives. Her 
maternal grandfather was diagnosed with a HNPCC cancer, pancreatic cancer at age 72. 
Two maternal aunts were diagnosed with double breast cancer primaries at ages 55, 56, 
and 43 and 72. Cancers reported in maternal cousins include a HNPCC cancer, CRC, at 
age 45, cervical cancer at age 45, a breast cancer at age 37, and bilateral breast cancers at 
ages 34 and 54. Basal cell cancer (bee) at age 40 and breast cancers at ages 41 and 42 
were reported in another cousin. This proband is a member of a previously identified 
hereditary breast cancer family. Extension of her maternal grandfather's family identifies 
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a strong family history of breast cancer. There is no hereditary breast cancer mutation 
known for this family. 
Pending Laboratory Analysis (n=l) 
Proband number 104 (pedigree 23) is a 74 year old female who was diagnosed, in 
1997, with a moderately differentiated cancer of the descending colon at age 69. She has 
a history of crohns/colitis. She was born in St. John's where she now resides. Her 
mother and her maternal grandmother originated from Kingscove, Bonavista Bay. Her 
maternal grandfather originated from Isle au Bois, Labrador. Her father and her paternal 
grandparents originated from St. John's. The pedigree constructed consists of 69 
relatives. She has 13 first degree relatives: 2 children, 9 siblings, and parents. Three 
HNPCC cancers were reported in first degree relatives. A CRC was reported in a brother 
at age 57, and oesophageal cancer was reported in another brother at age 51, and a 
stomach cancer was reported in his father at age 86. A lung cancer was reported in a 
brother at age 53. She has 52 second degree relatives. A HNPCC cancer, CRC, was 
reported in a nephew at age 51. A niece died at age 38 due to liver metastases from an 
ocular melanoma. There were no other reported cancers in second degree relatives. A 
HNPCC cancer, CRC, was reported in a paternal cousin. An unknown cancer was 
reported in another paternal cousin. There were no other reported cancers in this family. 
The proband was previously referred to Medical Genetics program. 
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3.72 INTERMEDIATE RISK FAMILIES (n= 22 families) 
INTERMEDIATE Criteria #1 (n= 14) 
MSI-H, hMSH2- and hMSH6- (n= 1 family) 
Proband number 45 (pedigree 24) is a 48 year old male who was diagnosed, in 
1997, with a moderately differentiated cancer of the cecum at age 43. Pathology revealed 
the presence of two polyps and chart review indicated the presence of two small 
hyperplastic polyps in 1999 and 4 hyperplastic polyps in 2000. He now resides in 
Paradise. His maternal grandmother originated from Fox Cove and his maternal 
grandfather originated from Oderin, PB. His paternal grandmother originated from Little 
Paradise and his paternal grandfather originated from Little Bonavista. The pedigree 
constructed consists of35 relatives. He has 7 first degree relatives; 3 children, 2 siblings, 
and parents. He has 11 second degree relatives. Two HNPCC cancers were reported in 
his mother. She was diagnosed with a CRC at age 52, an endometrial cancer at age 57, a 
villous adenoma at age 60, a villous adenoma at age 71, and a tubular adenoma at age 74. 
She died at age 76. His father was diagnosed with prostate cancer. Other cancers 
reported include a HNPCC cancer, stomach cancer, in his paternal grandmother at age 63 
and a breast cancer in a paternal aunt at age 70. This proband was previously referred to 
the Medical Genetics program. 
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MSI-H and hMLH1- (n = 1 family) 
Proband number 162 (pedigree 25) is a 72 year old female who was diagnosed, in 
1998, with a moderately differentiated cancer of the cecum at age 68. Pathology indicates 
the presence of numerous polyps. She was born in Port de Grave and her mother and 
maternal grandfather originated from Bishop's Cove. Her maternal grandmother 
originated from Blaketown. Her father and paternal grandparents originated from Port de 
Grave. The pedigree constructed consists of 66 relatives. She has 12 first degree 
relatives; 4 children, 6 siblings, and parents. Her brother was diagnosed with a HNPCC 
cancer, CRC, at age 64. No other cancers were reported in first degree relatives. Three 
siblings have had polyps removed. Her father died at age 92 and her mother died at age 
83 from heart complications. A sibling is deceased at age 32 due to an accident. She has 
34 second degree relatives. A HNPCC cancer, CRC, was diagnosed in a maternal aunt at 
age 70. A stomach cancer was reported in a maternal cousin at age 69, and breast cancer 
was reported in another maternal cousin. Unknown cancers were reported in her maternal 
grandmother, a maternal uncle, and a maternal cousin. A review of the pedigree 
connected this family through marriage to proband #100 in this study. 
MSI-H and pending me Analysis (n = 1 family) 
Proband number 10 (pedigree 26) is now deceased. He was diagnosed, in 1997, 
with a cancer of the rectosigmoid junction at age 65. He died three months following his 
diagnosis. He was previously diagnosed with a cancer of the colon in 1982. He 
underwent a right hemicolectomy at that time. He resided in St. John's. His mother and 
maternal grandmother originated from Islington, Trinity Bay. The origin of his maternal 
grandfather was not given. His father and his paternal grandfather originated from 
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Bishop's Cove. His paternal grandmother originated from Victoria, Carbonear. The 
pedigree constructed consists of 41 relatives. He had 12 first degree relatives: 4 children, 
6 siblings, and parents. Two HNPCC cancers, CRC, were diagnosed in siblings; at age 
60 in a sister, and at age 69 in a brother. His father died at age 55 from heart 
complications and his mother died at age 74 form diabetes complications. Two of the 
proband's brothers were diagnosed with colitis. No other cancers were reported in first 
degree relatives. He has 27 second degree relatives. A paternal uncle was diagnosed 
with a lung cancer at a young age. A paternal cousin was diagnosed with a breast cancer 
at age 56. No other cancers were reported in the family. 
MSS and no loss (n = 8 families) 
See appendix A, pedigrees 34 through 41 
MSS and pending me (n = 2 families) 
See appendix A, pedigrees 42 through 43 
No sample available for molecular and pathology analysis (n =1 family) 
See appendix A, pedigree 44 
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INTERMEDIATE RISK 2 (proband and relative with CRC ~5) (n = 1 family) 
MSI-H and hMSH2- and hMSH6-
Proband number 135 (pedigree 27) is a 56 year old male who was diagnosed, in 
1997, with a well differentiated cancer of the cecum at age 51. Pathology revealed the 
presence of three polyps and one was indicated to be a tubular adenoma. Follow-up 
colonoscopy revealed a tubular adenoma in 1999. He was born in Charleston, Bonavista 
Bay. His Mother and maternal grandparents originated from Cannings Cove, Bonavista 
Bay. His father and his paternal grandparents originated from Charleston, Bonavista Bay. 
The pedigree constructed consists of 77 relatives. He has 6 first degree relatives; 4 
sibling, and parents. Three siblings are deceased at ages 30, 45, and 50 from unrelated 
causes. His mother died at 54 from heart complications. He also reported that his mother 
had a questionable cancer, type unknown. There were no other cancers reported in first 
degree relatives. His father died of 78 after a stroke. His sister had had colonoscopy 
screening. He has 26 second degree relatives. Two HNPCC cancers were reported. A 
CRC was diagnosed in a maternal uncle at age 60 and a CRC is reported in a maternal 
cousin at age 35. No other cancers were reported in the family. 
INTERMEDIATE RISK 5- (DOUBLE PRIMARIES) (n = 3 families) 
MSI-H and hMLHl- (n=l family) 
Proband number 152 (pedigree 28) is a 62 year old female who was diagnosed, in 
1998, with 2 poorly differentiated cancers of the colon at age 56. She was born in St. 
John's where she now resides. Her parents and her grandparents originated form St. 
John's. The pedigree constructed consists of 77 relatives. She has 15 first degree 
relatives: 6 children, 7 siblings, and parents. Her mother died of heart complications at 
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age 76. Her father also died of heart complications at age 68. Her son had a skin cancer 
at age 34. A brother died from heart complications at age 38, another brother died 
accidentally at age 27. A sister died from lung cancer with metastasis at age 59. No other 
cancers were reported in her first degree relatives. She has 49 second degree relatives. A 
niece was diagnosed with a HNPCC cancer, brain cancer, at age 27. A maternal cousin 
was diagnosed with lung cancer with metastasis at age 65. No other cancers were 
reported in the family. 
MSS and no loss (n= 2) 
See appendix A, pedigrees 45 through 46 
INTERMEDIATE RISK 7- (n = 4 families) 
MSS and no loss (n=4 families) 
See appendix A, pedigrees 47 through 50 
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INFORMATIVE FAMILIES (n= 21) 
MSI-H and hMLH1- (n=1) 
Proband number 108 (pedigree 29) is a 60 year old male who was diagnosed, in 
1998, with a moderately differentiated cancer of the cecum at age 55. Chart review 
indicated the removal of polyps in follow-up colonoscopies. He was born in Freshwater, 
Carbonear where he now resides. His mother and maternal grandfather originated from 
Freshwater, and his maternal grandmother originated from Victoria. His father and 
paternal grandfather originated from Freshwater, and his paternal grandmother originated 
from Bristol's Hope. The pedigree constructed consists of 60 relatives. He has 8 first 
degree relatives: 3 children, 3 siblings, and parents. His mother died of heart 
complications at 78. His father is still alive and is 82 years old. Polyps have been 
reported in a sibling who is 54 years old. No other cancers were reported in his first 
degree relatives. He has 25 second degree relatives. There are 2 breast cancers reported 
in a paternal aunt at age 65 and 70. No other cancers were reported in the family. 
MSI-H and hMSH6- (n= 1) 
Proband number 180 (pedigree 30) is a 43 year old female who was diagnosed, in 
1998, with a poorly differentiated cancer of the cecum at age 38, and also a breast cancer 
at 38. She emigrated from Libya but now resides in St. John's. The pedigree constructed 
consists of23 relatives. She has 10 first degree relatives; 8 siblings, and parents. She has 
13 second degree relatives. No other cancers were reported in this family. She was 
previously referred to Medical Genetics because she was diagnosed with a double 
primary at a young age. 
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MSI-H and no loss (n= 1) 
Proband number 63 (pedigree 31) is a 74 year old male who was diagnosed, in 
1997, with a moderately differentiated cancer of the cecum at age 68. Pathology reveals 
the presence of two tubulovillous polyps. He was previously referred to Medical 
Genetics because of a family history of breast cancer. She was born in Upper Gullies 
(Kelligrews) and now resides in Bay Roberts. His mother and maternal grandparents 
originated from Foxtrap. His father and her paternal grandparents originated from Upper 
Gullies. The pedigree constructed consists of 36 relatives. He has 11 first degree 
relatives: 3 children, 6 siblings, and parents. His mother died at age 62 due to a cerebral 
haemorrhage. His father died at age 84 due to emphysema. A sister was diagnosed with 
a breast cancer and subsequently died at age 64 due to emphysema. Another sister is 
dead at age 69 due to a heart attack. A sister had pre-cancerous polyps and part of her 
bowel removed before age 64. A brother had polyps removed. No other cancers were 
reported in his first degree relatives. He has 11 second degree relatives. A cancer (type 
unknown) was reported in a maternal uncle. He also reported a breast cancer in her 
maternal grandmother who died at age 48. No other cancers were reported in his second 
degree relatives. A HNPCC cancer, stomach cancer was reported in a paternal cousin at 
age 60. Three breast cancers and a lung cancer were reported in paternal cousins. A 
breast cancer was reported in a maternal cousin. No other cancers were reported in this 
family. 
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MSS and hMSH6- (n= 1) 
Proband number 119 (pedigree 32) is a 69 year old male who was diagnosed, in 
1997, with a well differentiated cancer of the sigmoid colon at age 64. He was born in 
Arnolds Cove and he now resides in Green Harbour. His mother and his maternal 
grandparents originated from Woody Island, Placentia Bay. His father and his paternal 
grandparents originated from Arnolds Cove. The pedigree constructed consists of 3 9 
relatives. He has 5 first degree relatives: 2 children, 1 sibling and parents. His mother 
died from arthritis complications at age 82, and his father died from heart complications 
at age 61. His sibling died of heart complications at age 67. No other cancers were 
reported in his first degree relatives. He has 15 second degree relatives. A skin cancer 
was reported in his maternal grandfather who died at age 92 and a prostate cancer was 
reported in a maternal uncle who died at age 92. No other cancers were reported in this 
family. 
MSS and no loss (n = 15 families) 
See appendix A, pedigrees 51 through 65 
Pending laboratory results (n=2) 
See appendix A, pedigrees 66 through 67 
113 
66 
38 
Pedigree 29 
68 70 
45 
88 
l 
43 
low-Family 108 
MSI 
MlH1-
99 
74 79 
40 42 63 
.\ 
84 
br@65 
br@70 
23 25 30 33 
74 82 78 
34 32 28 24 
82 
22 39 
.i 
41 
76 74 70 
2. 
37 
81 
66 62 
2. 
32 34 

Pedigree 31 low-Family 63 
MSI 
no loss 
br 
62 
60's 60's 60's 64 -69 
\ 
63 
60 
64 
br CRC@68 
48 
br 
65 
br 
30 
,... 
G) 
.... 
.... 
~ I 
... 
'E rnco 
"' 
4l! rn:l:: :Ern 
:i: ::E 
.9 
N 
CO') 
Cl) 
e 
Q 
;:; 
Cl) 
1:1. 
LOW RISK- Uninformative (n= 13 families) 
MSI-H and hMLHl- (n=l family) 
Proband number 148 (pedigree 33) is a 71 year old female who was diagnosed, in 
1997, with a moderately differentiated cancer of the hepatic flexure at age 66. Chart 
review indicated the presence of 2 tubular adenomas in 1998. She was born in Cupids 
and now resides in St. John's. Her mother and her maternal grandparents originated from 
Cupids. Her father and her paternal grandmother originated from Cupids. She is unaware 
about the origins of his paternal grandfather. The pedigree constructed consists of 25 
relatives. She has 6 first degree relatives: 4 children, and parents. Her mother died an 
accidental death at age 84. Her father also died an accidental death at age 79. There 
were no reported cancers in her first degree relatives. She has 11 second degree relatives. 
A HNPCC cancer, stomach cancer, was reported in her maternal grandfather who died at 
age 70, and a throat cancer was reported in her maternal grandmother who died at age 55. 
A throat cancer was reported in a paternal uncle (age unknown). No other cancers were 
reported in this family. The family is uninformative because there are less than six 
siblings at risk. 
MSS and no loss (n = 12 families) 
See appendix A, pedigrees 68 through 79. 
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CHAPTER 4: DISCUSSION 
This study has provided information about hereditary CRC on the Avalon 
Peninsula of Newfoundland and Labrador. Since there was no single defining feature, 
family history was the most important tool in making a HNPCC diagnosis. However, the 
heterogeneous nature of HNPCC hinders the diagnosis. Diagnosis is further complicated 
because CRC and other HNPCC cancers most frequently occur as sporadic tumours, 
because of the small size of most of today' s families, and because individuals may die 
young of other causes before they develop the cancer. Individuals may also have limited 
knowledge about their families, so extensive pedigrees and family histories are not 
usually available in clinical practice (Vasen et al, 1999). Furthermore, when the criteria 
are used strictly, non-penetrance of cancer in a mutation carrier may prevent a HNPCC 
diagnosis. 
Advances in the understanding of molecular genetics of CRC have led to another 
method of diagnosis. We now know that individuals who harbour mutations in mismatch 
repair genes are at increased risk for a HNPCC cancer (Peltomaki and de la Chapelle, 
1997). Therefore this condition can now be identified by 2 different methods: clinical or 
molecular. Some individuals have both clinical and molecular evidence of the condition 
and such an overlap is a positive factor towards increasing the confidence in the 
diagnosis. 
The prevalence of HNPCC in the Newfoundland population was evident with 
potentially 41 families, previously identified through the Medical Genetics program, 
fulfilling Amsterdam Criteria I (AC I) or Amsterdam Criteria II (AC II). The occurrence 
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was further confirmed when a point mutation, A---+ T at nucleotide 943 + 3 in the 3' splice 
site of exon 5 was identified in affected members of one family. This mutation ("family 
C") results in the deletion of exon 5 and a truncated protein. So far this mutation was 
found to segregate among 13 families with at least 176 individuals testing mutation 
positive. 
Early studies (elsewhere) concentrated on high risk individuals to estimate the 
prevalence of HNPCC. These studies reported that 3.8-5.5% of CRC patients had 
HNPCC. Subsequent studies suggested that this was probably much higher than the 
overall population risk because of the biased sample used. However using a retrospective 
population-based approach we identified 22 of78 families (28.2%) at high risk (HR) and 
22 families (28.2%) at intermediate risk (IR) for HNPCC in the Eastern region of 
Newfoundland. The criteria used to categorise these families was assembled from the 
Amsterdam Criteria I (AC I), the Amsterdam Criteria II (AC II), and the Ontario Familial 
Colorectal Cancer Registry (OFCCR). 
Comparison With Other Studies 
Different study designs prevent comparison of several major population-based 
studies. Several groups have reported the frequency of HNPCC by using the AC I and 
other less strict HNPCC criteria. By the AC I, Mecklin et al (1995) reported 0.7% 
frequency of HNPCC in the Finnish population, Evans et al (1997) reported 0.3% 
frequency of HNPCC in a British population, Katballe et al (2002) reported a 0.9% 
frequency ofHNPCC in the Danish population. By comparing our study to these studies 
we found that a total of 7. 7% of our families ( 6 families) met the AC I. Using less strict 
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criteria these same authors reported the frequency of HNPCC to be 1. 7% (Mecklin et al, 
1995), 1.4% (Evans et al, 1997), and 2.3% (Katballe et al, 2002). Using less strict criteria 
we once again report a higher frequency of HNPCC, i.e. 56% of our families (44 
families). Differences in each study's less strict criteria may account for different results, 
though the criteria used by Evans et al (1997) are similar to ours. Population differences 
may also account for the different results. For example, the founder effect in the Finnish 
population may increase the HNPCC incidence in Finland. This could also be the case in 
our study due to our founder mutation ("family C") in one of our probands (# 122, 
pedigree 7). 
Today, most population-based studies attempt to determine the frequency of 
HNPCC by molecular detection. This molecular detection begins with Microsatellite 
instability (MSI) analysis of consecutive CRC cases. Those cases that are MSI-H are 
screened for germline mutations usually of the hMSH2 and hMLH1 genes (Aaltonen et 
al, 1998; Salovaara et al, 2000; Katballe et al, 2002). More recently 
immunohistochemistry (IHC) analysis to test for the protein expression of the MMR 
genes (particularly hMLH1, hMSH2, and hMSH6) has been added (Percesepe et al, 
2001). A combination of these molecular methods and family history criteria are used to 
estimate HNPCC frequencies in various studies. We chose to study each case with MSI 
analysis and IHC analysis, the results of which will be discussed later. 
The importance of utilising the AC II in our study criteria is demonstrated by the 
participation of a mutation positive proband. Proband 122 (pedigree 7) is a carrier of the 
"Family C" mutation. However, the proband's family does not meet the AC I because of 
infrequent CRC and frequent extracolonic cancers. There are only 2 individuals with 
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CRC and these are not first degree relatives. However the proband's mother is mutation 
positive and is affected with a double primary of endometrial and ovarian cancer. Many 
individuals in this family have not agreed to be investigated with clinical screenmg 
therefore it is possible that other individuals are affected. 
We further modified the AC by extending the threshold for youngest age of cancer 
to age 60, and also to include several other HNPCC cancers to make our 3rd HR group. 
This was called the "Age and Cancer Modified Amsterdam Criteria". The decision to 
increase the age range was based on a recent study on hMSH2 mutation carriers in the 
Newfoundland population (Green et al, 2002). Results of this study showed that a 
significant number of first cancers occurred after age 50. The cumulative risk of first 
cancer went from 72% at age 50 to 86% at age 60. Family 50 (pedigree 13) is an 
example of a family meeting our Age and Cancer Modified Amsterdam Criteria. CRC is 
observed in five individuals in two consecutive generations all over the age of 50, 
however one individual is diagnosed at 51, and another is diagnosed at age 53. 
The decision to add more cancers to the diagnostic criteria for the 3rd HR group 
was based on the high relative risk of these cancers in HNPCC as reported in the literature 
(Mecklin et al, 1991; Watson et al, 1993; Aarnio et al1995; Vasen et al, 1996a; Dunlop et 
al, 1997). The cancers selected, for the 3rd HR group, are those proposed by the 
International Collaborative Group on HNPCC and those cancers chosen by the OFCCR 
group. Family 183 (pedigree 12) is an example of a family we considered HR by the Age 
and Cancer Modified Amsterdam Criteria. There were 14 HNPCC cancers (including 
endometrial, pancreas, gall bladder, stomach, ovarian) reported in this family. 
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The OFCCR group included lymphomas in their intermediate criteria. The 
rational for including lymphomas comes from the development of lymphomas in HNPCC 
Knock-out mice. These mice form skin neoplasms (analogous to Muir-Torre syndrome) 
and also develop lymphomas (de Wind et al, 1999). The lymphoma was included as a 
HNPCC cancer in 2 families in this study. However it will not be included as a HNPCC 
cancer for the development of the NFCCR database as its significance in humans has not 
been clarified (Teruya-Feldstein et al, 2002). Other cancers are reported to occur in 
HNPCC. For instance we did not include bladder cancer as a HNPCC cancer. However, 
recently a new mutation (hMSH2 deletion exon 8) was identified in Newfoundland 
families (Jane Green, personal communication). A defining clinical feature in these 
families was transitional cell cancers of the renal pelvis, ureter and bladder. 
MSI and IHC analysis correlated extremely well. Fifteen of sixteen MSI-H cases 
(93.8%) had loss of expression of one or more proteins. One MSI-H case (pedigree# 31), 
which was classified as LR, did not show loss of protein expression. Several explanations 
may explain this finding. An area of uncertainty exists when interpreting IHC results. It 
is possible that the interpretation of the IHC analysis was incorrect and there actually was 
loss of protein expression. Even though the family history does not suggest inherited 
disease, it may be feasible that a missense mutation, occurring at the COOH terminus of 
the protein, results in expression of a non-functioning protein (R. Kolodner, personal 
communication in de la Chapelle, 2002). Or perhaps a new mutation exists in this 
individual and the defect lies in one of the MMR genes not investigated in this study. 
MSI and IHC analysis also did not correlate when two tumours (family 7, 
pedigree 25 and in family 119, pedigree 32) had MSS by microsatellite instability 
119 
analysis and did not express the hMSH6 protein. Mutations of hMSH6 with MSS by 
microsatellite instability analysis are previously reported in the literature (Wu et al, 1999). 
Family 7 is HR for HNPCC by the AC 1. The proband's family meets the criteria 
because several of his 2nd degree relatives have CRC and other HNPCC cancers (e.g. 
kidney, pancreas). The proband's mother (diagnosed with breast cancer at age 67 and 
died at age 75) was probably an obligate carrier as HNPCC is known to have a reduced 
penetrance (Lynch et al, 1996a). Other variables might affect the phenotypic expression 
of a certain mutation such as gene polymorphisms, modifier genes, and other 
environmental factors. For instance, patients who have HNPCC with a common 
polymorphism in the cyclin D 1 gene developed CRC eleven years earlier than patients 
who did not carry the polymorphism (Kong et al, 2000). Unlike family 7, there are no 
other HNPCC cancers reported in family 119. Furthermore, endometrial cancer, which is 
reported to be common in hMSH6 families, was not reported in these families. Further 
study of the pro bands and their family members is warranted. 
Another proband (# 189, pedigree 30) where the tumour did not express the 
hMSH6 protein was MSI-H. This individual (included in the LR group) was previously 
referred to the Medical Genetics program because she had a double primary of CRC and 
breast cancer at age 3 8. The significance of the breast cancer in this individual is 
unknown. It may be important to explore the stability and protein expression in the breast 
cancer tumour tissue. The proband reported no other cancers in the family. As she 
originates from another country it is possible that the reported information is incorrect as 
she may not be aware of her family history. 
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In this study 54 of 71 CRC cases (76.1%) had MSS tumours and expressed all 
three proteins (hMLH1, hMSH2, and hMSH6). An MSS result by MSI analysis suggests 
non-HNPCC. Our proportion ofMSS tumours is lower than reported by other population 
based studies. Salovaara et al (2000) reported MSS in 88% and Percesepe et al (2001) 
reported MSS in 91.7% of their populations. Twenty-seven of our 54 MSS cases (50%) 
were classified as LR on review of their family history. These cases are almost certainly 
sporadic. However 24.1% ofMSS cases (all 13 cases expressed all proteins) were HR by 
family history and in fact three of these cases met the AC 1. Peel et al (2000) reported 
MSS and no mutations (hMLH1 and hMSH2 genes) in 5 of 9 HNPCC families. In a 
Danish population-based study, mutations were found in 2 of 6 AC I families therefore it 
was suggested that mutation negative individuals from HR families have a 25% chance of 
meeting the AC I (Katballe et al, 2001a). The possibility exists that there are yet other 
undiscovered genes responsible for hereditary CRC and HNPCC. 
Germline mutations in other genes, besides the MMR genes, may be causing the 
cancers or a non-genetic clustering of CRC may be represented by various HNPCC 
criteria. Non-genetic clustering of cancers cannot be ruled out for both the HR and IR 
groups showing MSS on MSI analysis. However, this is unlikely in some families, for 
example the AC 1 family 35 (pedigree 4). Extension of this family reveals cancers in 
multiple generations and individuals and therefore it is very unlikely that non-genetic 
clustering occurs in this family. It is important to screen other tumours in this family by 
MSI analysis to determine if other clinically affected family members have the same 
molecular findings as the proband. If MSI-H tumours are found it is probable that our 
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proband is a phenocopy. If MSS tumours are found then another gene is undoubtedly 
responsible for the cancers in this family. 
In our population MSI-H tumours were found in 16 (21.6%) of 74 cases. This 
figure is higher than reported in other population based studies. Salovaara et al (2000) 
reported 12% and Percesepe et al (2001) reported 8.3%. One of our families, that is HR 
by the AC I, contains two probands, 11 (pedigree 1) and 12 (pedigree 2), that are first 
cousms. MSI analysis revealed that both probands were MSI-H, and IHC analysis 
demonstrated that neither tumour expressed the hMSH2 protein. The cousins are 
members of a high risk family already known to the Newfoundland Medical Genetics 
program. 
Recently, as part of an ongomg project, Dr. Michael Woods (personal 
communication) studied a number of the previously identified families in this cohort. His 
work includes the search for mutations. Several interesting findings, pertaining to this 
study, were made while using a fairly new method, multiplex ligation-dependent probe 
amplification (MLP A), to search for genomic deletions. First, the mutation segregating in 
family 11 and 12 was identified. This is a deletion of exon 8 of the hMSH2 gene. This 
mutation has now been determined to segregate in 6 families. Second, MSI analysis and 
IHC analysis results between this study and Dr. Wood's study are consistent. Dr. Woods 
also reports an alteration in the hMSH6 gene (Gll39S) in proband 45. This alteration 
has not been reported previously and its pathological significance is unknown at this time. 
It is interesting to note that IHC analysis showed loss of expression of both the hMSH6 
and hMSH2 proteins. It has been postulated that the loss of expression of hMSH6 may 
be secondary to that of mutations in hMSH2 (Cunningham et al, 2001; Planck et al, 2000; 
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Wu et al, 1999) because of the physical proximity of hMSH2 and hMSH6. However the 
alternative, loss of expression of hMSH2 due to a mutation in hMSH6 has not been 
reported. Further studies may lead to a better understanding of this factor. We chose to 
alter the criteria when considering family 45. This individual was given an IR 
classification (IR #2). However, there are not 3 cancers in 3 individuals in the family as 
required for inclusion in theIR group. Instead, for this case the criteria are interpreted to 
include 3 cancers in 2 individuals. It is possible that a new mutation is responsible for the 
cancers in this family, that the history given is incomplete, or that the small family size 
resulted in fewer affected, even in a true HNPCC family. It is also possible that a 
maternal grandparent is an obligate carrier. Non-penetrance has been demonstrated to 
play a role in HNPCC and it has been estimated that approximately 10% of carriers will 
never develop a cancer (Dunlop et al, 1997). 
Another family (#135, pedigree 27) where the hMSH2 and hMSH6 proteins were 
not expressed was MSI-H and is IR. This proband was classified as IR for HNPCC 
because a maternal cousin had CRC at age 35. The proband also reported that his mother 
possibly had a cancer. Efforts to review the mother's records are on-going. If she did 
have a HNPCC cancer, then this family will be reclassified as HR. The "family C" 
proband (# 122, pedigree 7) also had a loss of expression of the hMSH2 and hMSH6 
proteins. At the time of the discovery of the "family C" mutation the significance of the 
hMSH6 gene was not known and IHC analysis was not used for the detection of MMR 
proteins. It would be interesting to investigate whether all mutation positive "family C" 
individuals fail to express the hMSH6 protein. 
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Seven (43.8%) of the 16 MSI-H cases were deficient for the hMLH1 protein. 
Two of these were from theIR group and two from the LR group. It is probable that a 
number of these cases will be explained by the epigenetic mechanism of 
hypermethylation. In a study by Percesepe et al (2001) 14 of 20 cases (70%) that were 
MSI-H and did not express the hMLH1 protein were hypermethylated. 
Hypermethylation analysis will be performed on the promoter region of hMLH1 for cases 
which showed MSI-H, with loss ofhMLH1 expression. 
Study Difficulties 
Several studies (Aitken et al, 1985; Love et al, 1985; Sijmons et al, 2000) 
concluded that the diagnosis of cancer reported by first degree relatives is very likely to 
be accurate (77 -93% ). The use of population-based registries, HNPCC registries, and 
cancer registries enhance verification and ensure a more accurate estimate of those at risk. 
A recent Danish population based study (Katballe et al, 2001 b) using their specialised 
registries indicated that CRC was reported correctly 68.4% of the time in first degree 
relatives. Newfoundland does not have the same population registry or existing 
specialised registry. Furthermore access to records for research purposes is restricted by 
privacy laws that are enforced by ethics boards and consequently our ability to confirm 
information was limited. Permission to confirm reported cancers through the 
Newfoundland Cancer Treatment Research Foundation (NCTRF) registry was granted to 
ease the verification process. By using names, birth dates, and place of residence, we 
identified 207 reported cases. Ofthese only 21 discrepancies were identified giving us a 
false positive rate of 10.1%. However no information is available about the other 
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reported cancers (n = 229). The MCP (provincial medical ID) identity number is the only 
way to confidentially ensure that the correct identity was used. This number was not 
available to us without consent from the affected person. For the current NFCCR study, 
the NCTRF registry will be used only after consent has been obtained from the affected 
family member or from a next of kin if the affected is deceased. Access to the registry 
will ease the verification process, as the ability to use such a resource has proved 
invaluable in other population studies. 
It is important to verify the reported cancers histologically as this confirms the 
diagnosis which is a requirement of the AC. In this study all CRC, except one, in 
relatives in the AC I and AC IT families were confirmed. The cancer not confirmed is in a 
sibling of the proband who lives in a different province. Retrieval of the records and a 
tumour specimen is in process. All of our AC HR group were previously referred to the 
medical genetics program because of suspected hereditary cancer. This might 
overestimate the frequency ofHNPCC in our population because it is probable that those 
associated with a genetic clinic are more likely to participate in a research project as 
personal benefit is possible. However, this is not always the case as some individuals do 
not want to go through the process again so this could balance out those who were more 
likely to participate. For example we are aware of several individuals, including a 
mutation positive ("family C") individual, previously seen by the genetics program who 
opted not to participate. We also avoided an ascertainment bias by recruiting all 
participants in the same manner. 
The study by Katballe et al (2001) reported a false negative family history 
reporting rate of 39%. In their study, 7 of 18 AC I and AC IT families were initially 
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classified incorrectly and it was only after further investigation that the classification of 
AC I and AC II were given. False negative reporting of family history was also observed 
in our study. Two HR. probands, family 7 (pedigree 3) and family 35 (pedigree 5) did not 
report several CRC in their families which initially resulted in a LR classification. 
However their families were previously referred to the medical genetics program and the 
CRC in question were documented. It is probable that more AC families may be 
identified from further follow-up of the other LR and IR families. This follow-up will 
happen when these probands attend genetic counselling. It is at this step that records will 
be collected for cancer verification which is necessary to recommend appropriate 
screening in those with known and unknown mutation status. It will only be then that 
current risk classification will be verified. 
Germline mutations have been found in families not fulfilling the AC (Nystrom-
Lahti et al, 1996; Moslein et al, 1996; Wijnen et al, 1997; Genuardi et al, 1998). An 
inherent misclassification bias may exist when diagnosing a condition on the basis of 
family history alone, particularly in small families. The issue of family structure and 
family size has been addressed for assessing breast cancer risk. BRCAPRO is a statistical 
computer program that calculates probabilities of mutations in the known breast cancer 
susceptibility genes, BRCA1 and BRCA2, based on family history alone (Parmigiani et 
al, 1998; Berry et al, 2002). A program of this nature has not been developed for 
assessing HNPCC risk. Therefore, we chose to determine the informativeness of the low 
risk families. Our definition of informativeness was our preliminary effort to 
acknowledge the restrictive nature of the clinical diagnosing criteria. The definition was 
based on how many potential first and second degree relatives, in 2 generations, are at 
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risk for developing HNPCC. Since we proposed that there need be at least six at risk 
relatives (of the proband and/either parent) and since age 60 was our HR age threshold we 
used this as our cut off age for informativeness. Thirteen families (3 8.2%) were classified 
as uninformative, because there were too few and/or too young family members or 
insufficient family details. A number of families were suggestive of HNPCC but a lack 
of family details made it impossible to classify them as IR or HR. For example the 
information reported for family 164 (pedigree 77) was given by the proband's wife, and 
she was unaware of the proband's second degree relatives. Furthermore the available 
family history for family 65 (pedigree 68) is not sufficient to state that the family is not at 
risk for HNPCC. For this case the participant agreed to participate in the study but did 
not disclose any further information such as dates of birth and ages of death for his 
relatives. 
The utility of testing for MSI and MMR protein expression for the diagnosis of 
HNPCC in this population was poor. Only 30.0% of our HR families were picked up by 
MSI analysis. If we calculate the sensitivity of MSI analysis to detect AC and AC II 
families it increases to 33% in our population. This sensitivity is much lower than 
reported by Katballe et al (2002). They report a 61% sensitivity ofMSI analysis to detect 
AC I and AC II families. However they report a 100% sensitivity ofMSI to detect genes 
carriers. Therefore MSI is a sensitive tool for the identification of mutations in the MMR 
genes. This suggests that MSI analysis is a useful tool for detection of mutations in 
known genes but unreliable for the detection of AC families. However it may be a useful 
tool to rule out LR HNPCC families. In this study 84% of our LR families were MSS by 
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MSI analysis. It is important to remember that the original purpose ofMSI analysis was 
to identify cases in which to find mutations in the M1\1R genes. 
Lack of a uniform disease makes it difficult to assess the sensitivity, specificity, 
and predictive powers of the laboratory methods. Therefore, the question remains, will 
there be a need for both MSI and IHC analysis? Combining the results of both techniques 
is sometimes difficult as the use of both a histology lab and molecular lab are needed. 
MSI analysis is more costly, time consuming and more tissue is needed for a result, while 
IHC analysis directs the search for specific germline mutations, costs less, and is less time 
consuming (de la Chapelle, 2002). A criticism of the use ofiHC analysis alone is the 
possibility that some mutations may not be detected because they may result in 
expression of a protein even though it is not functioning. As previously mentioned, 
missense mutations may inhibit a protein's function but still allow IHC expression (de la 
Chapelle, 2002). As IHC analysis is a new technique its value is yet to be determined. 
No general consensus exists on whether MSI analysis, or IHC analysis, or both will be 
recommended in future. 
All of these efforts may answer many important questions such as how this 
information will be used, who will benefit, and who in the general population should be 
screened. Predictive testing for adult onset disorders could lead to preventing conditions. 
In some cases this testing may relieve unnecessary worry while in others it may increase 
anxiety and feelings of guilt (Huggins et al, 1992; Tibben et al, 1993), and for others may 
introduce potential for discrimination and stigmatization (Aktan-Collan et al, 2000). The 
safety, effectiveness, and quality of these tests must be evaluated. Screening should be 
tailored to the presentation of cancers occurring in the family. In the future it may be 
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possible to determine through genetic testing what the presentation will be like. One on 
one counselling may increase acceptance of predictive testing, and the use of prophylactic 
surgeries to keep a person cancer free at target organs, may be warranted in mutation 
positive individuals. 
Limitations 
A low number of subjects (50% of those eligible) enrolled in this study. As this 
was a pilot study, limited resources may have contributed to factors influencing 
enrolment such as a delay before follow-up after the letters were sent out and delays of 
ethics approval for amendments (Human Investigation Committee). It was not possible 
to collect reasons for non-participation because of the opt-out option of our study design. 
The retrospective study design probably contributed to the low uptake as three to four 
years had passed since the subjects were diagnosed with their CRC. It was possible that 
some individuals were ill, deceased, or did not want to revisit a painful time in their lives. 
Several changes to the design of our study and several amendments to ethics approval 
contributed to an easier transition for development of the NFCCR. Also the hiring of a 
professional staff will lead to a more accurate assessment of hereditary HNPCC in 
Newfoundland possibly by improved methods of ascertainment under strict timelines. 
The latest statistics released from this group indicated a 52% (of those eligible) enrolment 
of CRC probands. However there are many cases in process. 
Due to the heterogeneous nature of HNPCC the ascertainment of only CRC 
incident cases is limiting for its identification. This may underestimate the total 
prevalence of HNPCC in our population. Several studies have shown that the risk of 
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endometrial cancer is higher than the risk of CRC in female mutation carriers (Aarnio et 
al, 1995; Dunlop et al, 1997; Aarnio et al, 1999; Green et al, 2002). Even though only 
CRC was used as index cases it is necessary to establish the resources before registration 
begins. This can then be expanded to include other tumours, such as endometrial tumours 
in the future. 
For this study records of screening and interventions were not obtained. It is 
possible that individuals within each family had precancerous lesions (adenomas) 
removed, thus altering the natural history of HNPCC or CRC in these families. Also 
preventative surgeries such as hysterectomies could prevent the expression of other 
cancers. New criteria need to be developed and implemented to capture these families as 
they could easily be missed when identifying HNPCC families. The Bethesda Criteria 
does recommend MSI analysis in CRC probands who have first degree relatives with 
adenomas at less than 40 years and also in individuals who have adenomas at less than 40 
(Rodriguez-Bigas et al, 1997). However these criteria are currently not used in clinical 
practice in Newfoundland. 
We do not know the proportion of mutations in our group. This study did not 
complete mutation analysis on any individual. However, because numerous subjects 
were under the care of the medical genetics program the mutation status of some 
individuals was known. We did not stain for proteins hPMSl, hPMS2, and hMSH3, 
because the antibodies for these agents were not commercially available at the beginning 
of our study. Moreover our resources were limited, and because mutations in these genes 
appear less common they were excluded. 
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Future Research 
Hypermethylation analysis will be carried out on the promoter region of hMLH1 
for cases which showed MSI-H, with absence of expression of hMLHl. We did not 
report MSI-L tumours. Instead we reported MSI-L tumours as MSS. There were 4 MSI-
L cases in this series (families 68, 133, 137, 166). It is possible that MSI-L tumours have 
a more distinct phenotype than MSS tumours. For example tumours in MSH6 knockout 
mice may display an MSI-low phenotype (Edelmann et al, 1997). Several tissue samples 
were not available to us. Efforts to obtain them are underway. If it appears impossible to 
obtain them, then other tumours within the family will be obtained for molecular 
investigation as is currently the case with an AC family 157 (pedigree 7). 
In suspicious families attempts will be made to determine if tumours are not just 
phenocopies, and further contact will be made with family members in order to obtain 
medical records and extend pedigree information. The determination of consistent 
molecular characteristics in all affected family members could lead to an accurate 
diagnosis ofHNPCC. We did collect blood samples (DNA), where possible, at the time 
of interview. A search for known mutations will be carried out on cases showing absence 
of protein expression. Linkage analysis will be performed on all HR. and IR families 
where MSS was found. However this is a difficult task because of lack of DNA from 
deceased affected family members, and difficulties arising classifying family members 
because of variable expression and reduced penetrance of HNPCC genes. Estimates of 
cancer risk in these families will be calculated and will be the subject of :further research. 
Hormonal influences may influence the phenotypic explanation of gender 
differences (Froggatt et al, 1999; Dunlop et al, 1997). These differences may account for 
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the different phenotypes in males than females. This area of interest is being studied by a 
PhD student involved with the CRC-lliRT project. In addition, the NFCCR will evaluate 
psychosocial aspects of CRC, lifestyle and dietary habits of CRC cases. 
It may be possible to test for MSI in the general population; however this pilot 
study could not effectively determine its value as a screening test for the detection of 
HNPCC. Further population based studies with larger numbers are needed to interpret 
MSI analysis in order to improve its potential use as screening test for HNPCC. 
In future, the significance of such findings may lead to improved stratification of patient 
treatments, such as chemotherapy, and potentially gene therapy. It seems likely that 
improvement in the molecular genetics in CRC will also be applied to other cancers as 
well. 
Summary 
The present study concluded that the risk for HNPCC is high in the Eastern 
Newfoundland population. Nine percent of families (n=7) are at high risk for HNPCC, 
by the Amsterdam I and ll criteria. However, 3 of these families had MSS tumours and 
the tumours expressed all proteins. It is likely that there are unknown MMR repair genes 
or other genes responsible for HNPCC in this population. Another 37 families (47%) are 
also at higher risk for HNPCC by less strict criteria. Furthermore 5 LR families warrant 
further investigation because of molecular findings. To prevent overestimating HNPCC 
in this population a worse case scenario analysis was completed. If we assume that all 
non-responders (n=lOO or 56%) belong to non-Amsterdam Criteria families we could say 
that the potential frequency of Amsterdam Criteria I and ll families is 7/178 or 4%, and 
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the potential frequency of families at higher risk for HNPCC is 3 7/178 or 21%. Therefore 
the potential range in frequency of Amsterdam Criteria families is between 4 and 9%, and 
the potential range in frequency of families at higher risk for HNPCC is between 21 and 
47%. 
A combination of family history, microsatellite instability analysis, and 
immunohistochemistry analysis appear to be a valuable diagnostic tool in the search for 
mutations and also valuable for the identification of families that may warrant further 
exploration. In the near future, there will likely be strict clinical and pathological 
guidelines for testing specimens. A study of this nature demonstrates the need for a 
multidisciplinary approach to the identification and care of HNPCC families, as it 
involves the collection of a vast amount of information and would be difficult for any one 
discipline. It is difficult to draw any major conclusions because of the low number of 
families in our study. Therefore, further studies, such as the ClliR-lliRT study, should 
be performed to improve evaluation of the significance of our findings. The development 
of a specialised Newfoundland familial CRC registry is currently on going. Its 
development will take 5 or more years and will identify the true incidence of HNPCC 
within the Newfoundland population so that appropriate resources will be developed for 
its future identification and management. 
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INTERMEDIATE CRITERIA 1 (n= 11) 
MSS and no loss (n = 8 families) 
Proband number 2 (pedigree 34) is a 67 year old male who was diagnosed, in 
1997, with a moderately differentiated cancer of the transverse colon with liver 
metastasis at age 62. Pathology at the time of the surgery revealed the presence of 10 
villo-nodular and tubular polyps. He also had a prostate cancer at age 63 and a melanoma 
at age 54. The proband was born in Kingwell, Placentia Bay and he now resides in Little 
Harbour. His mother and his maternal grandfather originated from Kingwell, Placentia 
Bay. His maternal grandmother originated from Hopeall. His father and paternal 
grandparents originated from Kingwell, Placentia Bay. The pedigree constructed consists 
of 46 relatives. He has 9 first degree relatives: 1 child, 6 siblings and parents. His 
mother died of a HNPCC cancer, stomach cancer, at age 71. His father was diagnosed 
with a throat cancer at age 69 and he died at age 81. No other cancers were reported in 
his first degree relatives. He has 24 second degree relatives. Three HNPCC cancers 
were reported in second degree relatives. A liver cancer was reported in the maternal 
grandmother. A stomach cancer was reported in a paternal aunt, who died in her 70's, 
and a liver cancer in his paternal grandfather who died in his 60's. A bladder cancer was 
reported in a maternal aunt who died at age 78, a cancer (type unknown) was reported in 
his paternal grandmother, who died in her 60's and another cancer (type unknown) in a 
paternal uncle. No other cancers were reported in the family. 
Proband number 16(pedigree 3 5) is a 63 year old male who was diagnosed, in 
1997, with a moderately differentiated cancer of the sigmoid colon at age 57. He was 
diagnosed with a second primary of the colon in 1999. A chart review revealed 4 benign 
polyps and a hyperplastic polyp on follow-up colonoscopy in 2001. He was born in 
South River and now resides in Manuels. His mother and maternal grandfather 
originated from Clarke's Beach. His maternal grandmother originated from Brigus. His 
father and paternal grandfather originated from South River. His paternal grandmother 
originated from Cupids. The pedigree constructed consists of 43 relatives. He has 10 
first degree relatives: 5 children, 3 siblings, and parents. A brother was diagnosed with a 
HNPCC cancer, CRC, at age 63. His mother died at age 84 from natural causes. His 
father died at age 71 from complications of atherosclerosis. A brother died from prostate 
cancer metastasis at age 64. No other cancers were reported in his first degree relatives. 
He has 25 second degree relatives. Three HNPCC cancers were reported in second 
degree relatives. Endometrial cancer was reported in two maternal aunts at ages 78 and 
83, and stomach cancer was reported in a maternal uncle at age 72. A paternal aunt was 
diagnosed with cervical cancer and she died at age 61. No other cancers were reported in 
the family. 
Proband number 21(pedigree 36) is a 67 year old male who was diagnosed, in 
1997, with a moderately differentiated cancer of the splenic flexure at age 62. This was 
his second primary. His first primary was a cancer of the rectum in 1995. Chart review 
revealed a history of 6 polyps showing a tubular adenoma configuration. He was born in 
New Melbourne, Trinity Bay and now resides in Brownsdale. His mother and paternal 
grandmother originated from New Melbourne. His maternal grandmother originated 
from New Chelsea. His father and paternal grandparents originated form New 
Melbourne. The pedigree constructed consists of 35 relatives. He has 5 first degree 
relatives: 1 child, 2 siblings, and parents. His mother died from childbirth at age 18. His 
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father died at age 65 accidentally. No cancers were reported in his first degree relatives. 
He has 22 second degree relatives. There were four HNPCC cancers reported in second 
degree relatives. A HNPCC cancer, CRC, was reported in his maternal grandmother 
who died at age 88 and a cancer (type unknown) was reported in maternal grandfather 
who died at age 69. HNPCC cancers, stomach cancers were reported in both paternal 
grandparents and a paternal uncle. Another paternal uncle was diagnosed with a prostate 
cancer and died at age 50. No other cancers were reported in the family. 
Proband number 44 (pedigree 37) is a 70 year old female who was diagnosed, in 
1998, with a moderately differentiated cancer of the hepatic flexure at age 66. 
Chemotherapy was required. She was born in Brigus South. Her parents and 
grandparents originated from Brigus South. The pedigree constructed consists of 76 
relatives. She has 15 first degree relatives: 4 children, 9 siblings and parents. Her 
daughter died at age 36 from cervical cancer. Her sister was diagnosed with a breast 
cancer at age 59. Her mother died at age 85 from Alzheimer's and her father died at age 
91 from a stroke. There are no reported cancers in her first degree relatives. She has 
3 5 second degree relatives. There were three HNPCC cancers reported on the paternal 
side of her family. They included a CRC in a paternal uncle at age 68, a stomach cancer 
in a paternal aunt at age 49, and a stomach cancer in a paternal cousin (age unknown). 
Other cancers reported include a lip cancer and a breast cancer in 2 paternal cousins and a 
cancer (type unknown) in a paternal uncle. No other cancers were reported in the family. 
Proband number 72 (pedigree 38) is a 62 year old female who was 
diagnosed, in 1997, with a moderately differentiated cancer of the descending colon at 
age 57. She was diagnosed with liver metastasis in 1998, again in 1999, and then finally 
3 
metastasis to the lung in 2001. She was born in Dildo, Trinity Bay and now resides in 
Mt. Pearl. Her mother originated from Thornlea. Her maternal grandparents originated 
from Trinity Bay although the exact location was not given. Her father and paternal 
grandfather originated from Dildo, Trinity Bay. Her paternal grandmother originated 
from Norman Cove. The pedigree constructed consisted of80 relatives. She has 14 first 
degree relatives: 4 children, 8 siblings, and parents. Her mother died at age 53 from 
metastasis to her spine form a HNPCC cancer, kidney cancer. A sister was diagnosed 
with breast cancer at age 55. No other cancers were reported in first degree relatives. 
Polyps were reported in three siblings. Crohn' s was reported in two siblings. One child 
was scoped. Her father died at age 52 from complications of asthma. She has 33 second 
degree relatives. Three HNPCC cancers were reported in second degree relatives. A 
paternal aunt was diagnosed with CRC at age 63, her paternal grandfather was diagnosed 
with CRC before age 68, and a paternal uncle was diagnosed with a stomach cancer 
before age 62. Another paternal uncle was diagnosed with a lung cancer, age unknown. 
A paternal aunt was diagnosed with a skin cancer, age unknown. A cancer, unknown 
type, was reported in a maternal aunt in her 80's. No other cancers were reported in 
second degree relatives. A maternal cousin was diagnosed with prostate cancer at age 62, 
and another maternal cousin was diagnosed with lung cancer. Two maternal cousins are 
diagnosed with breast cancers, age unknown. 
family. 
No other cancers were reported in the 
Proband number 126 (pedigree 39) is a 58 year old male who was diagnosed, in 
1998, with a moderately differentiated cancer of the rectum at age 54. Chemotherapy and 
radiation were required. Past history reveals the presence of polyps (no details given). 
4 
He was born in Colliers where he now resides. His mother originated from Colliers. His 
paternal grandfather originated from Colliers and his paternal grandmother originated 
from Conception Harbour. He has 17 first degree relatives: 15 siblings, and parents. His 
mother died at age 74 from pneumonia and his dad died at age 57 from heart 
complications. A brother has crohn' s. He has 31 second degree relatives. Two HNPCC 
cancers are reported in his maternal family. A maternal uncle was diagnosed with CRC 
at age 73, and his maternal grandmother was diagnosed with stomach cancer at age 82. 
No other cancers were reported in the family. 
Proband number 112 (pedigree 40) is a 64 year old female who was diagnosed, in 
1997, with a moderately differentiated cancer of the colon .at age 59. Pathology revealed 
the presence of a tubular adenoma. She was born in Bauline and now resides in Pouch 
Cove. Her mother and her maternal grandfather originated from Bauline, and her 
maternal grandmother originated from Chelsea, Trinity Bay. Her father and paternal 
grandfather originated from Bauline. Her paternal grandmother originated from 
Blackhead. The pedigree constructed consists of 44 relatives. She has 7 first degree 
relatives: 2 children, 3 siblings, and parents. Her mother died of a basal cell carcinoma at 
age 87. Her father is alive and is age 89. A sister was diagnosed with breast cancer at 
age 58. There are no other reported cancers in first degree relatives. She has 26 second 
degree relatives. There were 2 HNPCC cancers reported in her second degree relatives. 
They included a CRC in a maternal aunt who died at 68 and a lymphoma at 68 in 
maternal aunt who also had a cervical cancer at 64. A bone cancer was diagnosed in her 
maternal grandmother who died at 76. No other cancers were reported in the family. 
5 
Family members were referred to the Medical Genetics Clinic because several members 
(maternal cousins) are affected with Bardet-Biedel Syndrome. 
Proband number 174 (pedigree 41) is a 57 year old female who was diagnosed, in 
1997, with a moderately differentiated cancer of the sigmoid colon at age 52. Pathology 
revealed 2 small polyps. She was diagnosed with liver metastasis in 2000. She was born 
in St. John's, where she now resides. The pedigree constructed consists of 96 relatives. 
She has 16 first degree relatives: 2 children, 12 siblings, and parents. A brother was 
diagnosed with a skin cancer at age 56 and another brother was diagnosed with a prostate 
cancer at 63. Her father died at age 56 from throat cancer. No other cancers were 
reported in first degree relatives. Her mother died at age 87 due to an aneurysm. She has 
52 second degree relatives. Two HNPCC cancers are reported in second degree relatives. 
CRC was diagnosed in a paternal aunt at age 60 and the paternal grandmother at age 50. 
Leukemia was reported in a maternal aunt at age 82. No other cancers were reported in 
the family. 
MSS and pending me (n = 2 families) 
Proband number 100 (pedigree 42) is now deceased. He was diagnosed, in 1998, 
with a well differentiated cancer ofthe sigmoid colon at age 64. Chart review indicated 
the presence of 2 tubulovillous polyps and a tubular polyp in 1999. He died 2 years later 
with liver and lung metastasis. He was also diagnosed with a skin cancer at age 65. A 
daughter was identified as a proxy. He was born in Port de Grave and resides in 
Bareneed. His mother and maternal grandfather originated from Bay Roberts. His 
maternal grandmother originated from Coley's Point. His father and his paternal 
grandfather originated from Port de Grave. His maternal grandmother originated form 
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Salmon Cove, South River. The pedigree constructed consists of 77 relatives. He has 10 
first degree relatives: 2 children, 6 siblings, and parents. A brother was diagnosed with a 
HNPCC cancer, CRC, at age 80. His father was diagnosed with leukemia and died at age 
61. A brother was diagnosed with prostate cancer at age 61 No other cancers were 
reported in his first degree relatives. His mother died at age 61 form a stroke. He has 46 
second degree relatives. A nephew was diagnosed with skin cancer at age 49. No other 
cancers were reported in his second degree relatives. There were 5 HNPCC cancers 
reported in maternal cousins. Two siblings were diagnosed with a CRC, one at age 65 
and the other at age 59. Another maternal cousin was diagnosed with a CRC and a 
stomach cancer at age 53. Two HNPCC cancers were diagnosed in paternal cousins. A 
CRC was diagnosed at age 60 in one cousin and CRC was reported at age 60 in another 
cousin. No other cancers were reported in the family. This proband is related to a family 
previously referred to the Medical genetics program for rod cone dystrophy. 
Proband number 137(pedigree 43) is now deceased. He was diagnosed, in 1998, 
with a well differentiated cancer of the rectosigmoid junction with liver metastasis at age 
56. He died the same year. His wife was identified as the proxy. He was born in 
Manuels. His mother and maternal grandfather originated from Heart's Desire. His 
maternal grandmother originated from Heart's Content. His father originated from 
Whitbourne. His paternal grandmother originated from Spaniards Bay and his paternal 
grandfather originated from Clarke's Beach. The pedigree constructed consisted of 47 
relatives. He had 6 first degree relatives: 2 children, 2 siblings, and parents. A HNPCC 
cancer, stomach (epigastric), was diagnosed in his brother at age 52. His father was 
diagnosed with prostate cancer and died at age 75. His mother died at age 75 from heart 
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complications. He had 19 second degree relatives. His paternal grandparents were 
diagnosed with 2 cancers, type unknown. A maternal aunt was diagnosed with a brain 
tumour and died at age 80. Two maternal uncles were diagnosed with lung cancers, one 
at age 57 and the other at age 78. No other cancers were reported in second degree 
relatives. Two HNPCC cancers were reported in cousins. A paternal cousin was 
diagnosed with a CRC at age 55. A maternal cousin was diagnosed with a liver cancer, 
age unknown. No other cancers were reported in this family. 
No sample available for Molecular and Pathology analysis (n=l family) 
Proband number 107 (pedigree 44) is a 66 year old male who was diagnosed, in 
1998, with a cancer of the descending colon at age 62. He was born in New Harbour, 
Trinity Bay and now resides in St. John's. His mother originated from Spread Eagle, 
Trinity Bay. The origin of his maternal grandparents was not given. His father 
originated from New Harbour and was raised by a "foster" family. The pedigree 
constructed consists of 55 relatives. He has 10 first degree relatives: 2 children, 6 
siblings, and parents. His sister died at age 71 due to metastases from lung cancer. His 
mother was diagnosed with breast cancer at age 93. No other cancers were reported in 
first degree relatives. He has 17 second degree relatives. A throat cancer was reported in 
a maternal aunt at age 40. No other cancers were reported in second degree relatives. 
Three HNPCC cancers were reported in maternal cousins; a CRC in one cousin (age >50) 
and CRC and stomach cancer in another cousin at age 59. No other cancers were reported 
in the family. 
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INTERMEDIATE RISK 5 (n =2) 
MSS and No loss (n=2 families) 
Proband number 6 (pedigree 45) is a 74 year old female who was diagnosed in 
1998 with a well differentiated cancer of the transverse colon at age 69. Records 
revealed that this was her second primary. She was diagnosed in 1996 with a cancer of 
the ascending colon. She also had a small polyp at the time of surgery. She was born in 
Carbonear, and now resides in Harbour Grace. Her parents and grandparents were from 
Carbonear. The pedigree constructed consisted of 41 relatives. She has 8 first degree 
relatives: 4 children, 2 siblings, and parents. Her father lived to age 61, and he died in 
1956 after suffering a severe asthma attack. He was reported to have had a cancer of the 
prostate. Her mother lived to age 76, and she died in 1970 due to heart trouble. Her two 
siblings both had a non HNPCC cancer. Her brother died at the age of 68 due to 
metastasis from a skin cancer. Her sister had a breast cancer, and died at the age of 62 
due to complications during a heart surgery. No other cancers were reported in her first 
degree relatives. She has 23 second degree relatives. Her maternal grandfather died from 
a HNPCC cancer, stomach cancer, at age 60. She reported a CRC in a paternal aunt at 
age 50. This aunt lived to be 90. She also reported non HNPCC cancers in 2 paternal 
aunts and 1 paternal uncle. They were a breast cancer, a prostate cancer and cancer (type 
unknown). No other cancers were reported in second degree relatives. She also reported 
a breast cancer at age 53 in a maternal cousin. No other cancers were reported in the 
family. 
Proband number 61 (pedigree 46) is a 72 year old woman who was diagnosed in 
1997 with a poorly differentiated cancer of the sigmoid colon at age 66. She was 
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diagnosed in 1999 with a second primary, a cancer of the rectosigmoid junction. She was 
born in St. John's where she resides. Her mother and her maternal grandmother 
originated from Winterton. She was unaware of her maternal grandfather's origin. Her 
father and her paternal grandfather originated from Whitbourne. She was unaware of the 
origin of her paternal grandmother. The pedigree constructed consisted of 58 relatives. 
She has 5 first degree relatives: 1 child, 2 half sibs (different father, previous marriage), 
and parents. Her mother died at age 83. Her father died at age 73 due to a cerebral 
haemorrhage. No other cancers were reported in her first degree relatives. She has 14 
second degree relatives. Two cancers were reported in her second degree relatives. A 
breast cancer was reported in a niece at approximately age 50. There was a reported 
cancer (type unknown) in her maternal grandmother who died in her 60's. No other 
cancers were reported in the family. 
INTERMEDIATE RISK 7- Pathology (n = 4 families) 
MSS and No loss (n= 4 families) 
Proband number 27(pedigree 47) is a 71 year old female who was diagnosed, in 
1997, with a moderately differentiated cancer of the colon at age 66. She was also 
diagnosed with a breast cancer at age 48. Chart review reveals the presence of 17 
hyperplastic and tubular adenomatous polyps in 1998. Follow-up colonoscopies 
revealed 6 polyps of which 3 were tubular adenomas. Her parents and grandparents 
originated :from Long Pond and Kelligrews, Conception Bay South. The pedigree 
constructed consists of 66 relatives. She has 9 first degree relatives: 4 children, 3 siblings, 
and parents. A HNPCC cancer, CRC, and a breast cancer were diagnosed in her mother 
at age 63. Her brother died at age 26 due to leukemia. No other cancers were reported in 
10 
first degree relatives. Multiple polyps are reported in 3 of her children. Her father died 
due to a stroke at age 76. She has 23 second degree relatives. No cancers were reported 
in second degree relatives. A HNPCC cancer, CRC, is reported (age unknown) in a 
paternal cousin. A cancer (type unknown) is reported in another paternal cousin. No 
other cancers were reported in the family. 
Proband number 73 (pedigree 48) is 54 year old man who was diagnosed, in 1998, 
with a moderately differentiated cancer of the ascending colon at age 49. Pathology 
revealed the presence of 20 polyps (tubular adenomata). There have been more on 
follow-up colonoscopies. He was born in Come by Chance, and now resides in Mt. 
Pearl. His mother originated from Lethbridge, Bonavista Bay. The pedigree constructed 
consists of 99 relatives. He has 13 fust degree relative; 2 children, 9 siblings (6 half 
siblings), and parents. A HNPCC cancer, esophageal cancer, was reported in a half sister 
at age 56. A lung cancer was reported in a brother at age 43. No other cancers were 
reported in first degree relatives. His mother died at age 73 due to a heart attack, and his 
father died at age 84 due to heart complications. He has 36 second degree relatives. Skin 
cancer was reported in 2 nieces (maternal) at ages 45 and 54. Another skin cancer was 
reported in a paternal uncle at age 81. There were no other reported cancers in second 
degree relatives. A HNPCC cancer, stomach cancer, was reported at age 37 in a paternal 
cousin. No other cancers were reported in the family. 
Proband number 97 (pedigree 49) is a 63 year old male who was diagnosed, in 
1998, with a moderately differentiated cancer of the hepatic flexure at age 58. Pathology 
revealed the presence of a cancer in a polyp and 7 adenomatous polyps. He was recently 
diagnosed with prostate cancer. He resides in Bishops Cove. His mother's family 
11 
originates :from Conception Bay. Information pertaining to his father and paternal family 
is not available. The pedigree constructed consists of 42 relatives. He has 8 first degree 
relatives: 4 children, 3 siblings (half, mother remarried), and a mother. His mom died at 
age 85. His son was diagnosed with HNPCC cancer, lymphoma at age 28. Two brothers 
were diagnosed with prostate cancer, one at age 49 and the other at age 51. He has 12 
second degree relatives. His maternal grandfather was diagnosed with HNPCC cancer, 
CRC at age 77. A maternal uncle was diagnosed with Hodgkin's at age 40. No other 
cancers were reported in the family. The proband was previously referred to the Medical 
genetics program. 
Proband number 118 (pedigree 50) is now deceased. He was a male who was 
diagnosed, in 1997, with a well differentiated cancer ofthe cecum with lung metastasis. 
He was diagnosed with a recurrent cancer in 1998. Polyps were reported as multiple 
villous adenomata with foci of carcinoma in situ. He had a 22 year history of ulcerative 
colitis. He was born in New York and resided in St. John's. His father and paternal 
grandparents originated from Italy. His mother and maternal grandparents originated 
:from Pennsylvania. The pedigree constructed consists of 47 relatives. He has 8 first 
degree relatives; 2 children, 4 siblings, and parents. Breast cancer was reported in his 
sister at age 49. His mother died at age 59 after she was diagnosed with a choroidal 
melanoma at age 56. No other cancers were reported in first degree relatives. He has 20 
second degree relatives. A HNPCC cancer, endometrial cancer was reported in his 
maternal grandmother at age 75. No other cancers were reported in the family. The 
proband was previously referred to the Medical genetic program because several other 
family members with crohn's and ulcerative colitis. 
12 
;· 
Pedigree 45 
84 60 
br@60 
Intermediate 5-Family 6 
MSS 
no loss 
60 86 
90 
CRC@65 
70 
19 19 
70 
5 8 
60 
73 . 68 
CRC @69 Sk @68 
CRC@67 
61 
pr@61 
19 21 16 19 22 
55 
60 
st@60 
76 
62 
br@57 
50 
70 
70 
70 
Br@53 
81 
Pedigree 46 
91 
50 
'SO's 70's 
Intermediate 5- Family 61 
MSS 
no loss 
childbirth 
90 
CRC@66 
CRC@68 
50 
73 90 78 
77 78 
65-80 
37 55 56 
br 
Pedigree 47 
CRC 
Intermediate 7-Famlly 27 
MSS 
no loss 
40 26 
lk@26 
63 
CRC@63 
br 
70 
CRC@66 
Br@45 
polyps 
29 20 
79 80 78 90 
sk 
Pedigree 48 
67 
st@37 
Intermediate 7 -Family 73 
MSS 
no loss 
54 
sk 
80 
45 
sk 
Pedigree 49 
71 
Pr@69 
BCC@70 
pr@51 
Intermediate 7-Family 97 
MSS 
no loss 
pr@49 CRC@58 
polyps 
lym @28 
82 
CRC@77 
lu@41 
O's 
72 74 76 78 80 
Pedigree 50 Intermediate 7-Famlly 118 
MSS 
no loss 
'O's 
62 
58 
br049 CRC056 
lBO 
polyps 
en 
35 34 
75 80 
LOW RISK (n=29 families) 
Informative (n= 17) 
MSS and No loss (15) 
Proband number 20(pedigree 51) is now deceased. He was a male who was 
diagnosed, in 1998, with a poorly differentiated cancer of the transverse colon at age 64. 
Pathology at the time of surgery revealed the presence of 3 hyperplastic polyps with and 
a tubular adenoma. He subsequently died at age 65 due to a metastasis to the liver. A 
review of his medical records was not possible (missing). The proxy identified was a 
sister. The proband was born in St. Lunaire and lived in St. John's. His mother and 
maternal grandfather originated from Harry's Harbour and his maternal grandmother 
originated from Twillingate. His father and paternal grandparents originated from St. 
Lunaire. The pedigree constructed consists of 68 relatives. The proband had 7 first 
degree relatives: 5 siblings, and parents. He had no children. His father lived to age 75 
and died due to an aneurysm. His mother lived to age 93. Polyps are reported in two of 
the proband's brothers. No cancers were reported in his first degree relatives. He had 27 
second degree relatives. A HNPCC cancer, lymphoma was reported in a paternal aunt at 
age 78 and a leukemia was reported in a paternal cousin at age 29. No other cancers were 
reported in the family. 
Proband number 54 (pedigree 52) is a 72 year old woman who was diagnosed in 
1997 with a moderately differentiated cancer of the descending colon at age 66. One 
polyp was also reported. She was also diagnosed with a basal cell carcinoma on the face. 
She was born in Botwood, where she now resides. Information about the parents and 
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grandparents demographics was not given. The pedigree drawn consists of 3 7 relatives. 
There are 10 first degree relatives: 2 children, 6 siblings, and parents. Her mother died at 
72 due to CV A. Her father died at age 82 due to complications of Alzheimer's. There is 
a bone cancer reported in a sibling at age 72. No other cancers were reported in the first 
degree relatives. There are 34 second degree relatives. A HNPCC cancer, kidney cancer 
with metastasis to the brain was reported in a nephew at age 50. A breast cancer was 
reported in a niece at age 47. No other cancers were reported in the family. 
Proband number 56 (pedigree 53) is a 45 year old woman who was diagnosed, in 
1998, with a moderately differentiated cancer of the rectum at age 42. A sessile polyp is 
also reported. She was born in New Melbourne and now resides in St. John's. Her 
mother and maternal grandparents originated from Whiteway, Trinity Bay. Her father 
and her paternal grandparents originated from New Melbourne, Trinity Bay. The 
pedigree constructed consists of 66 relatives. There are 8 first degree relatives: 1 child, 5 
siblings, and parents. Both of her parents are still alive, her mother is 78, and her father 
is 79. There are no cancers reported in the first degree relatives. There are 23 second 
degree relatives. There are 4 HNPCC cancers, 3 CRC and an ovarian cancer, all 
primaries, in one paternal aunt at age 59. There were 2 cancers (type unknown) 
reported in 2 paternal uncles. A HNPCC cancer, CRC was reported in a maternal aunt in 
her early 50's. No other cancers were reported in the family. 
Proband number 82 (pedigree 54) is a 58 year old male who was diagnosed, in 
1998, with a moderately differentiated cancer of the rectum at age 55. He was born in St. 
John's and now resides in Portugal Cove. His mother and his maternal grandfather 
originated from New Melbourne. His Maternal grandmother originated from Dunfield, 
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Trinity Bay. His father originated from New York City. Because his father originated 
from New York City, he was unaware of his paternal family history. The pedigree 
constructed consists of 34 relatives. He has 8 first degree relatives: 2 children, 4 siblings, 
and parents. His mother died from diabetes complications at age 65, and his father died 
from MI at age 80. No cancers were reported in his first degree relatives. He has 15 
second degree relatives. No cancers were reported in the family. 
Proband number 84 (pedigree 55) is a 52 year old male who was diagnosed, in 
1998, with a moderately differentiated cancer of the rectum at age 45. Pathology 
revealed the presence of a sessile polyp. He was born in St. John's, and he now resides in 
Mt. Pearl. His mother and his maternal grandfather originated from Colinet Island, St. 
Mary's Bay. His father and his parents originated from St. John's. The pedigree 
constructed consists of 61 relatives. He has 11 first degree relatives: 2 children, 2 
siblings, and parents. His mother is 73 years old. His father died of metastases to the 
lung from a prostate cancer at age 72. No other cancers are reported in first degree 
relatives. He has 35 second degree relatives. A HNPCC cancer, CRC was reported in his 
paternal grandfather who died at age 75. A cancer of the bone was reported in a paternal 
uncle who died at age 65, and a cancer (type unknown) was reported in another paternal 
uncle. He reported leukemia in his maternal grandfather who died at age 78 and a cancer 
(type unknown) in a maternal uncle, who died at age 70. No other cancers were reported 
in the family. 
Proband number 121(pedigree 56) is a 44 year old female who was diagnosed, in 
1997, with a poorly differentiated cancer of the cecum at age 37. The proband was born 
in St. John's where she now resides in St. John's. Her maternal family came from Old 
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Perlican. The origins of her paternal family were unknown. The pedigree consists of 47 
relatives. She has 14 first degree relatives: 1 child, 11 siblings, and parents. Her mother 
died at age 71 from heart complications. A sister is also deceased from heart 
complications. Polyps are reported in 2 siblings. No cancers were reported in first 
degree relatives. She has 35 second degree relatives. A HNPCC cancer, stomach cancer 
was reported in a maternal uncle in his 70's. A breast cancer is reported in a maternal 
aunt at age 64, a lung cancer is reported in a maternal uncle at age 72, and a prostate 
cancer (age unknown) in a maternal uncle. No other cancers were reported in the family. 
Proband number 125 (pedigree 57) is a 73 year old male who was diagnosed, in 
1997, with a moderately differentiated cancer of the rectum at age 68. Chart review 
indicates an adenoma and hyperplastic polyps. He was born in LongPond where he now 
resides. His mother originated from Paradise. His maternal grandparents originated from 
Island Cove. His father and paternal grandfather originated from Longpond. His 
paternal grandmother originated from Port de Grave. The pedigree constructed consists 
of 37 relatives. He has 7 first degree relatives: 3 children, 2 siblings, and parents. His 
mother is alive and is age 97. His father died of heart complications at age 62. No 
cancers were in his :first degree relatives. He has 24 second degree relatives. A HNPCC 
cancer, stomach cancer was reported in a maternal uncle who died in his 70's. A breast 
cancer was reported in his maternal grandmother at age 81 and a cancer (unknown type) 
in a maternal aunt who died at 68. No other cancers were reported in the family. 
Proband number 16l(pedigree 58) is a 62 year old male who was diagnosed, in 
1997, with a moderately differentiated cancer of the cecum at age 57. He was born in 
Hants Harbour. His mother and maternal grandfather originated from Hants Harbour. 
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His maternal grandmother originated from Hearts Content. His father and paternal 
grandparents originated from Hants Harbour. The pedigree constructed consists of 45 
relatives. He has 11 first degree relatives: 3 children, 6 siblings, and parents. His 
mother is still alive and is age 86. His father died from heart complications at age 76. A 
son was diagnosed with chrons at age 20. No cancers were reported in first degree 
relatives. He has 19 second degree relatives. No cancers were reported in second degree 
relatives. There is a cancer (unknown type) reported in a maternal cousin who died at 
age 49. No other cancers were reported in the family. 
Proband number 166 (pedigree 59) is a 62 year old male who was diagnosed with 
a cancer of the rectum at age 58. He was born in Little Harbour West, Placentia Bay. 
His mother and his maternal grandparents originated from Little Harbour West, Placentia. 
His father and paternal grandfather originated from Baie de Lou. His paternal 
grandfather originated from Oderin. The pedigree constructed consists of 91 relatives. 
He has 14 first degree relatives, 4 children, 8 siblings, and parents. His mother died from 
heart complications at age 80. His father died from heart complications at age 82, and he 
also had a skin cancer diagnosed at 58. A sister died of a pancreatic cancer at age 49. A 
brother was diagnosed with a skin cancer, he is now 52. He has 40 second degree 
relatives. There were 3 cancers reported in the second degree relatives. They included a 
breast cancer in a paternal aunt who died at age 80, a lung cancer in a paternal uncle who 
died at 49, and a skin cancer in a paternal uncle who died at age 50. No other cancers 
were reported in the second degree relatives. There is a HNPCC cancer, stomach cancer 
and a prostate cancer reported in 2 maternal cousins. No other cancers were reported in 
the family. 
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Proband number 22 (pedigree 60) is a 62 year old male who was diagnosed, in 
1998, with a moderately differentiated cancer of the sigmoid at age 58. Pathology at the 
time revealed the presence of a small hyperplastic polyp and a tubular adenoma. 
Chemotherapy was required. His cancer reoccurred in 2000. He is currently undergoing 
treatment for metastases to the liver and lungs. He was born in Woodstock, Ontario. He 
now resides in St. John's. His mother and his maternal grandmother originated from 
Ontario. His maternal grandfather originated from Surrey, England. His father and his 
paternal grandparents originated from Ontario. The pedigree constructed has 28 relatives. 
He has 5 first degree relatives: 3 siblings, and parents. He has no children. He reported 
that his father had a total colectomy at age 40 because of colonic polyposis and died at 
the age of 67 due to heart complications. Further investigation of his father's records is 
needed to rule out FAP or AFAP in the proband's family. His mother lived to age 83. 
No other cancers were reported in his first degree relatives. He has 14 second degree 
relatives. A paternal aunt had a bone cancer and died at 55. No other cancers were 
reported in the family. 
Proband number 24 (pedigree 61) is a 56 year old man who was diagnosed, in 
1998, with a moderately differentiated cancer ofthe sigmoid at age 52. He was born in 
Freshwater, Carbonear. He now resides in Norman's Cove. His mother and maternal 
grandfather originated from Carbonear. His Maternal grandmother originated from 
Western Bay, CB. His father and his paternal grandfather originated from Carbonear. 
His paternal grandmother originated from Small Point, Conception Bay. The pedigree 
constructed consists of 50 relatives. He has 9 first degree relatives: 2 children, 5 siblings, 
and parents. His father died at age 59 of a HNPCC cancer, stomach cancer, for which he 
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had no surgery. His father also had a benign brain tumour diagnosed at age 51. His 
mother is still alive and is 87 years old. A brother had a pre-cancerous mole removed at 
age 59. Polyps are reported in 2 other siblings. No other cancers were reported in his 
first degree relatives. He has 14 second degree relatives. A lung cancer is reported in his 
maternal grandfather. No other cancers were reported in the family. 
Proband number 41 (pedigree 62) is a 72 year old male who was diagnosed, in 
1997, with a well differentiated cancer of the sigmoid colon at age 67. He now resides in 
Dunville. He was born in Burin. His Mother and maternal grandparents originated form 
Marystown. His father originated from Burin. His Paternal grandmother originated from 
Paradise. His Paternal grandfather originated from Marystown. The pedigree 
constructed consists of 129 relatives. He has 17 1st degree relatives: 6 children, 9 
siblings, and 2 parents. His mother died an accidental death at age 58. His father died at 
age 54 due to a ruptured appendix. There were 2 cancers reported in his siblings. They 
included a melanoma at age 55 and a prostate cancer (age not given). All of his children 
were scoped. He has 22 second degree relatives. No other cancers were reported in his 
second degree relatives. There were 2 reported cancers in maternal cousins. They 
included a prostate cancer (age not given), and a brain cancer where the affected was 
dead by age 60. A Prostate cancer was reported in a paternal cousin who died at age 89. 
No other cancers were reported in the family. 
Proband number 81 (pedigree 63) is a 64 year old male who was diagnosed, in 
1998, with a moderately differentiated cancer of the cecum at age 61. Pathology at the 
time also revealed the presence of a hyperplastic polyp. Chart review indicated the 
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presence of a small tubulovillous polyp in 1999, 2 small tubular adenomas in 2000, and a 
small tubular adenoma in 2002. He was born in St. John's and now resides in Mt. Pearl. 
His mother and maternal grandfather originated from St. John's. His maternal 
grandmother originated from Harbour Main. His father and his parents originated from 
St. John's. The pedigree const~cted consists of 66 relatives. He has 10 first degree 
relatives: 5 children, 3 siblings, and parents. His mother died from diverticulitis at age 
69, and his father died of lung cancer at age 49. No other cancers were reported in his 
first degree relatives. He has 17 second degree relatives. He reported 3 cancers in his 
second degree relatives: a prostate cancer in a maternal uncle, a throat cancer in a 
maternal aunt, and a breast cancer in a paternal aunt. He reported 2 other cancers in 
maternal cousins. They included a lung cancer at age 64 and a breast cancer at age 59. 
No other cancers were reported in the family. 
Proband number 92(pedigree 64) is a 62 year old female who was diagnosed, in 
1997, with a moderately differentiated cancer ofthe sigmoid colon at age 57. Pathology 
revealed the presence of a polyp. She was born in Upper Island Cove, Conception Bay 
and now resides in St. John's. Her parents and her grandparents originated from Upper 
Island Cove. The pedigree constructed consists of 66 relatives. She has 10 first degree 
relatives: 5 children, 3 siblings, and parents. Her mother died of childbirth complications 
at age 29. Her father died of heart complications at age 57. No cancers were reported in 
her first degree relatives. She has 33 second degree relatives. Two HNPCC cancers, 
CRC were reported in a maternal uncle who died at age 80, and in a paternal aunt who 
died at age 80. A cancer (type unknown) was reported in another paternal aunt who died 
at age 70. No other cancers were reported in the family. 
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Proband number 115 (pedigree 65) is a 60 year old female who was diagnosed, in 
1998, with a moderately differentiated cancer of the rectosigmoid junction at age 55. 
Chart review indicated the removal of three benign polyps in 1999. She was born in St. 
John's and now resides in Paradise. Her mother originated from Wesleyville. Her 
maternal grandmother originated from Fogo. She did not know where her maternal 
grandfather originated. Her father and her paternal grandfather originated from 
Winterton, Trinity Bay. She did not know where her paternal grandmother originated. 
The pedigree constructed consists of 35 relatives. She has 3 first degree relatives: 1 
sibling and parents. Her mother died from diabetes complications at age 78. Her father 
died from natural causes at age 92. No cancers were reported in her first degree relatives. 
She has 18 second degree relatives. A HNPCC cancer, CRC was reported in a maternal 
aunt at age 55. A breast cancer was reported in a paternal cousin in her 60's. No other 
cancers were reported in the family. During consultation with Dr. Green it was noted that 
her maternal grandfather is a member of a previously identified "family C". The cancers 
reported in her family appear to be unrelated. Her blood sample (not yet collected) will 
be sent for mutation testing. 
Pending Laboratory results (n=2) 
Proband number 116 (pedigree 66) is now deceased. She was diagnosed, in 1997, 
with a poorly differentiated cancer of the rectosigmoid junction with liver metastasis at 
age 58. She subsequently died at age 59. Chart review indicated the presence of multiple 
benign hyperplastic polyps. Her daughter and her father were identified as the proxy. 
The proband was born in Woody Point, Bonne Bay and she resides in Holyrood. Her 
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mother and her maternal grandfather originated from Woody Point. Her maternal 
grandmother originated from Labrador, Lanse aux Clair. Her father originated from 
Woody Point, Bonavista Bay. Her paternal grandfather originated from Troix Rivieres, 
Quebec. The origin of her paternal grandmother was not known. The pedigree 
constructed consists of 42 relatives. She has 17 first degree relatives; 5 children, 10 
sibling, and parents. Breast cancers were reported her mother at age 76 and in 2 sisters 
at ages 44 and 48. No other cancers were reported in first degree relatives. She has 33 
second degree relatives. Breast cancer was reported in a maternal aunt at age 31 and the 
maternal grandmother at age 82. A breast cancer was also reported in a paternal aunt in 
her 40's. No other cancers were reported in second degree relatives. Three breast 
cancers were reported in 3 maternal cousins (siblings) at ages 49, 59, and age unknown .. 
Her husband was also diagnosed with a colorectal cancer at age 58. There are no other 
reported cancers in the family. This family was previously referred to the Medical 
Genetics Clinic because of a significant family history of breast cancer 
Proband number 145(pedigree 67) is a 60 year old male who was diagnosed, in 
1997, with a moderately differentiated cancer of the rectum at age 56. He was born in St. 
John's where he now resides. His parents and grandparents originated from St. John's. 
The pedigree constructed consists of 39 relatives. He has 13 first degree relatives: 4 
children, 7 siblings, and parents. His mother died of heart complications at age 79. His 
father died from complications of surgery at age 81. He has no reported cancers in his 
first degree relatives. He has 23 second degree relatives. There were 2 reported cancers 
in his second degree relatives: a pancreatic cancer in a paternal uncle who died at age 72 
22 
and a breast cancer in a paternal uncle who died at age 65. No other cancers were 
reported in the family. 
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Pending laboratory 
LOW RISK Uninformative families (n=12) 
Proband number 65 (pedigree 68) is a 58 year old male who was diagnosed, in 
1998, with a moderately differentiated cancer ofthe sigmoid colon at age 53. Pathology 
reveals the presence of two hyperplastic polyps. Previous history reports the removal of 
a benign mole. He was born in St. John's where he now resides. He wanted to 
participate in the research but at this time did not want to disclose much information 
therefore the pedigree drawn contains little information. The family is informative 
because there were insufficient family details given by the proband. The only 
information given was that his father died at the age of 67 following a surgery to give 
him a colostomy. The family is uninformative because there were insufficient family 
details given by the proband. 
Proband number 66 (pedigree 69) is 54 year old female who was diagnosed, in 
1998, with a moderately differentiated cancer ofthe transverse colon at age 51. She was 
born in St. John's where she now resides. Her mother and her father and their parents 
originated from Petty Harbour. The pedigree constructed consists of 57 relatives. She 
has 14 first degree relatives: 2 children, 10 siblings, and parents. Her mother is 74 years 
old. Her father died of an aneurysm at the age of 78. No cancers were reported in her 
first degree relatives. She has 30 second degree relatives. No cancers were reported in 
the family. The family is uninformative because there are less than six siblings at risk 
greater than 60 years old. 
Proband number 68 (pedigree 70) is now deceased. He was a male who was 
diagnosed, in 1997, with a moderately differentiated cancer of the rectosigmoid junction 
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with liver metastasis at age 49. Pathology revealed the presence of3 sessile polyps. He 
subsequently died a year later. His wife acted as the proxy. He was born in St. John's 
and resided in Mt. Pearl. Both ofhis parents and their parents originated from St. John's. 
The pedigree constructed consists of 34 relatives. He has 5 first degree relatives: 1 child, 
2 siblings, and parents. His mother died of Alzheimer's at age 72. His father died from 
heart complications at age 72. One brother died of a stroke at age 56. No cancers were 
reported in his first degree relatives. He has 15 second degree relatives. A breast cancer 
was reported at age 65 in a maternal aunt. No other cancers were reported in the second 
degree relatives. There were 2 cancers reported in maternal cousins. A HNPCC cancer, 
CRC, at age 45, and a cancer (unknown type) at age 45 in another cousin. No other 
cancers were reported in the family. The family is uninformative because there were 
insufficient family details given by the proband. 
Proband number 7 4 (pedigree 71) is a male who was diagnosed, in 1998, with a 
moderately differentiated cancer of the cecum at age 65. Chart review indicated that the 
proband had undergone a bowel resection in 1980. An adenoma was also reported in 
1995, and a he had a polyp removed in 2001. He was born in China. His Family 
originated from China. His father came to St. John's in 1927, and the family followed. 
He did not know his grandparents. The pedigree constructed consists of 23 relatives. He 
has 8 first degree relatives: 3 children, 3 siblings, and parents. His father died from high 
blood pressure at age 66. His mother died of natural causes at age 98. No cancers were 
reported in his first degree relatives. He has 17 second degree relatives. There were 2 
reported cancers in the family. They were a prostate cancer in a nephew, and a cancer 
(unknown type) in another nephew. No other cancers were reported in the family. The 
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family is uninformative because there were insufficient family details given by the 
proband. 
Proband number 77 (pedigree 72) is a male who was diagnosed in 1997 with a 
moderately differentiated cancer of the sigmoid colon at age of 61. Chart review revealed 
the presence of a few polyps. He was born in Moncton, New Brunswick. He now lives 
in St. John's. His mother and his maternal grandfather originated from New Brunswick. 
His maternal grandmother originated from Prince Edward Island. His father and his 
paternal grandfather originated from New Brunswick. His maternal grandmother 
originated from Nova Scotia. The pedigree constructed consists of23 relatives. He has 8 
first degree relatives: 5 children, 1 sibling, and parents. His mother died of Alzheimer's 
at age 86. His father died of heart complications at 84. No cancers were reported in his 
first degree relatives. He has 13 second degree relatives. A breast cancer was reported in 
a paternal aunt at age 59. No other cancers were reported in his second degree relatives. 
A breast cancer was reported in a maternal cousin at age 61. No other cancers were 
reported in the family. The family is uninformative because there are less than six 
siblings at risk. 
Proband number 123 (pedigree 73) is a 39 year old female who was diagnosed, in 
1998, with a moderately differentiated cancer of the sigmoid colon at age 36. She was 
born in Carbonear and now resides in Victoria. Her mother and her maternal 
grandparents originated from Whitbourne. Her father originated from Bell Island. Her 
paternal grandmother originated from Nova Scotia. The origins of her paternal 
grandfather originated are unknown. The pedigree constructed consists of 46 relatives. 
She has 13 first degree relatives: 2 children, 9 siblings, and parents. Her mother died 
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from a rare disease (unknown) at age 52. Her father is still alive and is 73 years old. No 
cancers were reported cancers in her first degree relatives. She has 32 second degree 
relatives. Leukemia was reported in a maternal uncle who died at age 70. No other 
cancers were reported in her second degree relatives. Leukemia was reported in a 
maternal cousin, who died at age 25. No other cancers were reported in the family. The 
family is uninformative because there are less than six siblings at risk greater than 60 
years old. 
Proband number 128(pedigree 74) is a 50 year old male who was diagnosed, in 
1998, with a moderately differentiated cancer of the sigmoid at age 46. He was born in 
Rumania. The pedigree constructed consists of 11 relatives. He has first degree relatives: 
2 children, 1 sibling, and parents. His father was diagnosed with a prostate cancer at age 
74. No other cancers were reported cancers in first degree relatives. He has 6 second 
degree relatives. A HNPCC cancer, CRC, was reported in his paternal grandmother at 
age 80. A prostate cancer was reported in his paternal grandfather at age 85. No other 
cancers were reported in the family. This proband was previously referred to the Medical 
Genetics Clinic. The family is uninformative because there are less than six siblings at 
risk. 
Proband number 133 (pedigree 75) is a 68 year old male who was diagnosed with 
a cancer of the sigmoid at age 62. He was born in St. John's. His Parents and 
grandparents both originated from St. John's. The pedigree constructed consists of 37 
relatives. He has 10 first degree relatives, 4 children, 4 siblings (halt), and parents. His 
mother died in her late 30's from a "tedious disease" when the proband was just 4. He 
did not know his mother's family. His father died at from heart complications at age 68. 
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No cancers were reported in his first degree relatives. He has 22 second degree relatives. 
HNPCC cancers, CRC are reported in a paternal aunt who died in her 70's and in a 
paternal cousin at age 70. No other cancers were reported are reported in the family. The 
family is uninformative because there were insufficient family details given by the 
proband. 
Proband number 149 (pedigree 76) is a male who is now deceased. He was 
diagnosed in 1998 with an undifferentiated cancer of the rectosigmoid junction with liver 
metastasis at age 4 7. He died shortly after he was diagnosed. His wife was identified as 
his proxy. Follow-up with the proband's siblings was attempted but not successful. He 
was born in Kilbride and resided in the Goulds. His mother originated from Kilbride and 
his father originated from Upper Gullies. His grandparent's demographics were not 
given. The pedigree constructed consists of38 relatives. He has 11 first degree relatives: 
2 children, 7 siblings, and parents. His mother died of heart complications at age 71 and 
his father died of a stroke at age 81. A sister died from a cancer (primary unknown, but 
CRC was implied) that had metastasised to her liver and pancreas at age 56. No other 
cancers were reported in his first degree relatives. He has 27 second degree relatives. No 
other cancers were reported in the family. The family is uninformative because there 
were insufficient family details given by the proband. 
Proband number 164 (pedigree 77) is a male who is now deceased. He was 
diagnosed, in 1997, with cancer of the rectosigmoid at age 4 7. He was diagnosed with 
liver and lung metastasis 2 years later and died in 2000. His wife was identified as his 
proxy. He was born and resided in Placentia. His mother and maternal grandfather 
originated from Presque, Placentia Bay. His maternal grandmother originated from 
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Paradic, Placentia Bay. His father and paternal grandparents originated from Placentia. 
The pedigree constructed consists of 44 relatives. He has 4 first degree relatives, 2 
children, and parents. His mother died from HNPCC cancer, CRC at age 62 and his 
father died from heart complications at age 83. No other cancers were reported in his 
first degree relatives. He has 13 second degree relatives. No cancers were reported in 
second degree relatives. There were reported cancers (type unknown) in 3 paternal 
cousins. No other cancers were reported in the family. The family is uninformative 
because there were insufficient family details given by the proband. 
Proband number 177 (pedigree 78) is a female who is now deceased. She was 
diagnosed, in 1997, with a moderately differentiated cancer of the colon with ovary, liver, 
and uterine metastasis at age 50. Her daughter was identified as her proxy. She was born 
in St. John's and resided in Mt. Pearl. Her parents and her grandparents originated from 
St. John's. The pedigree constructed consists of 23 relatives. She has 8 first degree 
relatives: 2 children, 4 siblings, and parents. Her mother died of breast cancer metastasis 
at age 76. Her father died of heart complications at age 70. A sister was diagnosed with 
a kidney cancer at age 66. No other cancers were reported in first degree relatives. She 
has 15 second degree relatives. No other cancers were reported in the family. The family 
is uninformative because there are less than six siblings at risk greater than 60 years old. 
Proband number 28(pedigree 79) is a 56 year old male who was diagnosed, in 
1998, with a moderately differentiated cancer of the descending colon at age 52. The 
proband was born in Twillingate and he now resides in St. John's. His mother and 
maternal grandfather originated from Derry, Ireland. His maternal grandmother 
originated from Scotland. The pedigree drawn consists of 33 relatives. He has 6 first 
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degree relatives: 2 child, 2 siblings, and parents. His mother is alive and is 71 years old. 
His father died at 73 due to heart disease. No cancers were reported in his first degree 
relatives. He had 18 second degree relatives. Breast cancer was reported in a maternal 
aunt at less than 30 years old. No other cancers were reported in the family. The family 
is uninformative because there were insufficient family details given by the proband. 
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March 15th, 2001 
«Title» «FirstName» «LastName» 
«Address 1 » 
«Address2» 
«City», «State» 
<<Postal Code» 
Dear Dr. Becker: 
RE: THE GENETICS OF COLO-RECTAL CANCER IN NEWFOUNDLAND 
I am writing on behalf of a research team of Memorial University to request your 
participation in this study of the genetics of colo-rectal cancer in Newfoundland. The 
investigators include Dr. P. Parfrey, Dr. J. Green, Dr. R. Green, Dr. B. Younghusband 
and myself. Much of the work will be done by graduate students - Fiona Curtis and 
Angela Hyde, who will have direct contact with patients and their families. 
This portion of the study wishes to determine the contribution of genetic factors to 
the incidence of colo-rectal cancer in Newfoundland. It will involve direct contact with 
patients or their families by the graduate students who will take detailed family histories. 
Patients and family members may be asked to contribute blood samples. This has been 
approved by the Human Investigation Committees of Memorial University of 
Newfoundland and the Health Care Corporation of St. John's. Part of the protocol 
requires that the initial contact with the patient should be initiated by their attending 
physician. I am writing to enquire whether you would be willing to sign a standardized 
letter (sample enclosed) which will be sent to your patients or their families asking for 
their participation in this research. 
If you agree to participate, addressed postage paid letters will be provided for you 
to sign which will then be sent to patients or their families. Patients will be asked to 
respond either directly to the research team or your office. 
. . ./2 
Dr. 
March 15th, 2001 
RE: The Genetics of Colo-rectal Cancer in Newfoundland 
We believe that this research may have important benefits in elucidating the 
epidemiology of colo-rectal cancer in Newfoundland and may result in significant 
clinical benefits for patients and their families. 
Thank you for considering this request. Please let me know if you are willing to 
participate at your earliest convenience. If you have any questions or concerns please 
contact me directly. 
WGP/sw 
Enclosure 
Yours sincerely, 
W.G. Pollett, MD, FRCSC 
Professor & Chair 
Discipline of Surgery 
Memorial University ofNF 
Health Sciences Centre 
PHONE: (709) 737-6612 
FAX: (709) 737-5050 
e-mail address: 
~ollett@morgan.ucs.mun.ca 
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Genetics of Colorectal Cancer in Newfoundland Research Project 
DATE: 
--------
DEAR 
Researchers at Memorial University are interested in learning more about the hereditary 
nature of colon and rectal cancer. Most cancers happen by chance but some kinds of 
cancer are inherited. Most colon and rectum cancers are diagnosed in people over 65. 
About I 0% of colon and rectum cancers are inherited, and they often occur before the age 
of 50. 
They need to find out how many people with a diagnosis of colon and rectum cancer in a 
single year have the inherited kind. If a family is found to have an inherited kind then 
research can be used to identify the kind of gene that may cause the cancer in that family. 
This could lead to an earlier diagnosis and treatment for families that have the gene. 
I would like to ask you to take part in the study on behalf of the research team (led by Dr 
Patrick Par:frey, Dr. William Pollett, and Dr. Jane Green). I know that your wife, 
Dorothy was diagnosed with colon and rectum cancer. Family members can give us 
valuable information for this research. Your participation is entirely voluntary. You may 
decide not to take part or you may withdraw from the study at any time. 
If you wish to take part in the study you may call the research team, collect at (709) 777-
7622, or you can contact our office and we will pass your name on to the research team 
and they will contact you by telephone. They will ask you for a convenient time to meet 
with you. During this meeting the researcher will ask you to help trace your family 
history. Ifthere seems to be a family history of colon and rectum cancer, you and your 
family members will be asked to have a simple blood test. This test may or may not be 
able to tell if you have a gene that put you at an increased risk for colon and rectum 
cancer. 
If you do not wish to take part in the research project please call my office between the 
hours of and give your name to my secretary. 
Your participation would be greatly appreciated. With your help the research team hopes 
to learn more about colon and rectum cancer, the role genes play, and how often colon 
and rectum cancer occurs in Newfoundland. 
Yours truly, 
Health Care 
Corporation of St. John's 
Genetics of Colorectal Cancer in Newfoundland Research Project 
DATE: ______ _ 
DEAR~--------------
Researchers at Memorial University are interested in learning more about the hereditary 
nature of colon and rectal cancer. Most cancers happen by chance but some kinds of 
cancer are inherited. Most colon and rectum cancers are diagnosed in people over 65. 
About 10% of colon and rectum cancers are inherited, and they often occur before the age 
of 50. 
They need to find out how many people with a diagnosis of colon and rectum cancer in a 
single year have the inherited kind. If a family is found to have an inherited kind then 
research can be used to identify the kind of gene that may cause the cancer in that family. 
This could lead to an earlier diagnosis and treatment for families that have the gene. 
I would like to ask you to take part in the study on behalf of the research team (led by Dr 
Patrick Parfrey, Dr. William Pollett, and Dr. Jane Green). I know that your ____ , 
---------was diagnosed with colon and rectum cancer. Family members 
can give us valuable information for this research. Your participation is entirely 
voluntary. You may decide not to take part or you may withdraw from the study at any 
time. 
If you wish to take part in the study you may call the research team, collect at (709) 777-
7622, or you can contact our office and we will pass your name on to the research team 
and they will contact you by telephone. They will ask you for a convenient time to meet 
with you. During this meeting the researcher will ask you to help trace your family 
history. If there seems to be a family history of colon and rectum cancer, you and your 
family members will be asked to have a simple blood test. This test may or may not be 
able to tell if you have a gene that put you at an increased risk for colon and rectum 
cancer. 
If you do not wish to take part in the research project please call my office between the 
hours of , and give your name to my secretary. 
Your participation would be greatly appreciated. With your help the research team hopes 
to learn more about colon and rectum cancer, the role genes play, and how often colon 
and rectum cancer occurs in Newfoundland. 
Yours truly, 
General Hospital 
.~00 Prince Philip Drive, St. John's, NcwtiJtmdland, Canada AlB 3V6 Tel. (709)737-6300 t:ax (709)737-6400 
SlTl·.'.· t.c·nn.llllmpn.ll • ).llH:ILll' ( 'hild 1-k.dth ( :,·mn·/<:hildrcn', Rl'lubilit.llion (:cntn: • lxt>n.ml .-\ .. \lilkr < c·ntrr 
St. <'l,lrc'• \lnn ll•"!'it.d • The S.1h.HHIIJ :\nm t;r.l'<' (;,·nn.ll !Jo,pital • lk \\',lltnTl.'mpkmanlk.llth ('rntrc • \\'.lt<Tit>:.: ii<"l''u: 
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FACULTY OF JvfEDICINE -1\lliMORlAL UNIVERSITY OF NEWFOUNDLAND 
AND 
HEALTH CARE CORPORATION OF ST. JOHN'S 
Consent To Participate In Bio-medical Research 
TITLE: The genetics of colo rectal cancer in Newfoundland 
INVESTIGATOR(S): Fiona Curtis, Angela Hyde, Dr. P. Parfrey, Dr. J. Green, Dr. B. Pollett, 
Dr. R. Green, Dr. B. Younghusband 
You have been asked to take part in a research study. Participation in this study is entirely 
voluntary. You may decide not to take part or may withdraw from the study at any time without 
affecting your normal treatment. 
Information obtained from you or about you during this study, which could identifY you, will be kept 
confidential by the investigator(s). The investigator will be available during the study at all times 
should you have any problems or questions about the study. 
1. Purpose of study: 
Most cancers affect individuals, but some cancers occur in several family members. These 
cancers may be inherited, that is they "run in the family" as a result of changes in some genes. 
The purpose of this study is to find out how many people with a diagnosis of colo rectal 
cancer have an inherited form of the disease and to develop laboratory tests to identify these 
cases. 
2. Description of procedures and tests: 
You will meet with the investigator at your convenience in person or by telephone if 
necessary. You will help trace your family medical history. If there is an indication of 
inherited colorectal cancer in your family then you will receive a referral to the Medical 
Genetics program for yourself and your family members for further consultation. We will ask 
your permission to review your medical records, obtain some of your cancer tissue which 
was removed during surgery and if you agree, a blood sample will be taken for further 
genetic studies. 
3. Duration of participant's involvement: 
The overall duration ofthe project is 2 years. Your direct involvement will be to meet with 
the researcher, in person or by telephone, to discuss your family history and to give a blood 
sample. 
4. Possible risks, discomforts, or inconveniences: 
e The interview may be an inconvenience. 
e A blood sample taken may lead to some bruising. 
5. Benefits which the participant may receive: 
If there is evidence of a hereditary cancer syndrome in your family, you will be given a 
referral to a geneticist which could then lead to screening and early detection and treatment 
of cancer in your family members. 
6. Alternative procedures or treatment for those not entering the study: 
If you decide not to enter this study, you will receive your normal care from your physician. 
7. Liability statement. 
Your signature indicates your consent and that you have understood the information 
regarding the research study. In no way does this waive your legal rights nor release the 
investigators or involved agencies from their legal and professional responsibilities 
8. Statement on genetic studies: 
In order to interpret the results of the genetic research, we need to have correct information 
about parents. Sometimes the research shows new information about birth parents. This 
could happen in the case of an adoption or a mistake in the identity of a mother or father. 
This information will not be given to anyone, including yourself or family members. 
9. Future use of tissue/DNA samples 
In order to preserve a valuable resource, your tissue/DNA samples may be stored at the end 
of this research project. It is possible that these samples may be useful in a future research 
project which may or may not be related to the current research project. Any future research 
would have to be approved by a Research Ethics Board (REB). 
Please tick one of the following options: 
1. 0 I agree that my tissue/DNA samples with my name can be used for any approved 
research project without asking me again. 
2. 0 I agree that my tissue/DNA samples with my name can be used for any approved 
research project but only if I am contacted again to give consent for the new project. 
3. 0 I agree that my tissue/DNA samples with my name can be used for any approved 
research project but only if my name* cannot be linked to the sample. 
4. 0 Under no circumstances may my tissue/DNA samples be used for future research. 
My samples must be destroyed at the end of the present project. 
*Includes name, MCP number or any other identifying information. 
The tissue/DNA samples from this stud will be stored in j.f.. !c.hn'.,. UF (city/province) for 
(approximately_ years ran indefinite eriod ofttme ) 
Signature: Date: ____________ _ 
Witness: 
Signature Page 
Name ofPrincipal Investigator: Fion~ Lu.rh's. ,J tJtL. Jtl.?'le. C-,-e.~ c~pe.rwJDr) 
To be signed bv participant 
I. , the undersigned, agree to my participation or to the 
participation of (my child, ward, relative) in the research study described above. 
Any questions have been answered and I understand what is involved in the study. I realise that participation is 
voluntary and that there is no guarantee that I will benefit from my involvement. 
I acknowledge that a copy of this form has been given to me. 
(Signature of Participant) (Date) 
(Signature of Witness) (Date) 
To be signed bv investigator 
To the best of my ability I have fully explained the nature of this research study. I have invited questions and 
provided answers. I believe that the participant fully understands the implications and voluntary nature of the 
study. 
(Signature of Investigator) (Date) 
Phone Number 
Assent of minor participant (if appropriate) 
(Signature of Minor Participant) (Age __ ) 
Relationship to Participant Named Above 
FACULTY OF MEDICINE- MEMORIAL UNIVERSITY OF NEWFOUNDLAND 
AND 
HEALTH CARE CORPORATION OF ST. JOHN'S 
Consent To Participate In Bio-medical Research 
TITLE: The genetics of colorectal cancer in Newfoundland 
INVESTIGATOR(S): Fiona Curtis, Angela Hyde, Dr. P. Parfrey, Dr. J. Green, Dr. B. Pollett, 
Dr. R. Green, Dr. B. Younghusband 
You have been asked to take part in a research study on behalf of your family member, -----
--- . Participation in this study is entirely voluntary. You may decide not to take part or may 
withdraw from the study at any time. 
Information obtained from you or about you and family members during this study, which could 
identifY you and other family members, will be kept confidential by the investigator(s). The 
investigator will be available during the study at all times should you have any problems or questions 
about the study. · 
1. Purpose of study: 
Most cancers affect individuals, but some cancers occur in several family members. These 
cancers may be inherited, that is they "run in the family" as a result of changes in some genes. 
The purpose of this study is to find out how many people with a diagnosis of colorectal cancer 
have an inherited form of the disease and to develop laboratory tests to identifY these cases. 
2. Description of procedures and tests: 
You will meet with the investigator at your convenience in person or by telephone if necessary. 
You will help trace your family medical history. If there is an indication ofinherited colorectal 
cancer in your family then you will receive a referral to the Medical Genetics program for 
yourself and your family members for further consultation. We will ask your permission to 
review your medical records and permission to obtain some of your ___ _ 
·cancer tissue which was removed during surgery. 
3. Duration of participant's involvement: 
The overall duration of the project is 2 years. Your direct involvement will be to meet with the 
researcher, in person or by telephone to discuss your family history. If you are willing a blood 
sample may also be taken. 
4. Possible risks, discomforts, or inconveniences: 
s The interview may be an inconvenience. 
s A blood sample taken may lead to some bruising. 
5. Benefits which the participant may receive: 
If there is evidence of a hereditary cancer syndrome in your family, you will be given a referral 
to a geneticist which could then lead to screening and early detection and treatment of cancer 
in you and your family members. 
6. Alternative procedures or treatment for those not entering the study: 
NA. 
7. Liability statement. 
Your signature indicates your consent and that you have understood the information regarding 
the research study. In no way does this waive your legal rights nor release the investigators or 
involved agencies from their legal and professional responsibilities 
8. Statement on genetic studie~: 
In order to interpret the results of the genetic research, we need to have correct information 
about parents. Sometimes the research shows new information about birth parents. This 
could happen in the case of an adoption or a mistake in the identity of a mother or father. This 
information will not be given to anyone, including yourself or family members. 
9. Future use of tissue/DNA samples 
In order to J9reserve a valuable resource, your tissue/DNA samples may be 
stored at the end of this research project. It is possible that these samples may be useful in a 
future research project which may or may not be related to the current research project. Any 
future research would have to be approved by a Research Ethics Board (REB). 
Please tick one of the following options: 
1. 0 I agree that my tissue/DNA samples with my----- name can be 
used for any approved research project without asking me again. 
2. 0 I agree that my tissue/DNA samples with my name can be 
used for any approved research project but only ifl am contacted again to give 
consent for the new project. 
3. 0 I agree that my tissue/DNA samples with my----- name can be 
used for any approved research project but only if my name* cannot be 
linked to the sample. 
4. 0 Under no circumstances may my tissue/DNA samples be used for future 
research. My samples must be destroyed at the end of the present. 
project. 
*Includes name. MCP number or any other identifying information. 
The tissue/DNA samples from this study will be stored in St . ')&.,.n a J IV F (city/province) for 
(approximately-year~ an indefinite period of hme);, 
Signature: Date: ____________ _ 
Witness: 
Signature Page 
Name ofPrincipal Investigator: hono-. ~ '.s J Ofl... "!~e.. ~ ( S-t.A-per-v.·~) 
To be signed bv participant 
I, , the undersigned, agree to my participation or to the 
participation of (my child, ward, relative) in the research study described above. 
Any questions have been answered and I understand what is involved in the study. I realise that participation is 
voluntary and that there is no guarantee that I will benefit from my involvement. 
I acknowledge that a copy of this form has been given to me. 
(Signature of Participant) (Date) 
(Signature of Witness) (Date) 
To be signed bv investigator 
To the best of my ability I have fully explained the nature of this research study. I have invited questions and 
provided answers. I believe that the participant fully understands the implications and voluntary nature of the 
study. 
(Signature oflnvestigator) (Date) 
Phone Number 
Assent of minor participant (if appropriate) 
(Signature of Minor Participant) (Age_) 
Relationship to Participant Named Above 
Newfoundland and Labrador Medical Genetics Program 
Information and Appointments 
Janeway Genetics Clinic 
Health Science Centre Genetics Clinic 
Outreach Program Genetics Clinic 
Central Region Phone 
Westem Region Phone 
(709) 778-4363 
(709) 737·6807 
(709) 651·3306 
(709) 637·5253 
DNA Consent Form 
Janeway Child Health Centre 
Janeway Place 
St. John's, NF 
A1A1R8 
I agree that a sample of blood may be drawn on-----------------
for genetic testing and/or banking and that the DNA obtained from the sample will be stored in 
the NLMGP Molecular Laboratory. 
I understand that: 
1. The sample will involve giving 10-15 mls of blood for preparation of the DNA. 
2. This process is voluntary and I may withdraw my consent at any time without penalty. 
3. lftlzere is no test currently available for the condition of concern in my family, the 
sample will be stored as DNA: This does not guarantee a test will be available in future. 
Banking this sample may be of no direct benefit to my family or me. 
4. If a test becomes available in tlze future, the NLMGP may contact me to discuss whether 
further DNA testing is appropriate. 
5. If a test is currently available for the condition of concern in my family, the possible 
results wiiJ be discussed with me. This includes the possibility that the testing may be 
inconclusive and a result will not be available. 
6. The test results will be strictly confidential. They may, however, be used anonymously to 
help interpret test results for other members of my family. 
7. These tests can sometimes point out discrepancies in parentage. Such information will be 
kept confidential and will not be released even to family members directly involved. 
8. The accuracy of any result is oased on the current knowledge of the disease gene in 
question. Due to limitations in our understanding, human error, or technical difficulties, 
there is a small chance that a result could prove to be incorrect. 
9. It is my responsibility to keep the NLMGP informed of any clzange of address so that they 
will be able to contact me in future if the need arises. 
meway FAX (709) 778-4190 
:atth Science Centre FAX (709) 737-3374 
Outreach FAXES - Central (709) 651-3341 
Western (709) 637-5160 
My signature.on this form indicates tbat I bav~·read the information on the··previous ·page 
and understand that: (tick one)'- :·. ·· .. :· :, ·:.= ... ,:: . .;:···::·:· . .:::.:.:. ; .. ·:·:~::{~,>:·t'.:::·::~:.:.·.,::::· .. ::'''f .. : .. :.· :;··:'·;:'·.·: ..... : ...,. :. 
0 Direct DNA analysis will be done on this sample to test for 
0 Linkage analysis comparing this sample to others in my family will be done to test for 
0 No test is available at this time and the sample will be stored as DNA in the 
NLMGP Molecular Diagnostic Laboratory. blAT ·I he DA/19 t..lli/ 6-e .J'~1 e.&,( 
h ;'tie,,,.; fit tw1 '1 G-hPr~9e:. /n c..::.lc:.n c .tWT c.~ 9e" e ~ . 
0 I would like the DNA sample destroyed following completion of the above test. 
0 I would like the DNA to remain banked for the future use of other family members. 
0 I agree to the anonymous use of this DNA for any future research approved by a 
Research Ethics Board 
0 This DNA may be used at any time without restriction. 
Patient's signature Date 
------------------'------------------Signature of legal guardian I Relationship to patient Date 
Signature of Witness Date 
DRAFT: 
dnacons.doc Feb. 2000 
--- ....... ,.._ ..... "'-', .. 
Jancw.'\y Clto&c.f ,,..,;,l:ta f:'"''": 
Janeway t•&oc:c 
Sa. John's. NF 
A1A 1R8 
Authorization for Release of Medical Information 
..,.., Please return a copy of this form with the medie2l record,.,.. 
Medic:a.J Records Requested: ./Clinical Diagnostic Summuics 
_ Birth Record : · ·. . 
....L. Consultants R.epons 
..L Laboratory repons 
"\?"'Diagnostic Imaging rcpons 
_ Operative and/or Pathology reports 
_Other: 
I, hereby consent to the release ofinfonnation to the Medi~ 
Genetics Program clo: Medical Genetics Program, Janeway Child Health Cetttre. Janeway Place. 
St. John's, Nfld., AlA IRS. from the medical records of. 
NAME:-------------- MAIDEN NAME:--------
ADDRESS: ____________ .PARENTS/SPOUSE------
DATEOFBmTH:~----------------D,ATEOFDEATH: ___________ __ 
MCP#: ____________________ __ CHART# ____________________ ___ 
DAT.EOFHOSPITAUZATION: _________________________________ _ 
NAM£/ADDRESSOFHOSPITAL: --------------------------------
StGNATllRE RELATIONSHlP DATE 
··········································································~··· 
Medical Genetics program Use: NLMGP# 
---------------------------------------
Patient Name: 
-------------------------------------
Geneticist I Genetic Counsellor. _______________ _ 
. FAX (709) 778·41 1 90 
cience Centre FAX (709) 737·3374 
Outreach FAXES • Central (709) 65 t -334 1 
Western (709) ~37 -2G 16 
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Colorectal Chart Extraction Form 
Date 
------
ID# ____ _ MCP# ______________ _ 
DOB ______________ __ 
Address _____________________________________________________ __ 
Telephonr # _______ _ 
Sex 
----
Physician. ___________________________ _ 
Attending Physician ______________________ _ 
Centre Physician'---------------------------
Diagnosis ___________________________ _ 
Date of Diagnosis _________ _ Age at Diagnosis _______ _ 
Diagnosing Hospital _______________________ _ 
Means of Diagnosis ________________________ _ 
Presenting Symptoms _______________________ _ 
Site Code ___________ Behaviour Code ___________ _ 
Topology Code Histology Code __________ _ 
Grade 
------------------------------------------------------------
Staging method. ______ _ Stage revision. _____ _ 
Clinical Stage _______ _ Pathological Stage ____ _ 
Presence of Polyps YIN if yes,# ____ Location-------------
Metastases YIN if yes, Location--------------------
Previous Cancer YIN if yes, Type. __________________ _ 
Age and year at Diagnosis ________ _ 
Treatme*: surgery YIN Type. ___________ _ 
Date 
------------------------
Hospital. __________ _ 
Chemo YIN Type and Duration. _____________ _ 
Radiation YIN Type and Duration. _____________ _ 
Patient Status. _________ _ 
Death Date. _________ _ 
Family History _________________________ _ 
Comments ______________________________________________________ ___ 
APPENDIX G: Microsatellite analysis methods and materials 
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DNA EXTRACTION USING THE QIAGEN DNeasy KIT 
(5 x lOJ.t paraffm sections) 
- Dewax paraffin tissue with lml of toluene, let sit 5 - 1 0 min 
- centrifuge 5 min, then decant toluene 
- repeat with toluene, centrifuge and decant 
-clear with ·1m1 absolute alcohol, let sit 5- 10 min 
- centrifuge 5 min, then decant alcohol 
- repeat with alcohol, centrifuge and decant 
-rinse with lml PBS, let sit 5- 10 min 
- centrifuge 5 min, then decant PBS 
- repeat with PBS, centrifuge and decant 
- air dry tissue at room temp for 10 - 15 min 
-Digestion at 55°ovemight (or until tissue digested). Add to each sample: 
- 180J.tl ATL buffer 
- 20J.tl proteinase K, then mix by vortexing, and incubate at 55 ofor a couple 
ofhours to overnight. 
(If tissue is not all digested, add more proteinase K.) 
- Vortex for 15 sec. Add 200J.tl Buffer AL to the sample, mix thoroughly by 
vortexing, and incubate at 70°C for lOmin. 
- Add 200J.tl absolute ethanol to the sample, and mix thoroughly by vortexing. (A 
white ppt may form, you must get all of it into the mini column) 
- Pipette the mixture into the DNeasy minicolumn sitting in a 2ml collection tube 
(provided). Centrifuge for 1 min at ~6000g (8000rpm). Discard flow-through 
and collection tube. 
- Place the DNeasy mini column in a new 2ml collection tube (provided), add 
500J.tl Buffer AWl, and centrifuge for 1 min at ~6000g (8000rpm). Discard 
flow-through and collection tube. 
- Place the DNeasy mini column in a 2ml collection tube (provided), add 500J.tl 
Buffer A W2, and centrifuge for 3 min at full speed to dry the DNeasy membrane. 
Discard flow-through and collection tube. 
-Place the DNeasy mini column in a clean 1.5ml microcentrifuge tube (not 
provided), and pipette 1 OOJ.tl Buffer AE directly onto the DNeasy membrane. 
Incubate at room temp for 1 min, and then centrifuge for 1 min at ~ 6000g 
(8000rpm) to elute. 
DNA EXTRACTION BY SALTING OUT 
(5 x 10,u PARAFFIN SECTIONS) 
- Dewax paraffm tissue with 1ml of toluene, let sit 5 - 10 min 
- centrifuge 5 min, then decant toluene 
- repeat with toluene, centrifuge and decant 
- clear with 1ml absolute alcohol, let sit 5 - 10 min 
- centrifuge 5 min, then decant alcohol 
- repeat With alcohol, centrifuge and decant 
-rinse with lml PBS, let sit 5- 10 min 
- centrifuge 5 min, then decant PBS 
- repeat with PBS, centrifuge and decant 
- air dry tissue at room temp for 10 - 15 min 
-Digestion at 55 o overnight (or until tissue digested). Add to each sample: 
- 425,ul of 0.5x TBE buffer 
- 50,ul of 10% SDS 
- 25,ul of proteinase K (0.5,ugl,ul) 
(If tissue is not all digested, add more proteinase K.) 
-Add 135,ul (0.27 volume) of saturated 6M NaCl (salting out protein). Mix well! 
- Centrifuge for 5 min at 2000 rpm 
-Transfer supernatant into similar tubes (discard original tube with pellet) 
-left with a volume- 600,ul 
-Add 1.5ml of cold absolute alcohol (-2.5x volume). (Just fill to top oftube) 
The DNA should suspend as strands near the top of the tube. If it doesn't: 
-add 12.5,ul3M sodium acetate and put in the freezer for a few minutes 
- centrifuge (cold) for 20 min, decant supernatant 
- wash pellet once with 70% ethanol 
- air dry pellet for a few min 
-dissolve pellet in 20-30 ,ul TE buffer 
8gNaCI 
0.2gKCl 
Buffers 
1.44gNa2HP04 (sodium phosphate) 
0.24g KH2P04 (potassium dihydrogen orthophosphate) 
Add above (in that order) to 800ml d.H20, dissolve by magnetic stirrer. 
Adjust pH to 7.4 with HCL Add d.H20 to bring to 1 litre. 
5xTBE 
54g Tris Base 
27.5g boric acid 
20ml 0.5MEDTA 
make up to I litre with dH20 
(Note: dilute with dH20 to make 0.5x TBE for this protocol) 
IOmM Tris.Cl (pH 8.0) 
lmMEDTA (pH 8.0) 
IOml of IM Tris.Cl stock and 2ml of0.5M EDTA stock made up to I litre 
with dH20. 
· .. ' 
Reagents 
6M NaCI (saturated) 
350.6g NaCl made up to I litre with dH20 
SM is saturated, but make up 6M to be sure. Leave on the magnetic stirrer 
overnight to be sure to dissolve as much as possible. 
lOo/o SDS 
lOg SDS 
Make up to I litre with dH20. (Carefully! Can easily form a lot of bubbles.) 
3M sodium acetate 
246.1 g sodium acetate 
Make up to 1 litre with dHi> 
(Or 12.3g made up to 50ml) 
Proteinase K (0.5JA-g/J.ll) 
0. 01 g proteinase K 
Make up to 20ml with d.H20. 
: ~!~ .• .. 
DNA EXTRACTION FROM WHOLE BLOOD 
(for 5 - 7ml blood collected in EDT A tubes) 
- Transfer blood to 50ml centifuge tubes. 
-Add 5 volumes of warm (37°C) red cell lysis buffer to 1 volume ofblood. 
Incubate at 3 7 o C for 5 min. 
-Centrifuge at 2500 rpm for 5 min. 
- Pour off supernatant leaving white cell pellet at bottom. 
- Add 1 Oml saline. Vortex and centrifuge for 5 min again. 
- Pour off supernatant. Add 3ml nuclei lysis buffer to the cell pellet. Vortex and 
transfer to a 15ml centrifuge tube. 
-Add 0.2ml of 10% SDS and 0.5ml of pronase E solution. 
-Incubate at 37°C overnight (or at 55°C for 2 hours). 
-Add lml saturated NaCI, shake vigorously for 15 sec, and centrifuge at 2500 
rpm for 15 min. 
- Gently pour supernatant into a 15ml tube and add 2 volumes of absolute ethanol; 
invert the tube several times to ppt the DNA. 
-Fish out the DNA clump with a 9" glass hook (9" Pasteur pipette; melt tip to form 
a hook). Wash several times with a stream of 70% ethanol. Let air dry. 
- Dissolve DNA in 300 - 500.ul TE overnight. Gently mix sample on a rotator for 
an hour or so. 
•. . ~ . - -::;·:;-.~-------------·--·-
Red Cell Lysis Buffer (lL) 
900ml 0.155MNH4Cl 
IOOml 0.17M Tris.HCl 
To make 0.155M NH4Cl: 
Buffers 
Since 53.49g/mol, need 53.49g!L for IM 
~eed 0.155M, therefore 53.49 x 0.155 = 8.29g!L 
To make 0.17M Tris.HCI: 
Since 157.6g/mol, need 157.6g!L for IM 
Need 0.17M, therefore 157.6 x 0.17 = 26.8g!L 
Nuclei Lysis Buffer (lL) 
IOmMTris.HCl 
400mMNaCl 
2mMEDTA 
Tris.HCl: 157.6g!L = IOOOmM 
1 OmM = 1.576g/L Tris.HCI 
NaCI: 58.44g!L = IOOOmM 
400mM = 23.38g/L NaCl 
EDTA: 4ml of stock 0.5M EDTA 
TE Buffer (lL) 
lOmM Tris.Cl (pH 8.0) 
lmM EDTA (pH 8.0) 
Tris.Cl: .lQml of stock IM Tris.Cl 
EDTA: 2ml of stock 0.5MEDTA 
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Reagents 
- 6~1 NaCI (saturated) 
350.6g NaCl made up to 1 litre with dH20 
5M is saturated, but make up 6M to be sure. Leave on the magnetic stirrer 
overnight to be sure to dissolve as much as possible. 
Saline (0.85% NaCI) 
85gNaC1 
Make up to 1 litre with dH20. 
10%, SDS 
lOg SDS 
Make up to I litre with dH20. (Carefully! Can easily form a lot of bubbles.) 
Protease working solution (7mg/ml in 1% SDS and 2mM EDTA) 
To make up 50ml: 
350mg protease 
5mll0% SDS 
200~1 0.5M EDTA 
Make up to 50ml with dH20. Invert (gently!!!) several times to mix. 
Store at -20°C in lOml aliquots. 
Proteinase K working solution (3mg/ml in 1% SDS and 2mM EDTA) 
To make up 50ml: 
15 Omg proteinase K 
5m110%SDS 
200,ul 0.5M EDTA 
Make up to 50ml with dH20. Invert (gently!!!) several times to mix. 
Store at -20°C in 1 Oml aliquots. 
Polymerase Chain Reaction (PCR) 
Final concentrations of reagents: 
lOx buffer:::::?- lx 
5x Q solution (optional):::} lx 
dNTPs:::} 0.2mM each 
MgC12 :::} 1.0- 4.0mM (usually 1.5mM) 
primers :::} as per directions 
(ex. from Research Genetics, 0.6J..LM) 
Taq :::} 1 unit per reaction up to 40-50J.!l (2.5 units per 1 OO!J.l reaction) 
example: 
For 22 reactions of25J.!l each,= 550J.ll volume. 
Allow for error= 625J.ll total volume. (Equiv. of25 rxns) 
625 J.!l - 25 J.!l DNA = 600J.ll cocktail 
301.25J.!l 
62.5J.!l 
125J,Ll 
31.25 J,Ll 
37 .5!-ll 
18. 75J,Ll 
18. 75J,Ll 
5J,Ll 
dH20 
lOx buffer (1x) 
5x Q solution (1x) 
4mM dNTPs (0.2mM) 
25mM MgC12 (1.5mM) 
20J.!M F-primer (0.6J.!M) 
20!J.M R-primer (0.6J.!M) 
5 U/!J.l Taq (1 U/reaction) 
Reagents 
4mM dNTPs ( to make 500,ul of stock) 
20,ullOOmM dGTP 
20,ullOOmM dATP 
20,ul IOOmM dTTP 
20,ullOOmM dCTP 
420,ul dH20 
Mix together, and store in aliquots at -20°C. 
Thermocycler Conditions 
For HotStar Taq from Qiagen, with primers from Research Genetics: 
36 cycles of: 
72 oc for 7 min 
soak at 4°C 
94 oc for 45 sec 
57°C for 45 sec 
72 oc for 1 min 
Agarose Gel 
For 0.75% gel (for DNA smear): 
0.375g agarose in 50ml 0.5x TBE 
For 2% gel (for PCR products): 
l.Og agarose in 50ml 0.5x TBE 
Use 0.5x TBE for running buffer. 
The 0.5x TBE used for both gel and.nmning buffer should have 0.5J.!g/ml ethidium 
bromide, so the gel doesn't need to be stained after it is run. 
Loading Dye 
Bromophenol blue 
0.025g bromophenol blue (0.25%) 
4g sucrose (40%) 
Make up to 1 Oml with dH20. 
Bromophenol blue and xylene cyanol FF 
0.025g bromophenol blue (0.25%) 
0.025g xylene cyanol FF (0.25%) 
3. Oml glycerol (3 0%) 
Make up to I Oml with d.H20. 
· Acrylamide Gel 
6%) acrylamide, 7M urea gel solution 
189g urea (7M) 
45ml 5x TBE (0.5x) 
67.5ml 40% acrylamide:bis 19:1 (6%) 
Make up to 450ml with dH20. 
Filter arid degas on vacuum suction for about 15 minutes. 
Store at 4 oc in a dark bottle. 
For a small gel (20 x 40cm): 
No need for a plug. 
For the gel: 
75ml gel solution 
500J..Ll 10% ammoniuim persulfate 
50J..1l TEl"vffiD 
Prerun at 65W, run gel at SOW. 
For a large gel (40 x 60cm): 
For the plug: 
30ml 
175Jll 
175Jll 
For the gel: 
gel solution 
10% ammonium persulfate 
TEl"vffiD 
120ml gel solution 
1ml 10% ammonium persulfate 
1 00 Jll TEl"vffiD 
Prerun at 150W, run at llOW. 
General Rules: 
2.5Jll 10% ammonium persulfate per ml acrylamide 
1 Jll TEMED per ml acrylamide 
5xTBE 
54g 
27.5g 
20ml 
Buffers and Reagents 
Tris Base 
boric acid 
0.5MEDTA 
Make up to I litre with dH20. 
1 0°/o ammonium persulfate 
Use O.lg ammonium persulfate per ml of dH20. 
Weigh APS directly into a 1.5ml tube, then add appropriate amount of dH20. 
Vortex to dissolve. 
(Note: If not using fresh, store in aliquots at -20°C.) 
Loading Dye 
10ml 
200J.1l 
formamide (98%) 
0.5MEDTA 
2.5mg xylene cyanol FF (0.025%) 
2.5mg bromphenol blue (0.025%) 
Add directly to a 15ml centrifuge tube. 
Spin on an electric rotator for awhile to mix thoroughly. 
Store in aliquots at -20°C. 
DNA Ladder 
4J.ll 
llJ.ll 
15 J.tl 
Store at 4 °C. 
1 OObp ladder 
dH20 
loading dye 
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Silver Staining Procedure 
Plate preparation: 
-Wipe a few drops ofRain Away onto the plate with the buffer chamber, 
allow to dry -5 min, then rinse with a paper towel saturated with dH20. 
-Add 3,ul Bind Silane to lml 0.5% acetic acid in 95% ethanol in a fume 
hood. Invert to mix, then wipe over the entire surface of the flat plate with a 
Kim Wipe. Allow to dry -5 min, then rinse 3 or 4 times with absolute 
ethanol. 
Assemble gel apparatus and run. 
Take down gel, and stain: 
Tray Solution 
1 fix/stop 
2 dH20 
3 dH20 
2 dH20 
3 silver stain 
2 dH20 
1 developer 
1 fix/stop 
2 dH20 
3 none 
Time 
20min 
2min 
2min 
2min 
30min 
10 sec 
-5 min (until proper exposure) 
5 min (add directly to developer solution) 
2 min (no longer, bands will fade) 
dry overnight 
Solutions 
0.5°/o acetic acid in 95% ethanol 
Add lml of glacial acetic acid to 199ml of95% ethanoL 
Store at -20°C. 
1 Omg/ml Sodium Thiosulfate 
200mg sodium thiosulfate made up to 20ml with dH20. 
Store at room temperature in 400).ll aliquots. 
Fix/stop Solution 
1800ml 
200ml 
Silver Stain. Solution. 
dH20 
glacial acetic acid 
2L dH20 
3ml formaldehyde 
2g silver nitrate 
Stir on magnetic stirrer to dissolve. 
Store in a dark cupboard until ready to use. 
Developer Solution 
2L dH20 
3ml formaldehyde 
400Jll 1 Omg/ml sodium thiosulfate 
60g sodium carbonate 
Stir on magnetic stirrer to dissolve. 
Store at 4 °C until ready to use, to bring temperature of solution to between 4 ° 
and l0°C. 
(Note: If colder than this, it will take longer for the gel to develop.) 
0°/o Sodium Hydroxide 
1 OOg NaOH made up to J L with dH20. 
Store at room temperature. 
MSH2 Immunohistochemistrv 
DAYl 
~ put a couple of inches of water in the pressure cooker, and put it on a hot plate set 
on high 
~meanwhile, put the slides: 
- 5 min in toluene 
- 5 min in toluene 
- 10 dips in 100% alcohol 
- 10 dips in 1 00% alcohol 
- 10 dips in 95% alcohol 
- 10 dips in 70% alcohol 
-run slides under tap water for about 5 min (to remove alcohol) 
- shake off excess water 
-put slides in 3% hydrogen peroxide for 10 min (to block endogenous peroxidases) 
~ rinse in running water for about 5 min 
Antigen Retrieval 
-add citrate buffer(pH 6.0) to the coplinjars (enough to cover the slides) 
-put the slides in the coplinjars and tighten the lids 
-put the coplinjars in the pressure cooker 
- heat on high until constant hissing, turn heat down to 5 Y2 and leave for 9 min 
~ turn off heat, gently lift pressure cooker to the bench 
-remove the black pressure valve, wait until the red valve drops, then remove lid 
-carefully take out the coplinjars and leave them on the bench for -25 min to cool 
(make sure the lids are still on tight) 
-remove the slides from the cop lin jars and lay them out on the humidifying 
chamber (as each row is laid out, spray with PBS to keep them from drying out) 
- one row at a time, stand the slides up and dry off the back and edges with gauze 
- put the slides back in the chamber, and add 2 to 4 drops of 5% goat serum in 
water onto each section, spread to fully cover each section 
- cover the humidifYing chamber and leave for 20 min· 
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Make up the Antibody 
-for MSH2 ==?- 1 in 30 dilution (antibody kept at -20°C) 
Dilute in 1% bovine serum albumin made up in PBS. 
Need -200J.ll per section 
-for 25 sections: 25 x 200!J.l = 5000!J.l 
-since 1 in 30 dilution: 5000-:-30 = 167!J.l antibody 
Mix 167!J.l antibody \vith 4833J.ll 1% BSA in PBS. 
-don't rinse off the goat serum! 
- stand the slides upright (one row at a time), and wipe the excess goat serum off 
the sides. Put the slides back in the chamber 
-drop 200!J.l (2 or 3 drops) of 1 o antibody onto each section, spread to make sure 
each section is fully covered 
- put the cover back on the chamber, and put in the fridge for 24 hours 
DAY2 
- remove the humidifying chamber from the fridge 
-rinse each slide twice with PBS (spray above the section, so the tissue won't 
come off) 
-wipe the back and edges of the slide dry 
-add 200Jll of Envision to each section, spread to make sure they are covered 
- cover the chamber and leave for 30 min 
Make up DAB (1 tablet ofDAB in 15ml PBS) 
-Need about 200f.ll per section, therefore, for 25 sections, need 5000!J.l. Make up a 
little extra, 5250!J.l. 
-for every lml of DAB, add 1 J.ll 30% hydrogen peroxide 
Therefore, 5250!J.l DAB and 5.25Jll 30% H20 2 
- rinse the slides twice with PBS 
- one row at a time, dry back and edges 
- add 3 drops DAB + H20 2 per section, set timer for 7 min for that row 
- make sure it covers each section entirely 
-repeat with the other rows of slides (each row gets its own timer) 
-after 7 min, give one rinse with PBS 
-once all slides are done, rinse them in running tap -vvater 
- shake off exces~"water 
- put them in hemotoxylin for 3 min 
- run in water for -5 min 
- dip once in 1% acid alcohol (gets rid of excess hemotoxylin) =? quickly get into 
water! 
-rinse in water 2-5 min 
-put in Scott's tap water until blue (about 1 min) 
- rinse in water for a couple of minutes 
- shake off excess water 
- dip slides 1 0 times in each: 
- 70% alcohol 
- 95% alcohol 
- 100% alcohol 
- 1 00% alcohol 
-toluene 
-toluene 
- leave in the fmal toluene 
- remove one slide at a time, put a drop of permount on the edge, and drop on a 
cover slip 
MLHl Immunohistochemistry 
DAYl 
-put a couple of inches of water in the pressure cooker, and put it on a hot plate set 
on high 
- meanwhile, put the slides: 
- 5 min in toluene 
- 5 min in toluene 
- 10 dips in 1 OOo/o alcohol 
- 1 0 dips in 100% alcohol 
- 10 dips in 95% alcohol 
- 10 dips in 70% alcohol 
-run slides under tap water for about 5 min (to remove alcohol) 
- shake off excess water 
-put slides in 3% hydrogen peroxide for 10 min (to block endogenous peroxidases) 
- rinse in running water for about 5 min 
Antigen Retrieval 
-add citrate buffer(pH 6.0) to the coplinjars (enough to cover the slides) 
-put the slides in the coplinjars and tighten the lids 
- put the cop lin jars in the pressure cooker 
- heat on high until constant hissing, tum heat down to 5 Y2 and leave for 9 min 
-turn off heat, gently lift pressure cooker to the bench 
- remove the black pressure valve, wait until the red valve drops, then remove lid 
-carefully take out the coplinjars and leave them on the bench for -25 min to cool 
(make sure the lids are still on tight) 
-remove the slides from the cop lin jars and lay them out on the humidifying 
chamber (as each row is laid out, spray with PBS to keep them from drying out) 
- one row at a time, stand the slides up and dry off the back and edges with gauze 
- put the slides back in the chamber, and add 2 to 4 drops of Universal Blocker 
onto each section, spread to fully cover each section 
- cover the humidifying chamber and leave for 20 min 
' ; 
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Make up the Antibody 
-for MLHl ::;. 1 in 50 dilution (antibody kept at 4°C) 
Dilute in 1 o/o bovine serum albumin made up in PBS. 
Need -200f..ll per section 
- for 25 sections: 25 x 200J.Ll = 5000f..ll 
- since 1 in 50 dilution: 5000 + 50 = 1 OOf..ll antibody 
Mix 1 OOJ.ll antibody with 4900f..ll 1% BSA in PBS. 
-don't rinse off the Universal Blocker! 
- stand the slides upright (one row at a time), and wipe the excess Universal 
Blocker off the sides. Put the slides back in the chamber 
- drop 200f..ll (2 or 3 drops) of 1° antibody onto each section, spread to make sure 
each section is fully covered 
-put the cover back on the chamber, and put in the fridge for 24 hours 
DAY2 
- remove the humidifying chamber from the fridge 
-rinse each slide twice with PBS (spray above the section, so the tissue won't 
come off) 
- wipe the back and edges of the slide dry 
-add 200f..ll ofLink Antibody (from the kit)* to each section, spread to make sure 
they are covered 
- cover the chamber and leave for 30 min 
- rinse the slides twice with PBS 
-add 200f..ll Streptavidin Peroxidase (from the kit)* to each section, spread to make 
sure they are covered 
-cover the chamber and leave for 30min 
Make up DAB (from the kit)* 
-Need about 200f..ll per section, therefore, for 25 sections, need 5000f..ll. Make up a 
little extra. 
-for every lml from the bi.g bottle, add 1 drop from the small bottle. Add both to 
the tube enclosed, and put the date on the cover (its good for one week). Shake to 
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- rinse the slides twice with PBS 
- one row at a time, dry back and edges 
- add 3 drops DAB per section, set timer for 7 min for that row 
- make sure it covers each section entirely 
- repeat with the other rows of slides (each row gets its own timer) 
-after 7 min, give one rinse with PBS 
- once all slides are done, rinse them in running tap water 
- shake off excess water 
- put them in hemotoxylin for 3 min 
- run in water for -5 min 
- dip once in 1% acid alcohol (gets rid of excess hemotoxylin) => quickly get into 
water! 
- rinse in water 2-5 min 
-put in Scott's tap water until blue (about 1 min) 
- rinse in water for a couple of minutes 
- shake off excess water 
- dip slides 1 0 times in each: 
- 70% alcohol 
- 95% alcohol 
- 100% alcohol 
- 1 00% alcohol 
-toluene 
-toluene 
- leave in the final toluene 
- remove one slide at a time, put a drop of permount on the edge, and drop on a 
cover slip 
* The kit is: DAKO LSAB + System, HRP 
it· """-------· 
MSH6 Immunohistochemistry 
DAY1 
- put a couple of inches of water in the pressure cooker, and put it on a hot plate set 
on high 
-meanwhile, put the slides: 
- 5 min in toluene 
- 5 min in toluene 
- 10 dips in 100% alcohol 
- 10 dips in 100% alcohol 
- 10 dips in 95% alcohol 
- 1 0 dips in 70% alcohol 
-run slides under tap water for about 5 min (to remove alcohol) 
- shake off excess water 
-put slides in 3% hydrogen peroxide for 10 min (to block endogenous peroxidases) 
- rinse in running water for about 5 min 
Antigen Retrieval 
-add citrate buffer(pH 6.0) to the coplinjars (enough to cover the slides) 
-put the slides in the coplinjars and tighten the lids 
-put the coplinjars in the pressure cooker 
- heat on high until constant hissing, tum heat down to 5 ~ and leave for 9 min 
- turn off heat, gently lift pressure cooker to the bench 
- remove the black pressure valve, wait until the red valve drops, then remove lid 
-carefully take out the coplinjars and leave them on the bench for -25 min to cool 
(make sure the lids are still on tight) 
-remove the slides from the coplinjars and lay them out on the humidifying 
chamber (as each row is laid out, spray with PBS to keep them from drying out) 
- one row at a time, stand the slides up and dry off the back and edges with gauze 
- put the slides back in the chamber, and add 2 to 4 drops of Universal Blocker 
onto each section, spread to fully cover each section 
- cover the humidifying chamber and leave for 20 min 
Make up the Antibody 
~for MSH6 ==?- 1 in 75 dilution (antibody kept at 4°C) 
Dilute in 1 °/o bovine serum albumin made up in PBS. 
Need -200Jll per section 
~ for 25 sections: 25 x 200J.!l = 5000!-!1 
~since 1 in 75 dilution: 5000-:- 75 = 66.7!-!1 antibody 
Mix 66.7jll antibody with 4933.3!-!llo/o BSA in PBS. 
~don't rinse off the Universal Blocker! 
~stand the slides upright (one row at a time), and wipe the excess Universal 
Blocker off the sides .. Put the slides back in the chamber 
~drop 200Jll (2 or 3 drops) of 1 o antibody onto each section, spread to make sure 
each section is fully covered 
~put the cover back on the chamber, and put in the fridge for 24 hours 
DAY2 
- remove the humidifying chamber from the fridge 
-rinse each slide twice with PBS (spray above the section, so the tissue won't 
come off) 
~ wipe the back and edges of the slide dry 
~add 200Jll of Link Antibody (from the kit)* to each section, spread to make sure 
they are covered 
~cover the chamber and leave for 30 min 
~ rinse the slides twice with PBS 
~add 200Jll Streptavidin Peroxidase (from the kit)* to each section, spread to make 
sure they are covered 
-cover the chamber and leave for 30min 
Make up DAB (from the kit)* 
~Need about 200Jll per section, therefore, for 25 sections, need 5000J.!l. Make up a 
little extra. 
- for every l ml from the big bottle, add l drop from the small bottle. Add both to 
the tube enclosed, and put the date on the cover (its good for one week). Shake to 
miX. 
- rinse the slides twice with PBS 
- one row at a time, dry back and edges 
- add 3 drops DAB per section, set timer for 7 min for that row 
-make sure it covers each section entirely 
- repeat with the other rows of slides (each row gets its own timer) 
- after 7 min, give one rinse with PBS 
- once all slides are done, rinse them in running tap water 
- shake off excess water 
- put them in hematoxylin for 3 min 
- run in water for -5 min 
-dip once in 1% acid alcohol (gets rid of excess hemotoxylin) =}quickly get into 
water! 
-rinse in water 2-5 min 
-put in Scott's tap water until blue (about 1 min) 
- rinse in water for a couple of minutes 
- shake off excess water 
- dip slides 10 times in each: 
- 70% alcohol 
-95% alcohol 
- 1 00% alcohol 
- 1 00% al coho I 
-toluene 
-toluene 
- leave in the final toluene 
- remove one slide at a time, put a drop of permount on the edge, and drop on a 
cover slip 
* The kit is: DAKO LSAB + System, HRP 
Treating Slides with Histogrip 
Treats 975 slides (13 boxes of 75). 
-Dilute Histogrip: 1 Oml bottle into 500ml acetone 
-Place glass slides into Histogrip solution for 2 minutes. 
' 
-After the 2 minutes, dip the slides 10 times in the same Histogrip solution. 
-Rinse quickly in 3 changes (1 0 dips each) of distilled water. 
-Dry slides in 60°C oven for about 1 hour. 
-Store slides in a dust-proofbox. 
Note: Histogrip is from Zymed Laboratories Inc. 
Immunohistochemistrv Solutions 
PBS (lL) 
31.~ 8.0g sodium chloride 
f;,t.~ 1.3g disodium phosphate 
\~.~4.0g monosodium phosphate 
At,_... Dissolve in dH20 (bring to just under lL). Adjust pH to 7.4 with 2M NaOH. 
Bring volume up to lL -vvith dH20. Store at room temp. 
lOmM Citrate Buffer (IL) 
2.lg citric acid 
Dissolve in dH20. Adjust pH to 6.0 with 21vi NaOH. Bring volume up tolL 
with dH20. Store at room temp. 
2M NaOH (500ml) 
40gNaOH 
Dissolve in dH20 and bring volume up to 500ml. 
1 °/o BSA in PBS (25rnl) 
0.25g bovine serum albumin (stored at 4°C) 
Dissolve in 25ml PBS. Store at 4°C. 
Note: make small volumes at a time, since crud seems to grow in this in the 
fridge in short periods of time. 
3°/o Hydrogen Peroxide (lL) 
30ml 30% H20 2 
970ml dH20 
Store at room temp. 
Add Alcohol (l 0/o) (1L) 
lOml cone. HCI (12M) 
990m1 70% alcohol 
Store at room temp. 
lrnmunohistochemistrv Solutions (cntd) 
'" 
Scotts Tap Water (enough for 2L) 
Mix half and half sodium bicarbonate and magnesium sulfate solutions, as 
follows: 
7 g sodium bicarbonate 
Dissolve in lL dH20. 
40g magnesium sulfate 
Dissolve in IL dH20. 
Note: Store separately, and only mi.x (50:50) when ready to use. Change the 
solution when it turns pink. 
Hematoxylin (~2L) 
~Dissolve 180g of aluminum ammonium sulfate in 1200ml dH20. 
~Dissolve 12g hematoxylin in 75ml of95% alcohol. 
- Combine the tWo solutions once each is dissolved. 
- Expose the mixture to light and air for one month in an unstoppered bottle (cover 
the top of the bottle with gauze). 
-After one month, filter and add 300ml glycerin and 300ml of95% alcohol. 
~ Allow to stand in light until colour is sufficiently dark. 
-Filter and keep in a tightly stoppered dark bottle at room temp. 
HMSH2 PCR work table 
Ex on primer Size(bp) PCR condition PCR Sscp gel Glvcerol ~el note 
I Sl-F Cgc att ttc ttc aac cag ga 279 contaminated 
-
SI-R Cct ccc cag cac gcg cc I 
I new S 1-S Cgc a~t ttc ttc aae cag ga 279 55C. Mg: l.Om.M ++. * * I 
Sl-A Cct ccc cag eae gcg cc I 
-· 
2.1 S2-0F Gtc cag eta ata cag tgc ttg 197 55C. Mg: l.5mM ++ * * I 
S2-fR Tee ttg gat gee tta ttt cc 
2.2 S2-IF Ctg cag agt gtt gtg ctt agt a 202 55C. Mg: 1.5mM ++ * * 
S2-0R Cac att ttt att ttt eta etc tta a I 
2 S2-0F Gtc cag eta ata eag tgc ttg 280 55C. Mg: 1.5m.M ++ ++ 
S2-0R Cac att ttt att ttt eta etc tta a I 
3 53-F Tat aaa att tta aag tat gtt caa g 389 55C. Mg:2mM ++ * * 
53-R Ttt cct agg cct gga ate tee tct 
"' 
S-+-F Ttt ttg ctt ttc tta ttc ctt ttc 309 55C. Mg: 3mM ++ ++ * 
.• 
S"'-R Tga cag aaa tat cct tct aa I 
5.1 S5-0F Cca !rtg gta tag aaa tct tcg 172 55C. Mg:2mJvf ++ * * 
S5-IR Gac tgc tgc aat ate caa tt 
- ., 
::1.- 55-IF Cag atg att cca act ttg ga 180/181 55C.Mg:2mM ++ * * 
55-0R Age ttc ttc agt ata t!rt caa tg 
5 5of+or 277 55C.Mg: 3mM 
6 56-F Ttc act aat gag ctt gee att c 2~6 Doesn't work 
SC>-R Gta taa tea t:..'t g.gg taa c 
6ncw 56-5 ~.'tt ttc act aat gag ctt gee 251 55C. Mg: 1.2mM ++ * * I 
56-A t,>tg gta taa tea tgt ggg ! 
7 S7-F Ctt acg tgc tta gtt gat aa 321 55C. Mg: 3mM ++ * * I 
57-R Tat att gta tga gtt gaa gga aaa 
s $8-F Ttt gta ttc tgt aaa atg aga tct tt 217 55C. Mg: 3mM ++ +* * 
.' SS-R Ctt tgc ttt tta aaa ata act act g 
') 59-F Ctt tac cca tta ttt ata gga tt 213 55C. Mg: 3m.M ++ * * 
59-R Ata gac aaa aga att att cca ac 
10 510-F Tag tag gta ttt atg gaa tac ttt t 255 55C. Mg: 3mM +++ * *+43.* 
SlO-R Tgt tag age att tag gga att 
ll S11-F Cat tgc ttc tag tac aca ttt 195 55 C. Mg: 1.5m.M ++ * *- 2. +2 
Sll-R Cag gtg aca ttc aga aca tta 
12 Sl2-F Tea !rta ttc ctg tgt aca ttt 323 55C. Mg: 2mM ++ * * 
SI2-R Tta ccc cca caa age cca a 
!] Nl6324 5 · cgc gat taa tea tea !rtg 3"'8 55C. Mg: l.5m.M ++ * * 
Cl6340 5' gga cag aga cat aca ttt eta tc 
1-+ 5 1"'-f Cca cat ttt atg tga tgg gaa 3"'9 55C. Mg: 1.5mM ++ * * 
Sl4-R Gm agt aag ttt ccc att ace aag I 
15 SI5-F Ctt etc atg ctg tee cct c 256 55 C. Mg: l.2mM ++ * * 
515-R Gag aag eta agt taa act atg 
16 Sl6-F Att act cat ggg aca ttc aca 225 55 C. Mg: 1.5mM ++ * * ; 
/ Sl6-R Ctt cat tee att act ggg at 
-
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INSTRUCTIONS 
Large Volume 
DAKO LSAB•+ Kit, 
Peroxidase 
Universal 
K0690 
These instructions apply to the Universal 
Large Volume DAKO LSAB•+ Kit, Peroxidase 
(L.V. DAKO LSAB•+ Kit, HAP) for use with 
primary antibodies from RABBIT, MOUSE and 
GOAT supplied by the user. 
1. INTENDED USE 
FOR LABORATORY USE. 
This kit, consisting of labeUed streptavidin biotin (LSAB) 
reagents, is intended for the qualitative demonstration 
of antigens in paraffin-embedded tissues, cryostat 
tissues and cell preparations. Tissues processed in 
a variety of fixatives including ethanol, 8·5, Bouin's, 
and neutral buffered formalin may be used. 
2. SUMMARY AND EXPLANATION 
The purpose of immunohistochemical (IHC) staining 
techniques is to allow for the visualization of tissue 
(cell) antigens. OriginaUy this was accomplished by 
the direct technique using enzymes conjugated directly 
to an antibody with known antigenic specificity. 
Aithough this technique lacked the sensitivity of later 
methods, it allowed the direct visualization of tissue 
antigens using a standard light microscope.' 
The sensitivity of IHC techniques was significantly 
improved with the development of an indirect method. 
In this two-step method several enzyme-labelled 
secondary antibodies reacted with the antigen-bound 
primary antibody. Subsequently the peroxidase-
antiperoxidase (PAP) methodology was introduced 
which used a three-step method consisting of the 
sequential application of primary antibody, link anti-
body and a PAP complex. This method rendered 
greater sensitivity than traditional two-step indirect 
techniques! Anally, the strong affinity of avidin for 
biotin was exploited in the threa-step avidin-biotin 
complex (ABC) method developed by Hsu et al! This 
method provided a further increase in sensitivity over 
other existing methods. 
The LV. DAKO LSAB•+ Kit, HRP utftizes a refined 
avidin-biotin technique in which a biotinylated 
secondary antibody reacts with several peroxidase-
conjugated streptavidin molecules.• 
The LV. DAKO LSAB•+ K"rt, HAP is a sensitive and 
versatile IHC staining procedure which permits the 
simultaneous processing of numerous specimens in 
just over one hour. When compared to the ABC 
method, labelled avidin-biotin methods have been 
shown to provide an increase in sensitivity of up to 
eight times .... The LV. DAKO LSAB•+ Kit, HRP is an 
extremely sensitive LSAB method, and, as a result, 
optimal dilutions of primary antibody are up to 20 
times higher than those used for the more traditional 
PAP technique, and several fold greater than those 
used in traditional ABC or LSAB methods. This kit 
offers an enhanced signal generating system for the 
detection of antigens present in low concentrations, 
or for increased staining intensity in compensation 
for low titer primary antibodies. Primary antibodies 
produced in rabbit, mouse or goat are labelled by the 
biotinylated link antibody provided in this kit. The color 
reaction is developed using a substrate-chromogen 
solution, resulting in a colored precipitate at the anti-
gen site. 
3. PRINCIPLES OF PROCEDURE 
The technique used in this kit is based on the LSAB 
method. Endogenous peroxidase activity can be 
quenched by first incubating the specimens for five min-
utes in 3% hydrogen peroxide (supplied by user). The 
specimens are then incubated with an appropriately 
characterized and diluted rabbit, mouse or goat primary 
antibody, followed by sequential incubations with 
biotinyleted link antibody and peroxidase-labelled strep-
tavidin. Staining is completed after incubation with sub-
strate-chromogen solution (supplied by user). For 
optimal sensitivity DAKo- Large Volume DAB+ (Code 
No. K3467) is recommended for substrate-chromogen. 
4.REAGENTS 
The following materials are included in this kit: 
Manual Staining Reagents 
Ouantity Description 
1x110 ml Link : Biotinylated anti-rabbit, anti-
mouse and anti-goat 
immunoglobutins in phosphate 
buffered saline (PBS), containing 
carrier protein and 15mM sodium 
azide. 
1 x11 0 ml Streptavldin Peroxidase: 
Streptavidin conjugated to 
horseradish peroxidase in PBS 
containing carrier protein and anti-
microbial agents. 
DAKO Autostainer Reagents• 
10x11 ml Link: Biotinylated anti-rabbit, anti-
mouse and anti-goat 
immunoglobufins in phosphate 
buffered saline (PBS), containing 
carrier protein and 15mM sodium 
azide. 
10x11 ml Streptavidln Peroxidase: 
Streptavidin conjugated to 
horseradish peroxidase in PBS 
containing carrier protein and anti-
microbial agents. 
*DAKO Autostainer is available only in North America, 
South America, Austrafia and New Zealand. 
MATERIALS REQUIRED BUT NOT SUPPLIED 
Primary antibody and negative control reagent 
Positive and negative control specimens 
Xylene, toluene or xylene substitutes 
Absolute ethanol 
95%ethanol 
3% hydrogen peroxide 
Distilled water 
Wash bottles 
Wash solution, NOT containing sodium azide 
Timer (2-30 minutes) 
Absorbent wipes 
Substrate-chromogen reagents, for optimal sensitivity 
DAKO" Large Volume DAB+ (Code No. 1<3468) is rec-
ommended due to its increased sensitivity; alternatively, 
DAKO" DAB Chromogen tablets (Code No. S3000), 
Large Volume DAKO" AEC Substrate System, Ready-
to-use (Code No. 1<3464) or Large Volume DAKO" AEC 
Substrate System (Code No. K0696) can be used. 
Staining jars 
Counterstain 
37mM ammonium hydroxide 
Mounting media, such as DAKO" Faramount (Code 
No. S3025) or DAKO GlycergeP (Code No. C0563) 
Coverslips 
Standard light microscope (2Q-800x) 
5. PRECAUTIONS 
A. Product Specific 
'1. FOR LABORATORY USE. 
2. Sodium azide which is used as a preservative is 
toxic if ingested. Sodium azide may react with lead 
and copper plumbing to form highly explosive metal 
azides. Upon disposal, flush with large volumes of 
water to prevent azide build-up in plumbing.•·" 
3. Do not use reagents beyond the expiration date. 
4. Do not subsfrtute reagents from other lot numbers 
or from kits of other manufacturers. 
5. Do not store kit components or perform staining in 
strong light, such as direct sunlight. 
B. General 
1. Specimens, before and after fixation, and ail 
materials exposed to them, should be handled as 
if capable of transmitting infection and disposed of 
with proper precautions." 
2. Inhalation or ingestion of the highly allergenic 
fixative formaldehyde is harmful. Prepare in hood. 
If swallowed, induce vomiting. If skin or eye 
contact occurs, wash thoroughly with water. 
3. Organic reagents are flammable. Do not use near 
open flame. 
4. Never pipette reagents by mouth and avoid their 
contact with skin and mucous membranes. 
5. Avoid microbial contamination of reagents as 
incorrect results may occur. 
6. Avoid splashing of reagents or generation of 
aerosols. 
6. REAGENT PREPARATION 
A. Wash Solution 
PBS, O.OSM Tris-HCI buffer or Tris Buffered Saline 
(DAKO" PBS, Code No. 83024, DAKoe TBS, 
Code No. S3001 ), pH 7.2-7.6, not containing sodium 
azide are suitable wash solutions. Distilled water may 
be used for rinsing off the hydrogen peroxide (Section 
9.B. Step 1), substrate-chromogen solution, and 
counterstain. Unused wash solution may be stored at 
2-8"C. Discard if solution becomes cloudy. 
B. Primary Antibody and Negative Control Reagent 
DAKO LSAB• Ready-to-use Primary Antibodies and 
Negative Controls (N·series) are not recommended 
for use with this kit. However, DAKO offers concen-
trated monoclonal and polyclonal antibodies suitable 
for use in IHC. Due to the high sensitivity of the LV. 
DAKO LSAB•+ Kit, HAP, primary antibody dHutions 
may range from five- to twenty-fold greater than those 
used in traditional IHC methods. Optimal dilutions 
must be determined experimentally by the user. 
DDutions should be prepared using O.OSM Tris-HCI 
buffer, pH 7.2-7.6, containing 1'Yo bovine serum 
albumin or DAKO" Antibody Diluent (Code No. S0809). 
For primary antibodies an incubation time of 30 
minutes is recommended. 
C. Substrate-chromogen Solution 
DAKO" Large Volume DAB+ (Code No. K3468) is 
recommended for use with the LV. DAKO LSAB-+ 
Kit, HAP due to its increased sensitivity. Alternatively, 
the DAKO'" DAB Chromogen tablets 
(Code No. S3000), the Large Volume DAKO" AEC 
Substrate System, Ready-to-use (Code No. K3464) or 
the Large Volume DAKO" AEC Substrate System 
(Code No. K0696) can be used. Please follow the 
instructions provided with each substrate system for 
substrate-chromogen preparation. 
D. Counterstain 
DAB chromogen yields an alcohol insoluble end-product 
and can be used with alcohol-based hematoxylin. The 
colored end-product of the AEC substrate-chromogen 
reaction is alcohol soluble and should only be used 
with aqueous-based counterstains such as Mayer's 
hematoxylin. When using hematoxylin, counterstaining 
is completed by immersing tissue sections into 37mM 
ammonia water. Ammonia water is prepared by mixing 
2.5 ml 15M (concentrated) ammonium hydroxide with 
1 liter water. Unused ammonia water may be stored 
at room temperature in a tightly capped bottle. 
E. Mounting Media 
DAKO" Faramount, Aqueous Mounting Medium, 
Ready-to-use (Code No. S3025) or DAKO Glycerge!-
Mounting Medium (Code No. C0563) is recommended 
for aqueous mounting. Uquify DAKO Glycergel" by 
warming to approximately 40 ± s•c prior to use. 
A nonaqueous mounting medium can be used with 
DAB chromogen. 
7. STORAGE AND HANDUNG 
Reagents of the L.V. DAKO LSAe-+ Kit, HAP are to 
be stored at 2-a•c. Do not freeze. 
8. SPECIMEN COLLECTION AND 
PREPARATION 
Specimens processed in a variety of fixatives may be 
used. The choice of fixative and method is best made 
by the user within the context of their own laboratory 
and institutional constraints. For recommended 
methods and techniques of specimen fixation, please 
refer to Histological and Histochemical Methods: 
Theory and Practice. 12 
Survival of tissue antigens for immunological staining 
may depend on the type and concentration of fixative, 
on fixation time, and on the size of the tissue specimen 
to be fixed.'3 It is thus important to maintain optimal, 
standardized fixation conditions whenever possible in 
order to obtain reproducible staining. Where possible, 
the use of thinner specimens coupled with shorter 
fixation times is recommended. Prolonged exposure 
to fixatives may result in the masking of antigens and 
hence contribute to reduced staining. Zenker's fluid, 
B-5, and Bouin's have often been recommended as 
milder fixatives for paraffin-embedded specimens.,._,. 
A. Paraffin-Embedded lissue 
Tissue Fixation in Formaldehyde-Based Solutions 
For optimal fixation in neutral buffered formalin, 
tissue should be cut in blocks of approximately 
1.0 x 1.0 x 0.5 em, and immediately placed in 5-1 0 mL 
formalin per block. The tissue should not remain in 
formalin for more than 24 hours or more than three 
hours in B-5. 
Please refer to the manufacturer's fixation protocol 
supplied with the fixing reagents for proper procedures. 
Processing may be completed using an automatic 
tissue processor, graded alcohols, xylene or xylene 
substitute, and paraffin wax. Temperatures greater 
than so•c MUST be avoided. Rapid high 
temperature processing destroys antigenicity. 
lissues fixed in mercuric chloride-containing fixatives 
(e.g. Zenker's, B-5, etc.) should be Mde-Zenkerized" 
prior to application of the primary antibody. 
Formaldehyde is known to induce steric changes in 
the antigen molecules by forming intermolecular 
cross-linkages. Excessive formalin fixation can mask 
antigenic sites and diminish specific staining. 
Enzymatic digestion of tissue sections prior to incuba-
tion with primary antibody may recover some of these 
sites. Deparaffinized and rehydrated tissue sections 
can be digested for six minutes at room temperature 
in a solution containing 0.025% protease Type XXIV 
and 0.025% CaCb, in Tris-HCI buffer, pH 7.2-7.6. 
The use of coatecf"slides is recommended for greater 
adherence of tissue sections to the glass slides. 
Rinse thoroughly with distilled water and continue with 
the staining procedure as outUned in Section 9.8. Step 1. 
Other proteolytic enzymes, such as proteinase K 
(DAKO" Proteinase K, Code No. S3004 or DAKO" 
Proteinase K, Ready-to-use, Code No. S3020), 
pepsin (DAKO" Pepsin, Code No. S3002), or trypsin 
can also be used. 
Tissue Fixation in Ethanol 
The following procedure for fixation in ethanol is 
recommended: immerse the tissue blocks in absolute 
ethanol for 48 hours at room temperature, followed by 
two 1-hour baths in fresh xylene and two 1-hour baths 
in liquid paraffin. The tissue may then be embedded. 
Adherence of Tissue Sections to Slides 
Poly-L-Iysine coated or DAKQ® Silanized Slides (Code 
No. S3003) are recommended for proper adherence 
of tissue sections during staining procedures. The 
use of coated slides is especially recommended 
when enzymatic predigestion is performed. The 
tissue sections should be dried onto the slides at 
temperatures not to exceed 37°C. 
Deparaffinization and Rehydration 
The embedding medium must be completely removed 
from the specimen. Any residual medium can cause an 
increase in background and obscure specific staining. 
Xylene and alcohol solutions should be changed after 
every 40 slides. Toluene or xylene substitute such as 
Histoclear may be used in place of xylene. 
1. Place slides in xylene bath and incubate for five 
minutes. Repeat once. 
2. Tap off excess liquid and place slides in absolute 
ethanol for three minutes. Repeat once. 
3. Tap off excess liquid and place slides in 95% 
ethanol for three minutes. Repeat once. 
4. Tap off excess liquid and place slides in distilled or 
deionized water for 30 seconds. Unless proteolytic 
predigestion is required, commence staining 
procedure as outlined in Section 9.8. Step 1. 
B. Frozen Tissue 
Cryostat sections (five to eight microns) should be 
cut from snap-frozen tissue blocks (approximately 
1.0 x 1.0 x 0.5 em) and air-dried for 2-24 hours. Dried 
sections are ready for immediate processing or may 
be wrapped air-tight and stored frozen at -20°C or 
lower. 
If stored frozen, sections should be brought to room 
temperature before unwrapping. Tissue sections may 
be fixed in acetone for 10 minutes. Alternatively, fixa-
tion may be performed after sectioning and air-drying, 
prior to frozen storage. Allow sections to air-dry after 
fixation. Submerge slides in buffer bath for five min-
utes, then commence staining procedure as outlined 
in Section 9.8., Step 2. 
9. STAINING PROCEDURE 
A. Procedural Notes 
Before using this kit for the first time the user should 
read the instructions carefully and become familiar 
with the contents. The colors of solutions are keyed to 
the condensed instructions on the inside cover of the 
kit box. See Section 5 for precaution information. 
The reagents and instructions supplied in this kit have 
been designed for optimal performance. Further 
dilution of the kit reagents or alteration of incubation 
times or temperatures may give erroneous results. 
All kit reagents should be equilibrated to room tempera-
ture prior to performing the procedure; Ukewise, all 
incubations should be performed at room temperature. 
Do not allow tissue sections to dry during the staining 
procedure. Provided that the workplace is not exposed 
to drafts, the slides need not be covered during the 
recommended incubation times. However, if incuba· 
tions are prolonged, cover or place slides in a humid 
environment. 
If the staining protocol must be interrupted, slides 
may be kept in the buffer bath which follows the link 
incubation (Step 3) for up to one hour without affecting 
staining performance. 
B. Staining Protocol 
STEP 1 HYDROGEN PEROXIDE 
Tap off excess water and carefully wipe 
around specimen. 
Apply enough user supplied 3% hydrogen 
peroxide to cover specimen. 
Incubate five minutes. 
Rinse gently with distilled water or wash 
solution from a wash bottle and place in 
fresh buffer bath. 
STEP 2 PRIMARY ANTIBODY AND NEGATIVE 
CONTROL REAGENT 
Tap off excess buffer and wipe slide as 
before. 
Apply enough user prepared primary 
antibody or negative control reagent to 
cover specimen. 
Incubate 30 minutes unless otherwise 
specified. 
Rinse gently with wash solution from a wash 
bottle and place in buffer bath. 
STEP3 LINK 
Immediately tap off excess buffer and wipe 
slide as before. 
Apply enough YELLOW drops of Link to 
cover specimen. 
Incubate 15 minutes. For further enhance-
ment of sensitivity incubate for 30 minutes. 
Rinse slide as in Step 2. 
STEP 4 STREPTAVIDIN PEROXIDASE 
Wipe slide as before. 
Apply enough RED drops of Streptavidin to 
cover specimen. 
Incubate 15 minutes. For further enhance-
ment of sensitivity incubate for 30 minutes. 
Rinse slide as before. 
STEP 5 SUBSTRATE-CHROMOGEN SOLUTION 
Wipe slide as before. 
Apply enough of the user prepared 
substrate-chromogen solution to cover 
specimen. 
Incubate as recommended in instructions 
provided with substrate-chromogen. 
Rinse gently with distilled water from wash 
bottle. 
STEP 6 COUNTERSTAIN (optional) 
Cover specimens with hematoxylin or place 
slides in a bath of hematoxylin (see 
Section 6.D.). Incubate for two to five 
minutes, depending on the strength of the 
hematoxylin used. 
Rinse gently with distilled water from a wash 
bottle. 
Dip 1 0 times into a wash bath filled with 
ammonia water (see Section 6.0.). 
Place in distilled or deionized water for two 
minutes. 
STEP 7 MOUNTING 
Specimen may be mounted and cover-
slipped with an aqueous-based mounting 
medium such as DAKO" Faramount (Code 
No. S3025) or DAKO GlycergeF 
(Code No. C0563). A nonaqueous mounting 
medium may be used with DAB chromogen. 
Note: The AEC reaction product is soluble 
in organic solvents and therefore not 
compatible with toluene- or xylene-based, 
permanent mounting media. 
10. QUAUTY CONTROl 
A. Positive Control Specimen 
In order to ascertain that all kit reagents are functioning 
properly, a positive control specimen should accompany 
each staining run. It should be noted that the known 
positive control specimen should only be utilized for 
monitoring the accurate performance of the kit 
reagents. If positive control specimens fail to demon-
strate positive staining, labelling of test specimens 
should be considered invalid. 
B. Negative Control Specimen 
A negative control specimen stained with primary 
antibody should be used with each staining run to 
verify the specificity of the primary antibody. If staining 
occurs in the negative control specimen, results with 
the test specimen should be considered invalid. 
C. Negative Control Reagent 
A negative control reagent, allowing the recognition 
of nonspecific staining should be used with each 
specimen. This will allow improved interpretation of 
specific staining at the antigen site. Altematively, an 
antibody not specific for any specimen antigen, diluted 
in Tris-HCI buffer, pH 7.2-7.6, containing 1% bovine 
serum albumin or DAKO" Antibody Diluent (Code 
No. S0809) may be used. 
For other suggested procedures to be used in quality 
control assessment, please see references 16 and 17. 
11.1NTERPRETATION OF STAINING 
Examine the positive control specimen for the presence 
of a colored end-product at the site of the target antigen. 
DAB chromogen yields a characteristic brown end-
product whereas AEC chromogen yields a red end-
product. The presence of these colors can be 
interpreted as a positive staining result, indicating 
proper performance of kit reagents. The absence of 
specific staining in the negative control specimen con-
firms the specificity of the primary antibody. 
Examination for any nonspecific staining present on 
the negative control reagent slide is recommended 
next. Nonspecific staining, if present, is of rather 
diffuse appearance and is frequently observed in 
connective tissue. 
Test specimens stained with primary antibody should 
then be examined. Positive staining intensity should 
be assessed within the context of any beckground 
staining of the negative control reagent. The presence 
of a colored end-product can be interpreted as a posi-
tive staining result. The absence of a staining reaction 
can be interpreted as a negative staining result. 
Use only intact cells for interpretation since necrotic 
or degenerated cells often stain nonspecifically. 
Precipitates may form if, for example, specimens are 
allowed to dry during the staining procedure. 
This may be apparent at the edge of the specimen. 
Use of low magnification for scanning will minimize 
this potential misinterpretation. 
Depending on the length of the incubation time in 
hematoxylin, counterstaining will result in pale to dark 
blue coloration of cell nuclei. 
12. LIMITATIONS 
Tissue staining is dependent on the handling and 
processing of the tissue prior to staining. Improper 
fixation, freezing, thawing, washing, drying, heating, 
or sectioning may produce artifacts or false-negative 
results. 
Results will not be optimal if old or unbuffered fixatives 
are used, or If excessive heat is used during embedding 
or during attachment of sections to slides. 
False-positive results may be seen due to nonspecific 
binding of proteins. AHhough DAKO LSAB"+ Kits do 
not require the use of a separate blocking reagent, in 
some cases the application of a blocking reagent 
containing an irrelevant protein, prior to incubation with 
the primary antibody may be useful for reducing back-
ground. A recommended blocking reagent may be 
DAKO" Protein Block Serum-Free (Code No. X0909), or 
a blocking solution can be made from normal swine 
serum such as DAKO" Serum Normal, Swine (Code 
No. X0901) diluted to 200/o in O.OSM Tris-HCI buffer, 
pH 7.2·7.6. 
Endogenous avidin-binding activity (EABA) has been 
noted in frozen sections of liver (entire hepatic nodule) 
and kidney (tubular epithelium), es well as in frozen 
and formalin-fixed lymphoid tissue (paracortical histio-
cytes).'"'" EABA can be suppressed by sequential 
10-minute incubations, first with 0.1% avidin and then 
with 0.01% biotin in O.OSM Tris-HCI buffer, pH 7.2-7.6, 
prior to Section 9.B. Step 1. 
Endogenous peroxidase or pseudoperoxidase activity 
can be found in hemoproteins such as hemoglobin, 
myoglobin, cytochrome, and catalase as well as in 
eosinophils ..... • In formalin-fixed tissue this activity can 
be inhibited by incubating the tissue in 3% hydrogen 
peroxide for five minutes prior to the application of 
primary antibody. Blood and bone marrow smears 
can be treated with DAKO" Peroxidase Blocking 
Reagent (Coda No. S2001), however, this procedure 
does not abolish the reddish-brown pigment of heme-
proteins. A solution of methanol-hydrogen peroxide 
can also be used, however, some antigens may 
become denatured with this procedure. 
Necrotic or degenerated cells wUJ offer stain non-
specifically, therefore examine only intact cells for 
staining interpretations. 13 
Excessive or incomplete counterstaining may 
compromise proper interpretation of results. 
13. TROUBLESHOOTING 
PROBLEM 
1. No staining 
of any slides 
2. Weak staining 
of all slides 
3. Excessive back-
ground staining 
in all slides 
PROBABLE CAUSE 
1.a. Reagents not used in proper order. 
b. Sodium azide in buffer bath. 
c. Substrate-chromogen reagent mixed incorrectly. 
2.a. Sections retain too much solution after wash bath. 
b. Substrate-chromogen mixture too old. 
c. Slides not incubated long enough with antibodies or 
substrate mixture. 
3.a. Specimens contain high endogenous peroxidase activity. 
b. Paraffin incompletely removed. 
SUGGESTED ACTION 
1.a. Review application of reagents. 
b. Use fresh azide-free buffer. 
c. Make a fresh substrate-chromogen using 
the instructions included with the product. 
2.a. Gently tap off excess solution before wiping 
around section. 
b. Prepare fresh substrate-chromogen solution. 
c. Review recommended incubation times. 
3.a. Incubate slides with fresh hydrogen peroxide 
(see Section 12). 
b. Use fresh xylene or toluene baths. If several 
slides are stained simultaneously, the second 
xylene bath should contain fresh xylene. 
c. Slides not properly rinsed. 
d. Faster than normal substrate reaction 
due to e.g. excessive room temperature. 
e. Sections dried during staining procedure. 
f. Nonspecific binding of reagents to tissue section. 
g. Primary antibody too concentrated. 
c. Use fresh solutions in buffer baths and wash 
bottles. 
d. Use shorter incubation time with substrate-
chromogen solution. 
e. Use humidity chamber. Wipe only three to 
four slides at a time before applying reagent. 
f. Apply a blocking solution containing an 
irrelevant protein (see Section 12). 
g. Use higher dilution of the primary antibody. 
Note: If the problem cannot be attributed to any of the above causes, or if the suggested corrective action fails to resolve the problem, please 
call the DAKO Technical Services Department for further assistance at 800/424-0021. 
Additional information on staining techniques and specimen preparation can also be found in the ''Handbook-lmmunochemical Staining 
Methods,"" available from DAKO Corporation, "Atlas of Immunohistology,'~' and ''lmmunoperoxidase Techniques, A Practical Approach to 
Tumor Diagnosis."'" 
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PROCEDURE 
DAKO® Liquid DAB + 
Large Volume 
Substrate-Chromogen System 
Code No.: K 3468 
This substrate-chromogen system is a high sensitivity DAB system suitable for use in 
peroxidase-based immunohistochemical (IHC) and in situ hybridization (ISH) staining 
methods. Upon oxidation, DAB forms a brown end product at the site of the target antigen 
or nucleic acid. 1 
FOR LABORATORY USE. 
The following materials, sufficient for preparation of 110 ml of substrate-chromogen 
solution, are included. This volume is sufficient for staining a minimum of 500 specimens. 
Quantity Description 
1 x 5 ml DAB Chromogen: 3,3'-diaminobenzidine in chromogen solution. 
1 x 110 ml Buffered Substrate: lmidazole-HCI buffer pH 7.5 containing hydrogen peroxide 
and an anti-microbial agent. 
1. The DAB Chromogen and Buffered Substrate are sensitive to contamination from a 
variety of oxidizing agents such as metals, bacteria, dust and commonly used 
laboratory glassware. To avoid contamination and premature expiration, avoid 
contact of these reagents with any potential source of contamination. 
2. To avoid contamination, never pipette DAB Chromogen or Buffered Substrate directly 
from bottles. Pour out required amounts into clean containers and pipette from them. Do 
not return excess solutions to primary storage containers. 
3. DAB has been demonstrated to be a potential carcinogen and skin contact should be 
avoided. If skiti contact does occur, flush with copious amounts of water. 
4. Handle the DAB Chromogen solution with care; use of personal protective equipment is 
recommended. 
5. Do not store the DAB components or perform staining in strong light, such as direct 
sunlight. 
6. Refer to the Material Saftey Data Sheet {MSDS} for additional information. 
Add 1 drop (or 20 J.LI) of the DAB Chromogen per ml of Buffered Substrate. Use the 
provided graduated tube to measure the amount of Buffered Substrate needed. Mix well 
and apply solution using the·provided transfer pipette. After use, rinse graduated test tube 
and pipette thoroughly with distilled water. Unused working DAB solution is stable for up to 
two weeks if stored at 2-8°C. If precipitate forms, mix well before using. 
For IHC and ISH staining, following incubation with the HRP reagent, place specimens in 
buffer bath. Tap off excess buffer and carefully wipe slide around specimen. 
1. Cover specimen with the DAB solution. Incubate for 5-30 minutes. If desired, the 
incubation with the DAB Substrate-Chromogen can be carried out at higher temperatures 
than room temperature. 
2. Rinse gently with distilled water. 
3. Counterstain, if desired. 
4. Coverslip with aqueous-based or permanent mounting media. 
(2) 
RESULTS 
LIMITATIONS 
STORAGE 
REFERENCES 
-2-
For the capillary gap slide method, please observe the following recommendations: 
1. There is no need to add detergents to this substrate-chromogen system to reduce 
surface tension. 
2. Draw up the DAB Substrate-Chromogen for 20 to 30 seconds and blot the solution at 
least twice before incubating for 5-30 minutes. 
In IHC and ISH procedures, the DAB Substrate-Chromogen yields a brown reaction end-. 
product at the site of the target antigen or nucleic acid. 
For proper interpretation, positive and negative controls should accompany each staining 
run. Positive controls serve as indicators that specimen processing and handling were 
carried out correctly. Negative controls are useful for assessing non-specific staining. 
Non-specific staining, if present, is rather diffuse in appearance. 
Endogenous peroxidase or pseudoperoxidase activity, found in hemoproteins such as 
hemoglobin, myoglobin, cytochrome, and catalase, as well as in eosinophils may yield 
false-positive results.2•3 In formalin-fixed tissue this activity can be inhibited by incubating 
the tissue in 3% hydrogen peroxide for five minutes prior to the application of primary 
antibody or probe. Blood, bone marrow smears and frozen tissue sections can be treated 
with DAKO® Peroxidase Blocking Reagent (Code No. S 2001). However, this procedure 
does not abolish the reddish-brown pigment of hemoproteins. A solution of methanol-
hydrogen peroxide can also be used, however, some antigens may become denatured 
with this procedure. 
Store DAB Substrate-Chromogen system in original container at 2-8°C. 
1. Graham RC and Kamovsky MJ. The early stages of absorption of injected horseradish peroxidase in the 
proximal tubules of mouse kidney: ultrastructural cytochemistry by a new technique. J Histochem 
Cytochem 1966; 14:291 
2. Escribano LM, et al. Endogenous peroxidase activity in human cutaneous and adenoidal mast cells. J 
Histochem Cytochem 1987; 35:213 
3. Elias JM. lmmunohistopathology: A practical approach to diagnosis. Chicago: Amer Soc Clin Pathol 
Press. 1990:46 
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1. INTENDED USE 
FOR lABORATORY USE. 
. ·w~\;~~ 
~rf.?iJ.r· 
These instructions apply to the LARGE VOLUME DAKO ENVISION® SYSTEM, PEROXIDASE (DAKO 
Envision® System, HRP). 
This kit is intended for use with primary antibodies from RABBIT or MOUSE supplied by the user for the 
qualitative identification of antigens by light microscopy in normal and pathological paraffin-embedded tissues, 
cryostat tissues and cell preparations. Tissues processed in a variety of fixatives including ethanol, B-5, 
Bouin's, zinc formalin, and neutral buffered formalin may be used. 
2. SUMMARY AND EXPLANATION 
lmmunoenzymaticlimmunohistochemical (IHC) staining techniques allow for the visualization of tissue (cell) 
antigens. These techniques are based on the immunoreactivity of antibodies and the chemical properties of 
enzymes or enzyme complexes which react with colorless substrate-chromogens to produce a colored end-
product. Initial immunoenzymatic stains utilized the direct method which conjugated enzymes directly to an 
antibody with known antigenic specificity (primary antibody). Although this technique lacked the sensitivity of 
later methods, it allowed for the visualization of tissue antigens using a standard light microscope. 
The sensitivity of IHC stains was significantly improved with the development of an indirect technique. In this 
method, enzyme-labelled secondary antibodies react with the antigen-bound primary antibody. A further 
increase in sensitivity over the indirect technique was achieved with the introduction of the peroxidase-
antiperoxidase (PAP) enzyme complex.1 In this method the secondary antibody serves as a linking antibody 
between the primary antibody and the PAP complex. 1 Subsequent developments in IHC exploited the strong 
affinity of avidin for biotin and resulted in the avidin-biotin complex (ABC) method of Hsu et al.2 This technique 
employs an enzyme labelled avidin-biotin complex which is mixed prior to use and forms a complex with a 
biotinylated secondary antibody. The ABC method increased sensitivity when compared to the PAP method. 
IHC was further improved with the labelled streptavidin biotin (lSAB) method which is based on a modified 
labelled avidin-biotin (lAB) technique. The lSAB method utilizes a biotinylated secondary antibody to form a 
complex with peroxidase-conjugated streptavidin molecules. 3'4 In comparison to the ABC method, the lAB 
and lSAB methods have been reported to be eight times more sensitive.s..7 
The large Volume DAKO Envision® System, HRP is a two-step IHC staining technique which allows the user 
to choose a short or a long protocol depending on the sensitivity required. This system is based on an HRP 
labelled polymer which is conjugated with secondary antibodies. All reagents in the large Volume DAKO 
Envision® System, HRP with AEC substrate are ready-to-use. Protocol #1 of the large Volume DAKO 
Envision® System, HRP is intended to be used with the DAKO® N-series Primary Antibodies 
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to achieve optimal sensitivity. When compared to the LSAB method, Protocol #1 is equivalent or better in 
sensitivity. Protocol #2 is an extremely sensitive method and, as a result, optimal dilutions of the primary 
antibody are up to 20 times higher than those used for the traditional PAP technique, and several-fold greater 
than those used for the traditional ABC or LSAB methods. Protocol #2 offers an enhanced signal generating 
system for the detection of antigens present in low concentrations or for low titer primary antibodies. 
Primary antibodies produced in either rabbit or mouse react equally well with the labelled polymer. The 
interpretation of any positive staining or its absence should be complemented by morphological and 
histological studies with proper controls. 
3. PRINCIPLES OF PROCEDURE 
Protocols #1 and #2 require the same number of steps although incubation times of the primary antibody and 
the labelled polymer vary. Both protocols quench any endogenous peroxidase activity by incubating the 
specimen for fiVe minutes with DAKO's Peroxidase Blocking Reagent. The specimen is then incubated with 
an appropriately characterized and diluted rabbit or mouse primary antibody, followed by the incubation with 
the labelled polymer. Protocol #1 requires two sequential 1 0-minute incubations and Protocol #2 requires two 
sequential 30-minute incubations. It should be noted that for antibodies requiring enzyme digestion or target 
retrieval. it may be necessary to increase incubation times of the primary antibody and labelled polymer by 5 
to 10 minutes. Staining is completed by a 5- to 10-minute incubation with 3-amino-9-ethylcarbazole (AEC) 
substrate-chromogen which results in a red-colored precipitate at the antigen site. (AEC is a potential 
carcinogen, see "Precautions" Section 5.) 
4. REAGENTS 
The following materials, sufficient for at least 500-800 tissue sections, are included in this kit: 
Bottle No. 
1 
3 
4 
Qty. 
1x110ml 
1x110 ml 
1x110 ml 
Description 
PEROXIDASE BLOCKING REAGENT: 0.03% hydrogen peroxide 
containing sodium azide. 
LABELLED POLYMER: Peroxidase labelled polymer conjugated to 
goat anti-rabbit and goat anti-mouse immunoglobulins in Tris-HCI 
buffer containing carrier protein and an anti-microbial agent. 
SUBSTRATE, AEC Chromogen: 3-amino-9-ethylcarbazole in 
N,N-dimethylformamide (DMF) and acetate buffer, pH 5.0, 
containing hydrogen peroxide, stabilizers, enhancers and an anti-
microbial agent. 
MATERIALS REQUIRED BUT NOT SUPPLIED 
Absorbent wipes 
Ammonium hydroxide, 15M diluted to 37mM 
Control tissue, positive and negative 
Counterstain; aqueous based, such as Mayer's hematoxylin (see Section 6.D.) 
Coverslips 
Distilled water 
Ethanol, absolute and 95% 
Light microscope (20x-800x) 
Mounting media, such as DAKO Glycergel® Mounting Medium (Code No. C0563) 
Primary antibodies and negative control reagent 
Slides, Poly-L-Lysine coated or DAKO® Silanized Slides (see Section 8.A.6.) 
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Staining jars or baths 
Timer (capable of 3-40 minute intervals) 
Wash bottles 
Wash Buffer Solution (see Section 6.A.) 
Xylene, toluene or xylene substitutes 
5. PRECAUTIONS 
5.A. Product Specific 
1. FOR LABORATORY USE. 
2. The sodium azide (NaN3 ) used as a preservative in this kit is toxic if ingested. Sodium azide 
may react with lead and copper plumbing to form highly explosive metal azides. Upon 
disposal, flush with large volumes of water to prevent azide build-up in plumbing.8•9 
3. 3-amino-9-ethylcarbazole (AEC) may be carcinogenic. This solution may cause irritation 
upon skin contact Avoid skin contact If skin contact occurs, flush affected area with water. 
Waste containing AEC should be disposed of according to local, state and federal 
regulations. 
4. N,N-dimethylformamide (DMF), used as a solvent for AEC, is a combustible compound. Use 
away from open flame. Avoid ingestion, inhalation or skin contact Formamide is classified 
as a teratogen and pregnant workers should keep exposure to a minimum. If contact with 
skin occurs, wash thoroughly with soap and water. 
5. Do not use reagents beyond expiration date for prescribed storage method. If reagents are 
stored under any conditions other than those specified in the product insert, they must be 
validated by the user. 
6. Do not substitute reagents from other lot number or from kits of other manufacturers. 
7. Enzymes and substrate-chromogens may be affected adversely if exposed to excessive light 
levels. Do not store kit components or perform staining in strong light, such as direct 
sunlight 
8. Incubation times or temperatures other than those specified may give erroneous results; any 
such changes must be validated by the user. 
5.8. General 
1. Specimens, before and after fixation, and ail materials exposed to them, should be handled 
as if capable of transmitting infection and disposed of with proper precautions. 10 Wear 
disposable gloves when handling tissues. 
2. Wear disposable gloves during staining procedures. 
3. inhalation or ingestion of xylene or the highly allergenic fixative formaldehyde is harmful. 
Prepare in fume hood. If swallowed, induce vomiting. If skin or eye contact occurs, wash 
thoroughly with water. 
4. Organic reagents are flammable. Do not use near open flame. 
5. Never pipette reagents by mouth and avoid their contact with skin and mucous membranes. 
6. Avoid microbial contamination of reagents or incorrect results may occur. 
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7. 
8. 
Avoid splashing of reagents or generation of aerosols. 
Avoid physical contact and inhalation of 15M ammonium hydroxide. Prepare in fume hood. 
If skin or eye contact occur. wash thoroughly with water. 
6. REAGENT PREPARATION 
It is convenient to prepare the following reagents prior to staining. 
6.A. Wash Buffer Solution 
0.02M Phosphate Buffered Saline (DAKO® PBS, Code No. S3024), 0.05M Tris-HCI buffer or 0.05M 
Tris Buffered Saline (DAKO® TBS, Code No. S3001 ), pH 7.2-7.6, without sodium azide, are 
suitable wash and rinse buffer solutions. Wash buffer solutions containing sodium azide inactivate 
enzyme-labelled complexes and result in negative staining. Store unused buffer at 2-BOC. Discard 
buffer if cloudy in appearance. 
Distilled water may be used for rinsing the peroxidase blocking reagent, substrate and counterstain. 
6.B. Primary Antibody 
A wide range of DAKO® N-series Primary Antibodies and Negative Control Reagents are available 
for use with Protocol #1 of the large Volume DAKO Envision® System, HRP. Concentrated 
antibodies are also available from DAKO; however, optimal dilutions for Protocol #1 and Protocol #2 
must be determined experimentally by the user. Due to the high sensitivity of Protocol #2 of the 
large Volume DAKO Envision® System, HRP primary antibody dilutions may range from five- to 
twenty-fold greater than those used in traditional IHC methods. Dilutions should be prepared using 
0.05M Tris-HCI buffer, pH 7.2-7.6, containing 1% bovine serum albumin (DAKO®Antibody Diluent, 
Code No. S0809). For most primary antibodies used with this kit, an incubation time of 10 minutes 
for Protocol #1 and 30 minutes for Protocol #2 is sufficient. 
6.C. Negative Control Reagent 
Ideally, a negative control reagent contains an antibody which exhibits no specific reactivity with 
human tissues or normal/nonimmune serum in the same matrix/solution as the diluted primary 
antibody. The negative control reagent should be the same subclass and animal species as the 
primary antibody, diluted to the same immunoglobulin or protein concentration as the diluted primary 
antibody using the same diluent The incubation period for the negative control reagent should 
correspond to the primary antibody. 
When using DAKO® N-series Primary Antibodies optimized for use in Protocol #1 of Large Volume 
DAKO Envision® System, HRP, use the provided negative control reagent A negative control 
reagent should also be used with Protocol #2 of the large Volume DAKO Envision® System, HRP. 
For specific information regarding negative control reagent preparation, refer to Quality Control, 
Section 10.C. 
6.D. Counterstain 
4 
The colored end-product of the staining reaction is alcohol soluble and should only be used with 
aqueous-based counterstains such as Mayer's hematoxylin. Follow counterstaining of hematoxylin 
with a thorough rinse in distilled water, then immerse tissue slides into a bath of 37mM ammonia (see 
Section 9.B. Step 5) or similar bluing agent. Thirty-seven millimolar ammonia water is prepared by 
mixing 2.5 ml of 15M (concentrated) ammonium hydroxide with 1 liter of water. 
Unused 37mM ammonia may be stored at room temperature {20-25/C) in a tightly capped bottle for 
up to 12 months. 
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Consult manufacturers' guidelines for alternative counterstaining procedures. 
6.E. Mounting Media 
DAKO Glycergel® Mounting Medium (Code No. C0563) is recommended for aqueous mounting. This 
reagent must be heated to at least 50/C just prior to use. 
1. STORAGE AND HANDliNG 
Reagents of the large Volume DAKO Envision® System, HRP are to be stored at 2-8°C. Do not freeze. 
large Volume DAKO Envision® Systems are suitable for use 12 months from the date of manufacture when 
stored at 2-8°C. Do not use after expiration printed on reagent vials and kit label. 
Alteration in the appearance of any reagent, such as precipitation, may indicate instability or deterioration. In 
such cases, the reagent(s) is (are) not to be used. 
8. SPECIMEN PREPARATION 
5 
Prior to IHC staining, tissues must be fixed and processed. Fixation prevents autolysis and putrefaction of 
excised tissues, preserves antigenicity, enhances the refractive index of tissue constituents and increases the 
resistance of cellular elements to tissue processing. Tissue processing includes dehydration, clearing of 
dehydrating agents, infiltration of embedding media, embedding and sectioning of tissues. The most 
common fixatives for IHC tissue preparations are discussed below. 
These are guidelines only. Optimal procedures must be determined and verified by the user. (For specific 
information regarding tissue fixation and processing, see references 11 and 12.) 
B.A. Paraffin-Embedded Tissue 
8.A.1. General Comments 
Although 10% neutral phosphate-buffered formalin is the most common fixative, the Large Volume 
DAKO Envision® System, HRP has been successfully used with tissues processed in a variety of 
fixatives. Consequently, the choice of fixative is dependent on the limitations of the primary antibody 
and the user's institutional or laboratory constraints. 
Survival of tissue antigens for immunological staining may depend on the type and concentration of 
fixative, on fixation time, and on the size of the tissue specimen to be fixed. 13 It is important to 
maintain optimal, standardized fixation conditions whenever possible in order to obtain reproducible 
staining. Where possible, use of thinner specimens coupled with shorter fixation times is 
recommended. Prolonged exposure to fixatives may result in the masking of antigens and contribute 
to reduced staining. Zenker's fluid, B-5 and Bouin's have often been recommended as alternative 
fixatives for the preservation of tissue antigens sensitive to routine formalin fixation (1 0% neutral 
buffered formalin). 14' 15 
See references 11 and 12, the primary antibody specification sheet(s} and the protocol(s} supplied 
with the fixing reagent(s) for additional information regarding tissue fixation. 
8.A.2. Tissue Fixation in Formaldehyde-Based Solution (Neutral Buffered Formalin and Bouin's) 
Most formaldehyde-based fixatives contain 10% formalin, a neutral salt, to maintain tonicity and a 
buffering system to maintain pH. These fixatives are well tolerated by tissues and exhibit good 
histological penetration. However, shrinkage or distortions may occur in poorly fixed and embedded 
tissue specimens. Fix small blocks of tissue {10 x 10 x 3mm} in 5-10 ml of neutral buffered formalin 
per block for up to 24 hours. 
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Bouin's solution is an alternative formaldehyde-based fixative which contains picric acid and is 
suitable for use on all tissues except kidney. Specimens may be fixed from 1-12 hours depending on 
tissue thickness. Excessively fixed tissues become brittle and adversely affect the appearance and 
quantity of lipids. Complete fixation with a 70% ethanol wash to precipitate soluble picrates prior to 
aqueous washes. 
6 
8.A.3. Mercuric-Chloride Containing Fixatives (B-5 and Zenker's) 
Mercuric-chloride fixatives, such as 85 and Zenker's, frequently include a neutral salt to maintain 
tonicity and may be mixed with other fixatives. In general, mercuric-chloride frxatives are poor 
histological penetrators and are not well tolerated by tissue specimens. Consequently, small tissue 
blocks (7 x 7 x 2.5mm) and short fixation periods (1-6 hours for 85, and 2-15 hours for Zenker's) are 
recommended. After fixation, the tissue block(s) should be rinsed well with water and placed in 70% 
ethanol for wet storage or until tissue processing can be completed. Conclude fixation with tissue 
processing and paraffin embedding (see Section 8.A.5.). 
Prior to immunostaining, clear tissue sections of mercury deposits using an iodine/ethanol/sodium 
thiosulfate solution.16 Exercise the necessary precautions when handling reagents containing 
mercury compounds. 
8.A.4. Tissue Fixation in Ethanol 
Ethanol is not widely employed as a fixative for routine histological techniques due to its poor 
penetrating ability. However, small pieces of tissue are fixed rapidly and show good cytological 
preservation. Fix tissue blocks (5 x 5 x 2mm) in absolute alcohol for 48 hours at room temperature 
(200- 250C) followed by two 1-hour baths in fresh xylene and two 1-hour baths in liquid paraffin. 
Follow paraffin infiltration with embedding. 
8.A.5. Processing and Paraffin Embedding 
After fixation, processing may be completed using an automatic tissue processor. Tissues are 
dehydrated using graded alcohols, cleared with xylene or xylene substitute, and infiltrated with 
paraffin wax. The tissue is subsequently embedded with paraffin wax in molds or cassettes which 
facilitate tissue sectioning. To minimize denaturing of antigens, do not expose tissues to 
temperatures in excess of 600C during processing. 
Tissue blocks may be stored or sectioned on completion of embedding. Properly fixed and paraffin-
embedded tissues will keep indefinitely if stored in a cool place. 
8.A.6. Adherence of Paraffin-Embedded Tissue Sections to Microscope Slides 
Collect sectioned tissues from paraffin-embedded blocks on clean glass slides. Dehydrate in an 
oven for one to two hours at 600C or less. For increased adhesion of tissue sections during IHC 
staining procedures, use of poly-L-Iysine coated slides or DAKO® Silanized Slides (Code No. 53003) 
is suggested. Coated slides are strongly recommended for staining procedures requiring proteolytic 
digestion or target retrieval. 
Slides with paraffin-embedded tissue sections can be kept indefinitely if stored in a cool place. 
8.A.7. Deparaffinization and Rehydration 
Prior to staining, tissue slides must be deparaffinized to remove embedding media and rehydrated. 
Avoid incomplete removal of paraffin. Residual embedding media will result in increased nonspecific 
staining. 
1. Place slides in a xylene bath and incubate for 5 (±1) minutes. Change baths and repeat 
once. 
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2. 
3. 
4. 
Tap off excess liquid and place slides in absolute ethanol for 3 (±1) minutes. Change baths 
and repeat once. 
Tap off excess liquid and place slides in 95% ethanol for 3 (±1) minutes. Change baths and 
repeat once. 
Tap off excess liquid and place slides in distilled or deionized water for a minimum of 30 
seconds. Unless proteolytic digestion is required, commence staining procedure as outlined 
in Section 9.8. 
Xylene and alcohol solutions should be changed after 40 slides. Toluene or xylene substitutes such 
as Histoclear may be used in place of xylene. 
If necessary, rehydrated tissues may be kept in buffer solution at 2-80C for up to 18 hours prior to 
use. Allow tissues to come to room temperature (200-250C) before staining. 
7 
8.A.8. Proteolytic Digestion and Target Retrieval 
Formaldehyde is known to induce conformational changes in the antigen molecules by forming 
intermolecular cross-linkages. Excessive formalin fixation can mask antigenic sites and diminish 
specific staining. However, these sites may be revealed with proteolytic digestion or target retrieval 
of tissue slides prior to immunostaining. To determine if either of these pretreatments of tissues is 
warranted, see the specification sheet provided with each primary antibody. 
Deparaffinized and rehydrated tissue sections can be digested for six minutes at room temperature 
(20°-25oC) in a solution containing 0.025% Protease type XXIV and 0.025% CaCI2 in a Tris-HCI 
buffer, pH 7.2-7.6. Rinse thoroughly with distilled water and continue with the staining procedure as 
outlined in Section 9.8. Other proteolytic enzymes, such as proteinase K (DAKO® Proteinase K, 
Code No.S3020), Pepsin (DAKO® Pepsin, Code No. S3002), pronase or trypsin can also be used. 
Target retrieval prior to IHC staining procedures results in an increase in staining intensity with many 
primary antibodies. For some antibodies, this procedure is required. The retrieval procedure 
involves immersion of tissue sections mounted on slides in solution (DAKO® Target Retrieval 
Solution, Code No. SHOO) and heating prior to IHC staining. Rinse thoroughly with 0.05M Tris-HCI 
and continue with the staining procedure outlined in Section 9.8. 
NOTE: Overdigestion may result in nonspecific staining and/or unacceptable morphology. 
8.8. Frozen Tissue 
Frozen sections should be cut from snap-frozen tissue blocks (approximately 1.0 x 1.0 x 0.5 em) and air-dried 
for 2-24 hours. Dried sections can be fixed in room temperature (200 - 250C) acetone for 10 minutes or in 
buffered formyl-acetone for 30 seconds. Allow sections to air-dry until completely dehydrated. Proceed with 
immunostaining or wrap slides in aluminum foil and store at -200C or lower for up to three to six months. 
Equilibrate wrapped, frozen sections to room temperature prior to use. 
If sections are too thick (greater than 4 Tm), incorrectly fixed, or unevenly dried, artifacts may result and 
interfere with interpretation of staining. This includes rupturing of cell membranes and chromatolysis. Nuclei 
may appear swollen and uniformly blue when counterstained with hematoxylin. 
B.C. Other Specimens 
The Large Volume DAKO Envision® System, HRP may also be used for staining antigens in bone sections, 
bone marrow, blood smears, cytospins and imprints. Smears may be air-dried for 2-24 hours and processed 
for immediate staining or wrapped in aluminum foil and stored at -200C or lower for up to three to six months. 
Air-dried or thawed smears may be fixed for 90 seconds in acetone-methanol (1 :1 ). Fixation in acetone or 
acetone-methanol-formalin (10:10:1) is also acceptable. 
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Osseous tissues must be decalcified prior to sectioning and processing to facilitate tissue cutting and prevent 
damage to microtome blades.11 
9. STAINING PROCEDURE 
9.A. Procedural Notes 
The user should read these instructions carefully and become familiar with the kit contents prior to use. 
Condensed instructions appear on the inside cover of the kit box and are keyed to the colors and numbers of 
each kit reagent. See Section 5 for precautions. 
8 
The Large Volume DAKO Envision® System, HRP offers the user a choice of two protocols depending on the 
sensitivity desired. Protocol #1 is intended to be used with DAKO® N-series Primary Antibodies. Protocol 
#2 is a more sensitive method and optimal dilutions of the primary antibody are several-fold greater than 
those used for the traditional ABC or LSAB methods. Protocol #1 and Protocol #2 use the same bottled 
reagents provided in the large Volume DAKO Envision® System. The only difference is an increase in 
incubation time of each step for Protocol #2. 
The reagents and instructions supplied in this kit have been designed for optimal performance. Further 
dilution of the kit reagents or alteration of incubation times or temperatures may give erroneous results. 
Bottle 1 and Bottle 3 should be equilibrated to room temperature (200- 250C) prior to immunostaining. 
Likewise, all incubations should be performed at room temperature. for convenience the AlEC substrate 
may be used immediately after removal from the refrigerator and does not have to be brought to room 
temperature before use. After use, return to 2-8/C storage. Storage at temperature above 8/C 
adversely affects the stability of the AlEC substrate-chromogen. 
Do not allow tissue sections to dry during the staining procedure. Dried tissue sections may display 
increased nonspecific staining. Cover slides exposed to drafts. If prolonged incubations are used, place 
tissues in a humid environment. 
The sensitivity of the large Volume DAKO Envision® System can be further increased by lengthening the 
incubation times of step 2 and 3 five to ten minutes. 
9.B. Staining Protocol 
STEP 1: PEROXIDASE BLOCK REAGENT 
Tap off excess buffer. Using a lintless tissue (such as Kimwipe or gauze pad), carefully wipe 
around the specimen to remove any remaining liquid and to keep reagent within the 
prescribed area. 
Apply enough Peroxidase Blocking Reagent from Bottle 1 to cover specimen. 
Incubate 5 (± 1) minutes. 
Rinse illill!Jy with distilled water or buffer solution from a wash bottle (do not focus flow 
directly on tissue) and place in fresh buffer bath. 
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STEP 2: PRIMARY ANTIBODY OR NEGATIVE CONTROL REAGENT 
Tap off excess buffer and wipe slides as before. 
Apply enough primary antibody or negative control reagent to cover specimen. 
Protocol #1 -incubate 10 (±1) minutes 
Protocol #2 - incubate 30 (±1) minutes 
Rinse gently with buffer solution from a wash bottle (do not focus flow directly on tissue) and 
place in fresh buffer bath. 
If the staining procedure must be interrupted, slides may be kept in a buffer bath following incubation of the 
primary antibody (Step2) for up to one hour at room temperature (20/- 25/C) without affecting the staining 
performance. 
STEP 3: 
STEP4: 
STEP 5: 
PEROXIDASE LABELLED POLYMER 
Tap off excess buffer and wipe slides as before. 
Apply enough drops from Bottle 3 (labelled Polymer) to cover specimen. 
Protocol #1 - Incubate 10 (±1) minutes. 
Protocol #2 -Incubate 30 (±1) minutes. 
Rinse slides as in Step 2. 
SUBSTRATE-CHROMOGEN 
Wipe slides as before. 
Apply enough of the ready-to-use substrate-chromogen solution to cover specimen. 
Incubate for 5-10 minutes. 
Rinse gently with distilled water from a wash bottle (do not focus flow directly on tissue). 
Collect substrate-chromogen waste in a hazardous materials container for proper disposal. 
HEMATOXYLIN COUNTERSTAIN (optional) 
Immerse slides in a bath of aqueous hematoxylin. Incubate for 2-5 minutes, depending on 
the strength of hematoxylin used. 
Rinse~ in a distilled water bath. 
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Dip slides 10 times into a bath of 37mM ammonia or similar bluing agent (See Section 6.0.) 
STEP 6: 
Rinse slides in a bath of distilled or deionized water for 2-5 minutes. 
MOUNTING 
Specimens may be mounted and coverslipped with an aqueous-based mounting medium 
such as DAKO G!ycergel® Mounting Medium (Code No. C0563). 
NOTE: The AEC reaction product is soluble in organic solvents and is therefore not 
compatible with toluene- or xylene-based permanent mounting media. 
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NOTE: Slides may be read when convenient. However, some fading may occur if slides are 
exposed to strong light over a period of one week. To minimize fading, store slides in the 
dark at room temperature (200 - 250C). 
10. QUALITY CONTROL 
Differences in tissue processing and technical procedures in the user's laboratory may produce significant 
variability in results, necessitating regular performance of in-house controls in addition to the following 
procedures. See the quality control guidelines of the College of American Pathologists (CAP) Certification 
Program for Immunohistochemistry and references 17 through 19 for additional information. Refer to the 
specification sheet of each primary antibody used for details regarding sensitivity and immunoreactivity. 
10.A. Positive Control Tissue 
Controls should be fresh surgical specimens or autopsy tissues fixed, processed and embedded in the same 
manner as the test sample(s). Positive control tissues are indicative of correctly prepared tissues and proper 
staining techniques. One positive control tissue for each set of test conditions should be included in each 
staining run. 
Commercially available tissue slides (such as DAKO® Control Slides, Code Nos. T1064 and T1065), or 
specimens processed differently from the test sample(s) validate reagent performance only, and do not verify 
tissue preparation. 
Known positive control tissues should only be utilized for monitoring the correct performance of processed 
tissues and test reagents. If the positive control tissues fail to demonstrate positive staining, results with the 
test specimens should be considered invalid. 
10.8. Negative Control Tissue 
One negative control tissue fixed, processed and embedded in a manner identical to the test sample(s) 
should be stained with each primary antibody used in each staining run to verify the specificity of each 
primary antibody. Additionally, the variety of different cell types present in most tissue sections frequently 
offers internal negative control sites, but this should be verified by the user. 
If specific staining occurs in the negative control tissue, results with the test specimen should be considered 
invalid. 
10.C. Negative Control Reagent 
Use a negative control reagent with each specimen to evaluate nonspecific staining and allow better 
interpretation of specific staining at the antigen site. Ideally, a negative control reagent contains an antibody 
which exhibits no specific reactivity with human tissues (non-human reactive) in the same matrix/solution as 
the diluted primary antibody. The non-human reactive antibody should be the same subclass and animal 
species as the primary antibody, diluted to the same immunoglobulin or protein concentration as the diluted 
primary antibody. Normallnonimmune serum from the same species as the primary antibody, at a protein 
concentration equivalent to the diluted primary antibody in the same matrix/solution may be suitable for use 
depending on the type of primary antibody used. Refer to the specification sheet of each primary antibody 
and the example below for specific recommendations. Diluent alone may be used as a less desirable 
alternative to the previously described negative control reagents. The incubation period for the negative 
control reagent should correspond to the primary antibody. 
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Examples of Negative c ontrol R eagents or Concentrate dA t"b d" n 1 o aes: 
Primary Antibody Type Suggested Negative Control Reagent 
monoclonal mouse antibody, produced in non-human reactive monoclonal mouse antibody, 
ascites produced in ascites; or normal/nonimmune mouse 
serum, Code No. X0910 
monoclonal mouse antibody, produced in tissue non-human reactive monoclonal mouse antibody 
culture, subclass lgG1 produced in tissue culture, subclass JgG1, DAKO 
Code No. X0931; or fetal calf serum* 
monoclonal mouse antibody produced in tissue non-human reactive monoclonal mouse antibody 
culture, subclass lgG28 produced in tissue culture, subclass lgG2a, DAKO 
Code No. X0943; or fetal calf serum* 
monoclonal mouse antibody produced in tissue non-human reactive monoclonal mouse antibody 
culture, subclass lgG2b produced in tissue culture, subclass lgG2b, DAKO 
Code No. X0944; or fetal calf serum* 
monoclonal mouse antibody produced in tissue non-human reactive monoclonal mouse antibody 
culture, subclass lgM produced in tissue culture, subclass lgM, DAKO 
Code No. X0942; or fetal calf serum* 
polyclonal rabbit antibody, immunoglobulin normallnonimmune rabbit serum, immunoglobulin 
fraction fraction, DAKO Code No. X0903 
polyclonal rabbit antibody, whole serum normallnonimmune whole rabbit serum, DAKO Code 
No. X0902 
..:_ fetal calf serum is also suitable for use as it is retained in the primary antibody after processing 
If panels of several antibodies are used on serial tissue sections, the negatively staining areas of one slide 
may serve as a negative/nonspecific binding background control for other antibodies. 
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NOTE: When using DAKO® N-series Primary Antibodies optimized for use with Protocol #1 of large Volume 
DAKO Envision® System, HRP use the provided negative control reagent. A negative control reagent should 
also be used with Protocol #2 of the large Volume DAKO Envision® System, HRP, using the above chart as 
a guideline to match the optimized primary antibody dilution. 
To differentiate endogenous enzyme activity or nonspecific binding of enzymes from specific 
immunoreactivity, additional test tissues may be stained exclusively with prepared substrate AEC chromogen. 
For remedial solutions to aberrant test results refer to Troubleshooting, Section 13. 
1 O.D. Assay Verification 
Prior to initial use of an antibody or staining system in a procedure, the user should verify the antibody's 
specificity by testing it on a series of in-house tissues with known immunohistochemical performance 
characteristics. Refer to the quality control procedures outlined in the above subsections A, B and C, and the 
Quality Control Section of specific primary antibody. Assay verification should be repeated for each new 
antibody lot or whenever there is a change in assay parameters. 
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11. ··INTIERPRIETATION Of STAINING 
11 A Positive Control Tissue 
The positive control tissue should be examined first to ascertain that all reagents are functioning properly. 
Presence of a red-colored end-product at the site of the target antigen is indicative of positive reactivity. If the 
positive control tissues fail to demonstrate positive staining, results with the test specimens should be 
considered invalid. 
11.8. Negative Control Tissue 
The negative control tissue should be examined after the positive control tissue to verify the specific labelling 
of the target antigen by the primary antibody. The absence of specific staining in the negative control tissue 
confirms the lack of antibody cross-reactivity to cells/cellular components. If specific staining occurs in the 
negative control tissue, results with the test specimen should be considered invalid. 
Nonspecific staining, if present, will be of a diffuse appearance. Sporadic light staining of connective tissue 
may be observed in sections from excessively formalin-fixed tissues. Use intact cells for interpretation of 
staining results. Necrotic or degenerated cells often stain nonspecifically. 
False-positive results may be seen due to non-immunologic binding of reagents to tissue sections. In some 
cases the application of blocking reagent prior to incubation with the primary antibody may be useful for 
reducing background. A recommended blocking reagent is DAKO® Protein Block Serum-Free (Code 
No. X0909). Alternatively, a blocking solution can be made from normal swine serum, such as DAKO® 
Serum {Normal) Swine (Code No. X0901), diluted to 20% in O.OSM Tris-HCI buffer, pH 7.2-7.6. 
11.C. Test Tissue 
Test specimens stained with the primary antibody should be examined last. Positive staining intensity should 
be assessed within the context of any nonspecific background staining of the negative control reagent. The 
absence of a specific positive staining reaction can be interpreted as no antigen detected. If necessary, use 
a panel of antibodies to identify false-negative reactions. 
11.0. General Comments 
Precipitates may form if specimens are allowed to dry during the staining procedure. This may be apparent 
at the edge of the specimen. Scan tissues at 40X magnification to avoid misinterpretation of results. 
Depending on the incubation length and potency of the hematoxylin used, counterstaining will result in a pale 
to dark blue coloration of cell nuclei. Excessive or incomplete counterstaining may compromise proper 
interpretation of results. 
12. LIMITATIONS 
Tissue staining is dependant on the proper handling and processing of tissues prior to staining. Improper 
fixation, freezing, thawing, washing, drying, heating, sectioning or contamination with other tissues or fluids 
may produce artifacts, antibody trapping, or false-negative results. 
Use of old or unbuffered fixatives, or exposure of tissues to excessive heat (greater than 600C) during 
processing may result in decreased staining sensitivity. 
Endogenous peroxidase or pseudoperoxidase activity can be found in hemoproteins such as hemoglobin, 
myoglobin, cytochrome, and catalase as well as in eosinophils. 20'21 This activity can be inhibited by 
incubating specimens with Peroxidase Blocking Reagent Bottle #1 of the Large Volume DAKO Envision® 
System, HRP for five minutes prior to the application of the primary antibody. Blood and bone marrow 
smears and frozen tissues can also be treated with this reagent However, this procedure does not abolish 
the reddish-brown pigment of hemoproteins. Alternately, a solution of methanol-hydrogen peroxide can be 
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used. Some antigens may become denatured with this procedure. 
Tissues from persons infected with hepatitis B virus and containing hepatitis B surface antigen (HBsAg) may 
exhibit nonspecific staining with horseradish peroxidase.22 
Normal/nonimmune sera from the same animal source as the secondary antisera used in blocking steps may 
cause false-negative or false-positive results due to auto-antibodies or natural antibodies. 
The reagents supplied in this kit have been optimally diluted. Further dilution may result in loss of antigen 
detection. 
13. TROUBLESHOOTING 
PROBLEM PROBABLE CAUSE SUGGESTED ACTION 
1. No staining of any slides ia. Reagents not used in proper order. ia. Review application of reagents. 
1b. Sodium azide in buffer bath. 1b. Use fresh azide-free buffer. 
2. Weak staining of all slides 2a. Sections retain too much solution 2a. Gently tap off excess solution 
after wash bath. before wiping around section. 
2b. Slides not incubated long enough 2b. Review recommended incubation 
with antibodies or substrate. times. 
3. Excessive background staining in 3a. Specimens contain high 3a. Use longer incubation time of 
all slides endogenous peroxidase activity. peroxidase block, Bottle #1. 
3b. Paraffin incompletely removed. 3b. Use fresh xylene or toluene baths. 
If several shdes are stained 
simultaneously, the second xylene 
bath should contain fresh xylene. 
3c. Slides not properly rinsed. 3c. Use fresh solutions in buffer baths 
and wash bottles. 
3d. Faster than normal substrate 3d. Use shorter incubation time with 
reaction due to e.g. excessive room 
temperature. 
substrate-chromogen solution. 
3e. Sections dried during staining 3e. Use humidity chamber. Wipe only 
procedure. three to four slides at a time before 
applying reagent. 
3f. Nonspecific binding of reagents to 3f. Apply a blocking solution containing 
tissue section. an irrelevant protein (see Section 
11.8.). 
NOTE: If the problem cannot be attributed to any of the above causes, or if the suggested corrective action fails to resolve the 
problem, please call the DAKO Technical Services Department for further assistance (1-800-424-0021 ). 
Additional~~forrnation on staining techniques and specimen preparation caR also be found in the "Handbook-lmmunochemical Staining 
Methods," available2Irom DAKO Corporation, "Atlas of Immunohistology," and "lmmunoperoxidase Techniques, A Practical Approach 
to Tumor Diagnosis.• 
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